{
  "Direct Muscarinic Agonists": [
    {
      "CATEGORY": "Direct Muscarinic Agonists",
      "DRUG NAME": "acetylcholine",
      "ACTIONS": "bradycardia,\n bronchoconstriction, \nmiosis,\n ↑ secretions, \n↑ GI motility,\n ↑ urination, \nvasodilation, \n↑ cognition, \ntremor",
      "ADRS": "any unintended action"
    },
    {
      "CATEGORY": "Direct Muscarinic Agonists",
      "DRUG NAME": "methacholine",
      "SPECIFIC USES/FACTS": "asthma testing",
      "ACTIONS": "bradycardia,\n bronchoconstriction, \nmiosis,\n ↑ secretions, \n↑ GI motility,\n ↑ urination, \nvasodilation, \n↑ cognition, \ntremor",
      "ADRS": "any unintended action"
    },
    {
      "CATEGORY": "Direct Muscarinic Agonists",
      "DRUG NAME": "carbachol",
      "SPECIFIC USES/FACTS": "glaucoma (eyedrops)",
      "ACTIONS": "bradycardia,\n bronchoconstriction, \nmiosis,\n ↑ secretions, \n↑ GI motility,\n ↑ urination, \nvasodilation, \n↑ cognition, \ntremor",
      "ADRS": "any unintended action"
    },
    {
      "CATEGORY": "Direct Muscarinic Agonists",
      "DRUG NAME": "bethanechol",
      "SPECIFIC USES/FACTS": "post-op urinary retention",
      "ACTIONS": "bradycardia,\n bronchoconstriction, \nmiosis,\n ↑ secretions, \n↑ GI motility,\n ↑ urination, \nvasodilation, \n↑ cognition, \ntremor",
      "ADRS": "any unintended action"
    },
    {
      "CATEGORY": "Direct Muscarinic Agonists",
      "DRUG NAME": "pilocarpine",
      "SPECIFIC USES/FACTS": "glaucoma (eyedrops), xerostomia",
      "ACTIONS": "bradycardia,\n bronchoconstriction, \nmiosis,\n ↑ secretions, \n↑ GI motility,\n ↑ urination, \nvasodilation, \n↑ cognition, \ntremor",
      "ADRS": "any unintended action"
    },
    {
      "CATEGORY": "Direct Muscarinic Agonists",
      "DRUG NAME": "cevimeline",
      "SPECIFIC USES/FACTS": "xerostomia",
      "ACTIONS": "bradycardia,\n bronchoconstriction, \nmiosis,\n ↑ secretions, \n↑ GI motility,\n ↑ urination, \nvasodilation, \n↑ cognition, \ntremor",
      "ADRS": "any unintended action"
    }
  ],
  "Indirect Muscarinic Agonists (Alzheimer's Acetylcholinesterase Inhibitors)": [
    {
      "CATEGORY": "Indirect Muscarinic Agonists (Alzheimer's Acetylcholinesterase Inhibitors)",
      "DRUG NAME": "tacrine",
      "SPECIFIC USES/FACTS": "no longer on market (hepatotoxic)",
      "ACTIONS": "Enhance cognition, mood, & behavior",
      "ADRS": "bradycardia,\ndizziness/lightheadedness,\n↑ urinary frequency,\nnausea,\ndiarrhea"
    },
    {
      "CATEGORY": "Indirect Muscarinic Agonists (Alzheimer's Acetylcholinesterase Inhibitors)",
      "DRUG NAME": "donepezil",
      "SPECIFIC USES/FACTS": "severe AD",
      "ACTIONS": "Enhance cognition, mood, & behavior",
      "ADRS": "bradycardia,\ndizziness/lightheadedness,\n↑ urinary frequency,\nnausea,\ndiarrhea"
    },
    {
      "CATEGORY": "Indirect Muscarinic Agonists (Alzheimer's Acetylcholinesterase Inhibitors)",
      "DRUG NAME": "rivastigmine",
      "SPECIFIC USES/FACTS": "mild/moderate AD, Parkinson's",
      "ACTIONS": "Enhance cognition, mood, & behavior",
      "ADRS": "bradycardia,\ndizziness/lightheadedness,\n↑ urinary frequency,\nnausea,\ndiarrhea"
    },
    {
      "CATEGORY": "Indirect Muscarinic Agonists (Alzheimer's Acetylcholinesterase Inhibitors)",
      "DRUG NAME": "galantamine",
      "SPECIFIC USES/FACTS": "mild/moderate AD ",
      "ACTIONS": "Enhance cognition, mood, & behavior",
      "ADRS": "bradycardia,\ndizziness/lightheadedness,\n↑ urinary frequency,\nnausea,\ndiarrhea"
    }
  ],
  "Indirect Muscarinic Agonists (Non-Alzheimer's Acetylcholinesterase Inhibitors)": [
    {
      "CATEGORY": "Indirect Muscarinic Agonists (Non-Alzheimer's Acetylcholinesterase Inhibitors)",
      "DRUG NAME": "edrophonium",
      "SPECIFIC USES/FACTS": "assess cholinergic/myasthenia crisis",
      "ACTIONS": "Increase ACh at NMJ",
      "ADRS": "muscarinic receptor activation,\nmuscle cramping,\ncholinergic crisis,\nmyasthenic crisis"
    },
    {
      "CATEGORY": "Indirect Muscarinic Agonists (Non-Alzheimer's Acetylcholinesterase Inhibitors)",
      "DRUG NAME": "neostigmine",
      "SPECIFIC USES/FACTS": "myasthenia gravis",
      "ACTIONS": "Increase ACh at NMJ",
      "ADRS": "muscarinic receptor activation,\nmuscle cramping,\ncholinergic crisis,\nmyasthenic crisis"
    },
    {
      "CATEGORY": "Indirect Muscarinic Agonists (Non-Alzheimer's Acetylcholinesterase Inhibitors)",
      "DRUG NAME": "pyridostigmine",
      "SPECIFIC USES/FACTS": "myasthenia gravis",
      "ACTIONS": "Increase ACh at NMJ",
      "ADRS": "muscarinic receptor activation,\nmuscle cramping,\ncholinergic crisis,\nmyasthenic crisis"
    },
    {
      "CATEGORY": "Indirect Muscarinic Agonists (Non-Alzheimer's Acetylcholinesterase Inhibitors)",
      "DRUG NAME": "physostigmine",
      "SPECIFIC USES/FACTS": "anticholinergic toxidrome",
      "ACTIONS": "Increase ACh at NMJ",
      "ADRS": "muscarinic receptor activation,\nmuscle cramping,\ncholinergic crisis,\nmyasthenic crisis"
    },
    {
      "CATEGORY": "Indirect Muscarinic Agonists (Non-Alzheimer's Acetylcholinesterase Inhibitors)",
      "DRUG NAME": "ambenonium",
      "SPECIFIC USES/FACTS": "myasthenia gravis",
      "ACTIONS": "Increase ACh at NMJ",
      "ADRS": "muscarinic receptor activation,\nmuscle cramping,\ncholinergic crisis,\nmyasthenic crisis"
    },
    {
      "CATEGORY": "Indirect Muscarinic Agonists (Non-Alzheimer's Acetylcholinesterase Inhibitors)",
      "DRUG NAME": "organophosphates",
      "SPECIFIC USES/FACTS": "irreversible,\nantidotes: atropine w/ pralidoxime (2-PAM)",
      "ADRS": "organophosphate toxicity"
    }
  ],
  "Direct Antimuscarinics (Antagonists)": [
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "atropine",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "belladonna",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "cyclopentolate",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "glycopyrrolate",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "scopolamine",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "homatoropine",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "trihexyphenidyl",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "benztropine",
      "SPECIFIC USES/FACTS": "Parkinson's",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "dicyclomine",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "hyoscyamine",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "ipratorpium",
      "SPECIFIC USES/FACTS": "COPD",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "tiotropium",
      "SPECIFIC USES/FACTS": "COPD",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "aclidinium",
      "SPECIFIC USES/FACTS": "COPD",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "umeclidinium",
      "SPECIFIC USES/FACTS": "COPD",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "tolterodine",
      "SPECIFIC USES/FACTS": "Overactive bladder",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "fesoterodine",
      "SPECIFIC USES/FACTS": "Overactive bladder",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "oxybutynin",
      "SPECIFIC USES/FACTS": "Overactive bladder",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "darifenacin",
      "SPECIFIC USES/FACTS": "Overactive bladder",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "solifenacin",
      "SPECIFIC USES/FACTS": "Overactive bladder",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "trospium",
      "SPECIFIC USES/FACTS": "Overactive bladder",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    },
    {
      "CATEGORY": "Direct Antimuscarinics (Antagonists)",
      "DRUG NAME": "flavoxate",
      "SPECIFIC USES/FACTS": "Overactive bladder",
      "ACTIONS": "tachycardia,\n bronchodilation,\nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition, \n↓ tremor",
      "ADRS": "any unintended action,\nanticholinergic toxidrome (hyperthermia, dry mucous membranes, skin flushed, confusion/delirium, mydriasis/blurred vision, seizures, urinary retention, tachycardia)"
    }
  ],
  "Neural Nicotinic Agonist": [
    {
      "CATEGORY": "Neural Nicotinic Agonist",
      "DRUG NAME": "varenicline (Chantix)",
      "SPECIFIC USES/FACTS": "smoking cessation,\npartial agonist of α4β2",
      "ACTIONS": "supresses nicotine withdrawal symptoms",
      "ADRS": "vivid/abnormal dreams,\nnasuea/vomiting,\nconstipation,\nneuropsychiatric disorders"
    }
  ],
  "Non-depolarizing NMB (muscle nicotinic antagonists)": [
    {
      "CATEGORY": "Non-depolarizing NMB (muscle nicotinic antagonists)",
      "DRUG NAME": "atracurium",
      "ACTIONS": "competatively bind receptor at NMJ inhibiting muscle contraction",
      "ADRS": "prolonged apnea from diaphragm paralysis"
    },
    {
      "CATEGORY": "Non-depolarizing NMB (muscle nicotinic antagonists)",
      "DRUG NAME": "cisatracurium",
      "ACTIONS": "competatively bind receptor at NMJ inhibiting muscle contraction",
      "ADRS": "prolonged apnea from diaphragm paralysis"
    },
    {
      "CATEGORY": "Non-depolarizing NMB (muscle nicotinic antagonists)",
      "DRUG NAME": "rocuronium",
      "ACTIONS": "competatively bind receptor at NMJ inhibiting muscle contraction",
      "ADRS": "prolonged apnea from diaphragm paralysis"
    },
    {
      "CATEGORY": "Non-depolarizing NMB (muscle nicotinic antagonists)",
      "DRUG NAME": "vecuronium",
      "ACTIONS": "competatively bind receptor at NMJ inhibiting muscle contraction",
      "ADRS": "prolonged apnea from diaphragm paralysis"
    },
    {
      "CATEGORY": "Non-depolarizing NMB (muscle nicotinic antagonists)",
      "DRUG NAME": "pancuronium",
      "ACTIONS": "competatively bind receptor at NMJ inhibiting muscle contraction",
      "ADRS": "prolonged apnea from diaphragm paralysis"
    }
  ],
  "Depolarizing NMB (agonist)": [
    {
      "CATEGORY": "Depolarizing NMB (agonist)",
      "DRUG NAME": "succinylcholine",
      "SPECIFIC USES/FACTS": "short acting",
      "ACTIONS": "continual depolarization of NMJ",
      "ADRS": "malignant hyperthermia (uncontrolled calcium release)"
    }
  ],
  "Indirect Sympathomimetic (agonists)": [
    {
      "CATEGORY": "Indirect Sympathomimetic (agonists)",
      "SUBCATEGORY": "Amphetamines",
      "DRUG NAME": "amphetamine & dextroamphetamine",
      "SPECIFIC USES/FACTS": "ADHD, obesity, narcolepsy\n\ncentral stimulants",
      "ACTIONS": "promotes release of NE and some dopamine"
    },
    {
      "CATEGORY": "Indirect Sympathomimetic (agonists)",
      "SUBCATEGORY": "Amphetamines",
      "DRUG NAME": "dextroamphetamie",
      "SPECIFIC USES/FACTS": "ADHD, obesity, narcolepsy\n\ncentral stimulants",
      "ACTIONS": "promotes release of NE and some dopamine"
    },
    {
      "CATEGORY": "Indirect Sympathomimetic (agonists)",
      "SUBCATEGORY": "Amphetamines",
      "DRUG NAME": "lisdexamfetamine",
      "SPECIFIC USES/FACTS": "ADHD, obesity, narcolepsy\n\ncentral stimulants",
      "ACTIONS": "promotes release of NE and some dopamine"
    },
    {
      "CATEGORY": "Indirect Sympathomimetic (agonists)",
      "SUBCATEGORY": "Amphetamines",
      "DRUG NAME": "methamphetamine",
      "SPECIFIC USES/FACTS": "ADHD, obesity, narcolepsy\n\ncentral stimulants",
      "ACTIONS": "promotes release of NE and some dopamine"
    },
    {
      "CATEGORY": "Indirect Sympathomimetic (agonists)",
      "SUBCATEGORY": "Non-amphetamines",
      "DRUG NAME": "methylphenidate",
      "ACTIONS": "promotes release of dopamine and some NE"
    },
    {
      "CATEGORY": "Indirect Sympathomimetic (agonists)",
      "SUBCATEGORY": "Amphetamines",
      "DRUG NAME": "dexymethylphenidate",
      "SPECIFIC USES/FACTS": "ADHD, obesity, narcolepsy\n\ncentral stimulants",
      "ACTIONS": "promotes release of NE and some dopamine"
    },
    {
      "CATEGORY": "Indirect Sympathomimetic (agonists)",
      "DRUG NAME": "cocaine",
      "SPECIFIC USES/FACTS": "topical anesthesia",
      "ACTIONS": "increases SANS effect"
    },
    {
      "CATEGORY": "Indirect Sympathomimetic (agonists)",
      "SUBCATEGORY": "Amphetamines",
      "DRUG NAME": "atomoxetine",
      "SPECIFIC USES/FACTS": "ADHD "
    },
    {
      "CATEGORY": "Indirect Sympathomimetic (agonists)",
      "SUBCATEGORY": "Amphetamines",
      "DRUG NAME": "modafinil",
      "SPECIFIC USES/FACTS": "narcolepsy,\ncircadian rhythm disturbances"
    }
  ],
  "Alpha ": [
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "midodrine",
      "SPECIFIC USES/FACTS": "orthostatic hypotension",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "phenylephrine",
      "SPECIFIC USES/FACTS": "cough/cold,\nIV vasopressor",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "pseudoehedrine",
      "SPECIFIC USES/FACTS": "decongestant",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "oxymetazoline",
      "SPECIFIC USES/FACTS": "nasal spray,\nrhinitits",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "naphazoline",
      "SPECIFIC USES/FACTS": "eyedrops for redeye",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Antagonists",
      "DRUG NAME": "prazosin",
      "SPECIFIC USES/FACTS": "PTSD",
      "ADRS": "hypotension,\ndizziness,\nreflex tachycardia,\nfirst dose phenomenon"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "terazosin",
      "SPECIFIC USES/FACTS": "hypertension,\nbenign prostatic hyperplasia (BPH)",
      "ACTIONS": "decrease blood pressure",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "doxazosin",
      "SPECIFIC USES/FACTS": "orthostatic hypotension",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "alfuzosin",
      "SPECIFIC USES/FACTS": "very selective for α1A (BPH),\nleast hypotensive",
      "ACTIONS": "relaxation of prostate smooth muscle",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "tamsulosin",
      "SPECIFIC USES/FACTS": "orthostatic hypotension",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "silodosin",
      "SPECIFIC USES/FACTS": "orthostatic hypotension",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 2 Agonists",
      "DRUG NAME": "clonidine",
      "SPECIFIC USES/FACTS": "hypertension, pain, withdrawal, muscle relaxation",
      "ACTIONS": "decrease SANS outflow,\ndecrease NE release,\nmiosis,\ndecreased aqueous humor production"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "tizanidine",
      "SPECIFIC USES/FACTS": "orthostatic hypotension",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "methyldopa",
      "SPECIFIC USES/FACTS": "hypertension in pregnancy",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "guafacine",
      "SPECIFIC USES/FACTS": "ADHD, hypertension",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "brimonidine",
      "SPECIFIC USES/FACTS": "glaucoma",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "apraclonidine",
      "SPECIFIC USES/FACTS": "orthostatic hypotension",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 1 Agonists",
      "DRUG NAME": "dexmedetomidine",
      "SPECIFIC USES/FACTS": "IV sedative",
      "ACTIONS": "vasoconstriction, \nnasal mucosa vasoconstriciton, \ncontraction of bladder, urethra, prostate,\nmydriasis",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Selective Alpha 2 Antagonist",
      "DRUG NAME": "Yohimbine",
      "SPECIFIC USES/FACTS": "erectile dysfunction\n(Not FDA approved, naturally occuring drug)",
      "ACTIONS": "Increased SANS outflow, increased NE release, mydriasis"
    },
    {
      "CATEGORY": "Alpha ",
      "SUBCATEGORY": "Non-Selective Alpha Antagonist",
      "DRUG NAME": "phenoxybenamine",
      "SPECIFIC USES/FACTS": "excessive sweating, hypertension\nIRREVERSIBLE ",
      "ACTIONS": "vasodilation, \nincreased cardiac output",
      "ADRS": "nasal congestion,\nmiosis,\northostatic hypotension"
    }
  ],
  "Beta": [
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "dobutamine",
      "SPECIFIC USES/FACTS": "cardiogenic shock, septic shock, acute CHF,\nVasopressor",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Antagonists",
      "DRUG NAME": "acebuolol",
      "ACTIONS": "↓sinus rate,\n↓ conduction rate,\n↓ force of contraction and SV,\n↓ renin release",
      "ADRS": "may become non-selective at high doses"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "atenolol",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "betaxolol",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "bisoprolol",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "esmolol",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "metoprolol",
      "SPECIFIC USES/FACTS": "most commonly used",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "nebivolol",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 2 Agonists",
      "DRUG NAME": "albuterol",
      "SPECIFIC USES/FACTS": "local administration ideal",
      "ACTIONS": "bronchodilation,\nrelaxation of uterus,\nvasodilation,\n↑ glycogenolysis,\n↑ tremor,\n↑gluconeogenesis,\n↑ aqueous humor production",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "levalbuterol",
      "SPECIFIC USES/FACTS": "cardiogenic shock, septic shock, acute CHF,\nVasopressor",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "formoterol",
      "SPECIFIC USES/FACTS": "cardiogenic shock, septic shock, acute CHF,\nVasopressor",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "salmeterol",
      "SPECIFIC USES/FACTS": "cardiogenic shock, septic shock, acute CHF,\nVasopressor",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "terbutaline",
      "SPECIFIC USES/FACTS": "cardiogenic shock, septic shock, acute CHF,\nVasopressor",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Non-Selective Beta Antagonists",
      "DRUG NAME": "carteolol",
      "SPECIFIC USES/FACTS": "eye drops",
      "ACTIONS": "bronchoconstriction,\ncontraction of uterus,\n↓ glycogenolysis,\n↓gluconeogenesis,\n↓tremor,\n↓ aqueous humor production,\n↓sinus rate,\n↓ conduction rate,\n↓ force of contraction and SV,\n↓ renin release",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "timolol",
      "SPECIFIC USES/FACTS": "cardiogenic shock, septic shock, acute CHF,\nVasopressor",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "levobunolol",
      "SPECIFIC USES/FACTS": "cardiogenic shock, septic shock, acute CHF,\nVasopressor",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "nadolol",
      "SPECIFIC USES/FACTS": "portal hypertension",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "propranolol",
      "SPECIFIC USES/FACTS": "migraine",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "sotalol",
      "SPECIFIC USES/FACTS": "anti-arrhythmic",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Selective Beta 1 Agonist",
      "DRUG NAME": "pindolol",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Beta",
      "SUBCATEGORY": "Beta 3 Agonist",
      "DRUG NAME": "mirabegron",
      "SPECIFIC USES/FACTS": "over active bladder",
      "ACTIONS": "relaxation of detrusor m. of bladder (↑bladder capacity)",
      "ADRS": "BP elevation,\ntachycardia"
    }
  ],
  "Beta 1, Beta 2, & Alpha 1 Antagonists": [
    {
      "CATEGORY": "Beta 1, Beta 2, & Alpha 1 Antagonists",
      "DRUG NAME": "labetlol",
      "SPECIFIC USES/FACTS": "hypertension in pregnancy",
      "ACTIONS": "bronchoconstriction,\ncontraction of uterus,\n↓ glycogenolysis,\n↓gluconeogenesis,\n↓tremor,\n↓ aqueous humor production,\n↓sinus rate,\n↓ conduction rate,\n↓ force of contraction and SV,\n↓ renin release,\nrelaxation of prostate smooth muscle",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Beta 1, Beta 2, & Alpha 1 Antagonists",
      "DRUG NAME": "carvedilol",
      "ACTIONS": "bronchoconstriction,\ncontraction of uterus,\n↓ glycogenolysis,\n↓gluconeogenesis,\n↓tremor,\n↓ aqueous humor production,\n↓sinus rate,\n↓ conduction rate,\n↓ force of contraction and SV,\n↓ renin release,\nrelaxation of prostate smooth muscle",
      "ADRS": "unintended action"
    },
    {
      "CATEGORY": "Beta 1, Beta 2, & Alpha 1 Antagonists",
      "DRUG NAME": "labetlol",
      "SPECIFIC USES/FACTS": "hypertension in pregnancy",
      "ACTIONS": "bronchoconstriction,\ncontraction of uterus,\n↓ glycogenolysis,\n↓gluconeogenesis,\n↓tremor,\n↓ aqueous humor production,\n↓sinus rate,\n↓ conduction rate,\n↓ force of contraction and SV,\n↓ renin release,\nrelaxation of prostate smooth muscle",
      "ADRS": "unintended action"
    }
  ],
  "Vasopressors (Adrenergic Agonists)": [
    {
      "CATEGORY": "Vasopressors (Adrenergic Agonists)",
      "SUBCATEGORY": "Selective Alpha 1 Agonist",
      "DRUG NAME": "phenylephrine",
      "ACTIONS": "↑ vascualar resistance"
    },
    {
      "CATEGORY": "Vasopressors (Adrenergic Agonists)",
      "SUBCATEGORY": "Selective Beta Agonist",
      "DRUG NAME": "dobutamine",
      "SPECIFIC USES/FACTS": "cardiogenic shock, septic shock, acute CHF",
      "ACTIONS": "increase sinus rate,\nincrease coducition rate,\nincrease force of contraction and SV,\nincrease renin release"
    },
    {
      "CATEGORY": "Vasopressors (Adrenergic Agonists)",
      "SUBCATEGORY": "Non-Selective Beta Agonist",
      "DRUG NAME": "isoproterenol",
      "ACTIONS": "positive inotrope"
    },
    {
      "CATEGORY": "Vasopressors (Adrenergic Agonists)",
      "SUBCATEGORY": "Agonist at Alpha-1, Alpha-2, Beta-1",
      "DRUG NAME": "norepinephrine",
      "SPECIFIC USES/FACTS": "Given IV,\nhypotension, \nshock,\nsepsis"
    },
    {
      "CATEGORY": "Vasopressors (Adrenergic Agonists)",
      "SUBCATEGORY": "Non-Selective Adrenergic  Agonist",
      "DRUG NAME": "epinephrine",
      "SPECIFIC USES/FACTS": "Given IV (low dose: beta, high dose: alpha)\nanaphylaxis,\nasystole,\nhypotension,\nshock",
      "ACTIONS": "bronchodilator (w/ lidocaine; topical administration)"
    },
    {
      "CATEGORY": "Vasopressors (Adrenergic Agonists)",
      "SUBCATEGORY": "Dopamine-1 Receptor Agonists (D1)",
      "DRUG NAME": "dopamine",
      "SPECIFIC USES/FACTS": "IV (dose dependent: low [D1 receptor], med [+ beta-1], high [+ alpha-1],\nsevere CHF,\nhemodynamic support",
      "ACTIONS": "vasodilation of coronary vessels, \n↑ GFR (renal vasodilation)",
      "ADRS": "hypoperfusion,\ndysrhythmias,\nperipheral IV concerns"
    },
    {
      "CATEGORY": "Vasopressors (Adrenergic Agonists)",
      "SUBCATEGORY": "Selective Alpha 1 Agonist",
      "DRUG NAME": "fenoldopam",
      "SPECIFIC USES/FACTS": "IV,\nhypertensive emergency ",
      "ACTIONS": "↑ vascualar resistance"
    }
  ],
  "Class 1 (Sodium Channel Blockers)": [
    {
      "CATEGORY": "Class 1 (Sodium Channel Blockers)",
      "SUBCATEGORY": "Class 1A",
      "DRUG NAME": "Procainamide",
      "SPECIFIC USES/FACTS": "cleared renally,\nmost clinically used",
      "ACTIONS": "increase duration of refractory period,\nslows conduction rate,\ntreat atrial & ventricular arrhythmias",
      "ADRS": "hypotension, \nlupus-like syndrome,\nagranulocytosis"
    },
    {
      "CATEGORY": "Class 1 (Sodium Channel Blockers)",
      "SUBCATEGORY": "Class 1A",
      "DRUG NAME": "Quinidine",
      "SPECIFIC USES/FACTS": "antimalarial also",
      "ACTIONS": "increase duration of refractory period,\nslows conduction rate,\ntreat atrial & ventricular arrhythmias",
      "ADRS": "vertigo,\ntinnitus,\nGI Disturbance,\nhemolytic anemia,\nhepatitis,\nnew arrhythmia"
    },
    {
      "CATEGORY": "Class 1 (Sodium Channel Blockers)",
      "SUBCATEGORY": "Class 1A",
      "DRUG NAME": "Disopyramide",
      "SPECIFIC USES/FACTS": "negative inotrope",
      "ACTIONS": "increase duration of refractory period,\nslows conduction rate,\ntreat atrial & ventricular arrhythmias",
      "ADRS": "anticholinergic effects,\nexacerbate heart failure"
    },
    {
      "CATEGORY": "Class 1 (Sodium Channel Blockers)",
      "SUBCATEGORY": "Class 1B",
      "DRUG NAME": "lidocaine",
      "SPECIFIC USES/FACTS": "used IV or IM,\nacute ventricular arrhythmias",
      "ACTIONS": "ventricular arrhythmias,\nslows conduction rate",
      "ADRS": "CNS toxicity (paresthesia, confusion, seizure, tremor, GI upset)"
    },
    {
      "CATEGORY": "Class 1 (Sodium Channel Blockers)",
      "SUBCATEGORY": "Class 1A",
      "DRUG NAME": "mexiletine",
      "SPECIFIC USES/FACTS": "used PO,\nlong duration",
      "ACTIONS": "increase duration of refractory period,\nslows conduction rate,\ntreat atrial & ventricular arrhythmias",
      "ADRS": "hypotension, \nlupus-like syndrome,\nagranulocytosis"
    },
    {
      "CATEGORY": "Class 1 (Sodium Channel Blockers)",
      "SUBCATEGORY": "Class 1C\n*DO NOT USE IF PT HAS STRUCTURAL HEART DISEASE*",
      "DRUG NAME": "flecainide",
      "SPECIFIC USES/FACTS": "eliminated via kidney & liver",
      "ACTIONS": "slows conduction rate"
    },
    {
      "CATEGORY": "Class 1 (Sodium Channel Blockers)",
      "SUBCATEGORY": "Class 1A",
      "DRUG NAME": "propafenone",
      "SPECIFIC USES/FACTS": "mild beta blocking properties",
      "ACTIONS": "increase duration of refractory period,\nslows conduction rate,\ntreat atrial & ventricular arrhythmias",
      "ADRS": "conduction abnormalities, HF exacerbation, metallic taste, constipation"
    }
  ],
  "Class 2 (Beta Blockers)": [
    {
      "CATEGORY": "Class 2 (Beta Blockers)",
      "SUBCATEGORY": "See adrenergic drug list",
      "DRUG NAME": "esmolol",
      "SPECIFIC USES/FACTS": "acute arrhythmias",
      "ACTIONS": "heart rate control",
      "ADRS": "bronchospasm,\ncardiac depression,\nAV block,\nhypotension,\nexercise intolerance,\nsexual dysfunction"
    }
  ],
  "Class 3 (Potassium Channel Blockers)": [
    {
      "CATEGORY": "Class 3 (Potassium Channel Blockers)",
      "DRUG NAME": "ibutilide",
      "SPECIFIC USES/FACTS": "acute atrial fibrillation,\nblocks K, Na, and Beta",
      "ACTIONS": "delay repolarization,\nincrease action potential & refractory period,\nused for atrial & ventricular arrhythmias",
      "ADRS": "torsades de pointes"
    },
    {
      "CATEGORY": "Class 3 (Potassium Channel Blockers)",
      "DRUG NAME": "sotalol",
      "SPECIFIC USES/FACTS": "ventricular arrhythmia & atrial fibrillation,\nrenaly cleared,\nblocks K and Beta (weak)",
      "ACTIONS": "delay repolarization,\nincrease action potential & refractory period,\nused for atrial & ventricular arrhythmias",
      "ADRS": "torsades de pointes,\ncardiac depression,\nbradycardia,\nbronchospasm",
      "DDI's": "No significant DDI's"
    },
    {
      "CATEGORY": "Class 3 (Potassium Channel Blockers)",
      "DRUG NAME": "amiodarone",
      "SPECIFIC USES/FACTS": "widely used, has class 1,2,&4 electrophy siolofical properites\nmany DDI's,\nhas class 1,2,&4 electrophysiological properties",
      "ACTIONS": "delay repolarization,\nincrease action potential & refractory period,\nused for atrial & ventricular arrhythmias",
      "ADRS": "pulmonary fibrosis,\nhepatic dysfunction,\ngrey-blue skin,\ncorneal deposits,\nhypo/hyperthyroidism",
      "DDI's": "MANY DDI's including digoxin, warfarin, etc."
    },
    {
      "CATEGORY": "Class 3 (Potassium Channel Blockers)",
      "DRUG NAME": "dofetilide",
      "SPECIFIC USES/FACTS": "treatment/prophylaxis of a fib,\nmust be started inpatient",
      "ACTIONS": "delay repolarization,\nincrease action potential & refractory period,\nused for atrial & ventricular arrhythmias",
      "ADRS": "torsades de pointes,\nproarrhythmia",
      "DDI's": "DDI w/ HCTZ and verapamil"
    },
    {
      "CATEGORY": "Class 3 (Potassium Channel Blockers)",
      "DRUG NAME": "dronedarone",
      "SPECIFIC USES/FACTS": "also blocks Ca & Na,\nstrong CYP3A4 interactions",
      "ACTIONS": "delay repolarization,\nincrease action potential & refractory period,\nused for atrial & ventricular arrhythmias",
      "ADRS": "GI intolerance",
      "DDI's": "Strong CYP 3A4 interactions"
    }
  ],
  "Class 4 (Calcium channel Blockers)": [
    {
      "CATEGORY": "Class 4 (Calcium channel Blockers)",
      "DRUG NAME": "verapamil",
      "SPECIFIC USES/FACTS": "IV or PO",
      "ACTIONS": "slows conduction in AV node, \ninreases refractory period",
      "ADRS": "constipation (more so w/ verapimil),\nhypotension,\nheart block,\nexacerbation of HF",
      "DDI's": "DDI w/ digoxin, dofetilide, simvastatin, lovastatin"
    },
    {
      "CATEGORY": "Class 4 (Calcium channel Blockers)",
      "DRUG NAME": "diltiazem",
      "SPECIFIC USES/FACTS": "IV or PO",
      "ACTIONS": "slows conduction in AV node, \ninreases refractory period",
      "ADRS": "constipation (more so w/ verapimil),\nhypotension,\nheart block,\nexacerbation of HF"
    }
  ],
  "Influenza ": [
    {
      "CATEGORY": "Influenza ",
      "DRUG NAME": "Amantidine (Symmetrel)",
      "SPECIFIC USES": "treatment & prophylaxis of influenza A",
      "MOA": "inhibit uncoating of viral RNA, prevents replication",
      "ADRS": "↑ CNS dopamine,\npsychosis,\ncaution in pregnancy",
      "FACTS": "monitor: renal,\nNOT reccommended by CDC for flu",
      "DOSING": "200mg/day within 1-2 days of onset, continue 2-4 days after resolution"
    },
    {
      "CATEGORY": "Influenza ",
      "DRUG NAME": "Rimantidine (Flumadine)",
      "SPECIFIC USES": "treatment & prophylaxis of influenza A",
      "MOA": "inhibit uncoating of viral RNA, prevents replication",
      "ADRS": "caution in pregnancy,\nless CNS effects than amantidine",
      "FACTS": "tabelet or syrup,\nmonitor: renal, LFT's,\nNOT reccommended by CDC for flu",
      "DOSING": "100mg QID within 2 days onset, total 5-7 days"
    },
    {
      "CATEGORY": "Influenza ",
      "DRUG NAME": "Oseltamivir (Tamiflu)",
      "SPECIFIC USES": "treatment & prophylaxis of influenza A & B",
      "MOA": "inhibit neuraminidase, prevent release of virions from host cell & prevents cell entry",
      "ADRS": "caution in pregnancy ",
      "FACTS": "prodrug (active form: oseltamivir carboxylate),\ngive prophylactically to those around someone w/ flu",
      "DOSING": "renally adjust,\n75mg PO BID x 5 days, begin within 2 days of onset,\nif given within 24 hrs of onset can decrease length of illness"
    },
    {
      "CATEGORY": "Influenza ",
      "DRUG NAME": "Znamivir (Relenza)",
      "SPECIFIC USES": "treatment & prophylaxis of influenza A",
      "MOA": "inhibit uncoating of viral RNA, prevents replication",
      "ADRS": "caution in pregnancy",
      "FACTS": "avoid in dairy allergy",
      "DOSING": "10mg (2 inhalations) q 12hrs x 5 days,\ninhaled drug, given w/ bronchodilator (albuterol)"
    }
  ],
  "HHV": [
    {
      "CATEGORY": "HHV",
      "SUB-CATEGORY": "Pyrimadine Analog",
      "DRUG NAME": "Trifluridine (Viroptic)",
      "SPECIFIC USES": "Ocular HSV",
      "MOA": "thymidine analog,\ncauses termination of DNA chain, prevents replication",
      "FACTS": "storage: refrigerate",
      "DOSING": "opthalmic solution only,\n1 drop q2 hrs while awake until resolved (max 9 drops/day), then 1 drop q4 hrs x 7 days (max 5 drops/day)"
    },
    {
      "CATEGORY": "HHV",
      "SUB-CATEGORY": "Pyrimadine Analog",
      "DRUG NAME": "Cidofovir (Vistide)",
      "SPECIFIC USES": "CMV, HSV",
      "MOA": "cytidine analog, cause termination in DNA chain, prevent replication",
      "ADRS": "renally toxic",
      "FACTS": "hydrate prior to therapy,\ngive w/ probenecid to maintain plasma concentrations",
      "DOSING": "IV only,\n5mg/kg once a week, duration depends on type of infection"
    },
    {
      "CATEGORY": "HHV",
      "SUB-CATEGORY": "Purine Analog",
      "DRUG NAME": "Acyclovir (Zovirax)",
      "SPECIFIC USES": "HSV, VZV, CMV (limited), EBV (limited)",
      "MOA": "guanine analog, causes termination of DNA chain, prevents replication",
      "ADRS": "renal injury",
      "FACTS": "hydrate pt (prevent renal injury),\nsafe in pregnancy,\npoor bioavailability",
      "DOSING": "oral, IV, topical,\nvaries based on stage of disease,\nrenally adjusted"
    },
    {
      "CATEGORY": "HHV",
      "SUB-CATEGORY": "Pyrimadine Analog",
      "DRUG NAME": "Valacyclovir (Valtrex)",
      "SPECIFIC USES": "Ocular HSV",
      "MOA": "thymidine analog,\ncauses termination of DNA chain, prevents replication",
      "FACTS": "safe in pregnancy,\nprodrug of acyclovir",
      "DOSING": "oral,\nless frequent dosing than acyclovir (QD)"
    },
    {
      "CATEGORY": "HHV",
      "SUB-CATEGORY": "Pyrimadine Analog",
      "DRUG NAME": "Famciclovir (Famvir)",
      "SPECIFIC USES": "prevention & treatment of HSV & VZV",
      "MOA": "guanine analog, utilizes viral thymidine kinase for activation, inhibits DNA polymerase, prevents viral DNA synthesis",
      "ADRS": "renal injury",
      "FACTS": "safe in pregnancy,\nprodrug of penciclovir,\nmore bioavailability compared to acyclovir",
      "DOSING": "BID"
    },
    {
      "CATEGORY": "HHV",
      "SUB-CATEGORY": "Pyrimadine Analog",
      "DRUG NAME": "Penciclovir (Denavir)",
      "SPECIFIC USES": "HSV ",
      "MOA": "thymidine analog,\ncauses termination of DNA chain, prevents replication",
      "FACTS": "active metabolite of famciclovir",
      "DOSING": "topical,\nq2 hrs x 4 days"
    },
    {
      "CATEGORY": "HHV",
      "SUB-CATEGORY": "Pyrimadine Analog",
      "DRUG NAME": "Ganciclovir",
      "SPECIFIC USES": "treatment & prevention of CMV",
      "MOA": "guanine analog,\ncauses termination of DNA chain, prevents replication",
      "ADRS": "thrombocytopenia,\nrenal toxicity,\nliver injury,\nelectrolyte imbalance,\ncaution in pregnancy",
      "FACTS": "monitor: CBC w/ diff, LFT's, Renal funcition, serum electrolytes (Na, K, Ca)",
      "DOSING": "oral, IV, topical ophthalmic, intravitreal,\nIV give slowly over 1 hr in PICC or Central line,\ndose varies based on disease and administration"
    },
    {
      "CATEGORY": "HHV",
      "SUB-CATEGORY": "Pyrimadine Analog",
      "DRUG NAME": "Valganciclovir (Valcyte)",
      "SPECIFIC USES": "Ocular HSV",
      "MOA": "thymidine analog,\ncauses termination of DNA chain, prevents replication",
      "ADRS": "renal injury",
      "FACTS": "monitor: CBC w/ diff, renal function,\nprodrug of ganciclovir",
      "DOSING": "oral tablet,\ntake w/ food,\ndose varies based on disease"
    },
    {
      "CATEGORY": "HHV",
      "DRUG NAME": "Foscamet (Foscavir)",
      "SPECIFIC USES": "prevention & treatment of CMV, treatment of HSV & VZV",
      "MOA": "inhibits DNA polymerase & reverse transcriptase at pyrophosphate binding site, prevents viral DNA synthesis",
      "ADRS": "renal toxicity,\nbone toxicity,\ncartilage toxicity,\nEKG changes,\nbone marrow suppression,\nelectrolyte imbalance,\ncaution in pregnancy",
      "FACTS": "monitor: Chem 10, CBC w/ diff, EKG changes,\nhydrate to prevent renal toxicity",
      "DOSING": "IV only,\ndose varies depending on disease"
    }
  ],
  "HBV": [
    {
      "CATEGORY": "HBV",
      "DRUG NAME": "Peg-Interferon Alfa-2a",
      "SPECIFIC USES": "HBV",
      "MOA": "interfere w/ viral replication, activate NK cells and macrophages",
      "ADRS": "anemia,\ninfections,\narrhythmias,\nliver injury,\nhypothyroidism,\npsych changes/mood,\nrenal injury",
      "FACTS": "monitor: CBC w/ diff, CXR, EKG (at baseline & q month), LFT's, thyroid function, renal function,\npegylation extends half life",
      "DOSING": "180mg SQ q week x 48 weeks"
    },
    {
      "CATEGORY": "HBV",
      "DRUG NAME": "Interferon Alfa-2a",
      "SPECIFIC USES": "HBV",
      "MOA": "interfere w/ viral replication, activate NK cells and macrophages",
      "ADRS": "anemia,\ninfections,\narrhythmias,\nliver injury,\nhypothyroidism,\npsych changes/mood",
      "FACTS": "monitor: CBC w/ diff, CXR, EKG (at baseline & q month), LFT's, thyroid function",
      "DOSING": "IV, SQ, IM,\n5M IU SQ/IM QD x 16 weeks"
    },
    {
      "CATEGORY": "HBV",
      "DRUG NAME": "Adefovir (Hepsera)",
      "SPECIFIC USES": "HBV (effective against lamivudine-resistant HBV)",
      "MOA": "adenosine analog (prevents DNA synthesis),\nmay also stimulate NK cells & endogenous interferon alpha production",
      "ADRS": "renal injury,\nliver injury",
      "FACTS": "prodrug,\nmonitor: renal function, LFT's, HBV labs",
      "DOSING": "renally dosed when CrCl<50,\n10mg PO q 7 days "
    },
    {
      "CATEGORY": "HBV",
      "DRUG NAME": "Lamivudine-HBV",
      "SPECIFIC USES": "HBV, HIV-1, HIV-2",
      "MOA": "cytosine analog, nucleoside reverse transcriptase inhibitor",
      "ADRS": "renal injury,\nliver injury",
      "FACTS": "montor: blood glucose?, CBC w/ diff, HIV VL/CD4 count, HBV VL, LFT's, renal function",
      "DOSING": "renall dosed when CrCl<50,\noral tablet/solution,\nHIV: 300mg PO QD\nHBV: 100mg PO QD"
    },
    {
      "CATEGORY": "HBV",
      "DRUG NAME": "Entecavir (Baraclude)",
      "SPECIFIC USES": "HBV",
      "MOA": "guanosine analog, inhibits HBV reverse transcriptatse",
      "ADRS": "renal injury,\nliver injury,\nhyperbilirubinemia",
      "FACTS": "monitor: renal function, LFT's, T.bili, blood glucose (esp in DM pt's)",
      "DOSING": "oral tablet/solution (dosage forms NOT bioequivalent 1:1)\ntake on empty stomach,\ntreatment niave: 0.5mg PO QD,\ntreatment experienced/HIV: 1mg PO QD"
    },
    {
      "CATEGORY": "HBV",
      "DRUG NAME": "Telbivudine (Tyzeka)",
      "SPECIFIC USES": "HBV",
      "MOA": "thymidine analog, inhibits HBV DNA polymerase",
      "ADRS": "renal injury,\nliver injury",
      "FACTS": "monitor: LFT's",
      "DOSING": "600 mg PO QD,\nHD: 600mg PO q96hrs after HD,\nrenally dosed when CrCl<50"
    },
    {
      "CATEGORY": "HBV",
      "DRUG NAME": "Tenofovir (Viread)",
      "SPECIFIC USES": "HBV, HIV ",
      "MOA": "see HIV ",
      "ADRS": "see HIV ",
      "FACTS": "see HIV ",
      "DOSING": "see HIV "
    }
  ],
  "HCV": [
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Ribavirin",
      "SPECIFIC USES": "HCV, variety of viral infections",
      "MOA": "guanosine analog, inhibits monophosphate dehydrogenase, increrases production of antiviral cytokines",
      "ADRS": "anemia,\npsych changes,\nalopecia,\nfatigue,\nhypothyroidism,\narrhythmias,\nteratogenic",
      "DOSING": "renally dosed (rebetol: avoid if CrCl<50),\nweight based dosing:\n>75kg: 600mg PO q12hrs\n<75kg: 400mg PO qAM + 600mg PO qPM,\ngiven in combination w/ Peg-INF (for HCV)"
    },
    {
      "CATEGORY": "HCV",
      "SUB-CATEGORY": "Old Protease Inhibitors (d/c as of Oct. 2014)",
      "DRUG NAME": "Telaprevir",
      "SPECIFIC USES": "HCV",
      "MOA": "inhibit viral replication (blocks protease activity)",
      "ADRS": "rash, SJS,\nanemia,\nleukopenia,\nhemorrhoids,\nrectal burning,\nhyperbilirubinemia,\nhyperuricemia",
      "FACTS": "substrate & inhibitor of CYP3A4",
      "DOSING": "1125mg PO q12hrs + pegINF + ribavirin,\ntake w/ food (20g fat)"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Boceprevir",
      "SPECIFIC USES": "HCV, variety of viral infections",
      "MOA": "guanosine analog, inhibits monophosphate dehydrogenase, increrases production of antiviral cytokines",
      "ADRS": "hematologic effects (anemia),\nrash,\nCNS,\nGI,\nalopecia (irreversible)",
      "FACTS": "substrate & inhibitor of CYP3A4 & p-glycoprotein",
      "DOSING": "pegIFN + Ribavirin x 4wks then add 800mg Boceprivir PO q8hrs,\ntake w/ food"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Simeprivir (Olysio)",
      "SPECIFIC USES": "HCV (genotypes 1 & 4)",
      "MOA": "NS3/4A protease inhibitor",
      "DDI's": "metabolized by CYP3A4 & 1A2",
      "ADRS": "rash, \nLFT changes,\nGI upset (explosive diarrhea),\nhyperbilirubinemia,\nsulfa allergy",
      "FACTS": "take with food to avoid GI ADRS ",
      "DOSING": "varies based on what it is coadministered with"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Sofosbuvir (Solvadi)",
      "SPECIFIC USES": "HCV (genotypes 1, 2, 3, & 4)",
      "MOA": "NS5B RNA nucleotide polymerase inhibitor",
      "DDI's": "substrate of p-gp efflux pump",
      "ADRS": "fatigue,\nanemia, \nheadache,\ninsomnia",
      "FACTS": "caution in pregnancy,\nmonitor: CBC w/ diff,\nprodrug,\npangenotypic",
      "DOSING": "400mg once daily w/ coadministered HCV agent"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Sofosbuvir/ Ledipasvir (Harvoni)",
      "SPECIFIC USES": "HCV (genotypes 1, 4, & 5)",
      "MOA": "NS5B RNA nucleotide polymerase inhibitor",
      "DDI's": "substrate of p-gp efflux pump",
      "ADRS": "hyperbilirubinemia",
      "FACTS": "avoid coadministration w/ tenofovir w/ CrCl <50,\nmonitor renal function",
      "DOSING": "1 tablet (400mg/90mg) PO QD for 12-24 wks"
    },
    {
      "CATEGORY": "HCV",
      "SUB-CATEGORY": "Viekira Pak",
      "DRUG NAME": "Paritaprevir",
      "SPECIFIC USES": "HCV (genotypes 1 & 4)",
      "MOA": "NS3/4A protease inhibitor",
      "DDI's": "metabolized by CYP3A4  ",
      "ADRS": "GI upset,\nrash,\nLFT changes",
      "FACTS": "LFT's 3 or 4 times upper limit ok if pt asymptomatic,\nLFT's 5 times upper limit d/c drug ASAP",
      "DOSING": "150mg/100mg/25mg tablet PO QD + 250mg dasabuvir PO q12hrs + RIB x 12-24 wks w/ food"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Rionavir",
      "SPECIFIC USES": "HCV, variety of viral infections",
      "MOA": "CYP3A4 booster",
      "ADRS": "anemia,\npsych changes,\nalopecia,\nfatigue,\nhypothyroidism,\narrhythmias,\nteratogenic",
      "DOSING": "renally dosed (rebetol: avoid if CrCl<50),\nweight based dosing:\n>75kg: 600mg PO q12hrs\n<75kg: 400mg PO qAM + 600mg PO qPM,\ngiven in combination w/ Peg-INF (for HCV)"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Ombitasvir",
      "SPECIFIC USES": "HCV, variety of viral infections",
      "MOA": "NS5A inhibitor",
      "ADRS": "anemia,\npsych changes,\nalopecia,\nfatigue,\nhypothyroidism,\narrhythmias,\nteratogenic",
      "DOSING": "renally dosed (rebetol: avoid if CrCl<50),\nweight based dosing:\n>75kg: 600mg PO q12hrs\n<75kg: 400mg PO qAM + 600mg PO qPM,\ngiven in combination w/ Peg-INF (for HCV)"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Dasabuvir",
      "SPECIFIC USES": "HCV, variety of viral infections",
      "MOA": "non-nucleoside NS5B palm polymerase inhibitor",
      "DDI's": "metabolized by CYP 2C8 & 3A4",
      "ADRS": "anemia,\npsych changes,\nalopecia,\nfatigue,\nhypothyroidism,\narrhythmias,\nteratogenic",
      "DOSING": "renally dosed (rebetol: avoid if CrCl<50),\nweight based dosing:\n>75kg: 600mg PO q12hrs\n<75kg: 400mg PO qAM + 600mg PO qPM,\ngiven in combination w/ Peg-INF (for HCV)"
    },
    {
      "CATEGORY": "HCV",
      "SUB-CATEGORY": "Viekira XR (PrOD)",
      "DRUG NAME": "Paritaprevir",
      "SPECIFIC USES": "HCV (genotypes 1a & 1b)",
      "MOA": "NS3/4A protease inhibitor",
      "DDI's": "metabolized by CYP3A4  ",
      "ADRS": "GI upset,\nrash,\nLFT changes",
      "FACTS": "LFT's 3 or 4 times upper limit ok if pt asymptomatic,\nLFT's 5 times upper limit d/c drug ASAP",
      "DOSING": "150mg PO QD"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Rionavir",
      "SPECIFIC USES": "HCV, variety of viral infections",
      "MOA": "CYP3A4 booster",
      "ADRS": "anemia,\npsych changes,\nalopecia,\nfatigue,\nhypothyroidism,\narrhythmias,\nteratogenic",
      "DOSING": "99.99mg PO QD"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Ombitasvir",
      "SPECIFIC USES": "HCV, variety of viral infections",
      "MOA": "NS5A inhibitor",
      "ADRS": "anemia,\npsych changes,\nalopecia,\nfatigue,\nhypothyroidism,\narrhythmias,\nteratogenic",
      "DOSING": "24.99mg PO QD"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Dasabuvir",
      "SPECIFIC USES": "HCV, variety of viral infections",
      "MOA": "non-nucleoside NS5B palm polymerase inhibitor",
      "DDI's": "metabolized by CYP 2C8 & 3A4",
      "ADRS": "anemia,\npsych changes,\nalopecia,\nfatigue,\nhypothyroidism,\narrhythmias,\nteratogenic",
      "DOSING": "600mg PO QD"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Elbasvir/ Grazoprevir (Zepatier)",
      "SPECIFIC USES": "HCV (genotype 1 & 4)",
      "MOA": "NS5A inhibitor (elbasvir),\nNS3/4A protease inhibitor (grazoprevir)",
      "DDI's": "metabolized by CYP3A4",
      "ADRS": "GI upset,\nLFT's,\nhyperbilirubinemia,\nrash",
      "FACTS": "cannot dose adjust for drug interactions",
      "DOSING": "1 tablet PO QD"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Daclatasvir (Daklinza)",
      "SPECIFIC USES": "HCV (genotypes 1 & 3)",
      "MOA": "NS5A protein inhibitor",
      "DDI's": "metabolized by CYP3A4",
      "ADRS": "LFT's,\nfatigue,\nheadache,\nrash",
      "FACTS": "CAN be dose adjusted for drug interactions",
      "DOSING": "60mg PO QD + sofosbuvir x 12wks,\nw/ CYP inhibitor: 30mg PO QD\nw/ CYP inducer: 90mg PO QD"
    },
    {
      "CATEGORY": "HCV",
      "DRUG NAME": "Velpatasvir/ Sofosbuvir (Epclusa)",
      "SPECIFIC USES": "HCV (pangenotypic: 1-6)",
      "MOA": "NS5A inhibitor,\nsee sofosbuvir",
      "DDI's": "metabolized by 2B6, 2C8, 3A4",
      "ADRS": "anemia,\nheadache,\nfatigue,\nGI upset",
      "FACTS": "caution in CrCl <30 mL/min/1.73m2,\nCAN be used in pt w/ chronic kidney disease before dialysis is required)",
      "DOSING": "1 tablet (100mg/400mg) PO QD"
    }
  ],
  "NRTIs (nucleoside reverse transcriptase inhibitors)": [
    {
      "CATEGORY": "NRTIs (nucleoside reverse transcriptase inhibitors)",
      "DRUG NAME": "Abacavir (Ziagen) ABC",
      "SPECIFIC USES": "HIV",
      "MOA": "competitively inhibits HIV-1 reverse transcriptase",
      "ADRS": "rash, \nCVD risk",
      "FACTS": "check HLA-B5701 allele for mutation (allergy),\nC/I: baseline HIV VL > 100K copies/mL"
    },
    {
      "CATEGORY": "NRTIs (nucleoside reverse transcriptase inhibitors)",
      "DRUG NAME": "Didanosine (Videx) ddI",
      "SPECIFIC USES": "HIV",
      "MOA": "competitively inhibits HIV-1 reverse transcriptase",
      "ADRS": "pancreatitis (dose dependent),\nperipheral neuropathy,\nlipoatrophy",
      "FACTS": "weight dosed"
    },
    {
      "CATEGORY": "NRTIs (nucleoside reverse transcriptase inhibitors)",
      "DRUG NAME": "Emtricitabine (Emtriva) FTC",
      "SPECIFIC USES": "HIV",
      "MOA": "competitively inhibits HIV-1 reverse transcriptase",
      "ADRS": "hyperpigmentation (palms of hands)"
    },
    {
      "CATEGORY": "NRTIs (nucleoside reverse transcriptase inhibitors)",
      "DRUG NAME": "Lamivudine (Epivir) 3TC",
      "SPECIFIC USES": "HIV",
      "MOA": "competitively inhibits HIV-1 reverse transcriptase",
      "ADRS": "headache",
      "FACTS": "selects for M184V mutation"
    },
    {
      "CATEGORY": "NRTIs (nucleoside reverse transcriptase inhibitors)",
      "DRUG NAME": "Stavudine (Zerit) d4T",
      "SPECIFIC USES": "HIV",
      "MOA": "competitively inhibits HIV-1 reverse transcriptase",
      "ADRS": "pancreatitis,\nperipheral neuropathy,\nlipoatrophy,\nlactic acidosis w/ hepatic steatosis",
      "FACTS": "weight dosed"
    },
    {
      "CATEGORY": "NRTIs (nucleoside reverse transcriptase inhibitors)",
      "DRUG NAME": "Tenofovir (Viread) TDF",
      "SPECIFIC USES": "HIV",
      "MOA": "competitively inhibits HIV-1 reverse transcriptase",
      "ADRS": "nephrotoxicity,\nosteomalacia,\nfanconi syndrome",
      "FACTS": "avoid if CrCl <50,\nformulated in lactose (lactose intolerance)"
    },
    {
      "CATEGORY": "NRTIs (nucleoside reverse transcriptase inhibitors)",
      "DRUG NAME": "Tenofovir Alafenamide Fumarate TAF",
      "SPECIFIC USES": "HIV",
      "MOA": "competitively inhibits HIV-1 reverse transcriptase",
      "ADRS": "safer than TDF (no renal/bone changes)",
      "FACTS": "avoid if CrCl <30,\nprodrug of TDF",
      "DOSING": "depends on formulation"
    },
    {
      "CATEGORY": "NRTIs (nucleoside reverse transcriptase inhibitors)",
      "DRUG NAME": "Zidovudine (Retrovir)AZT, ZDV",
      "SPECIFIC USES": "HIV",
      "MOA": "competitively inhibits HIV-1 reverse transcriptase",
      "ADRS": "bone marrow supression,\nmacrocytic anemia,\nneutropenia",
      "FACTS": "monitor: CBC,\nhigh level resistance generally seen"
    },
    {
      "CATEGORY": "NRTIs (nucleoside reverse transcriptase inhibitors)",
      "DRUG NAME": "Emtricitabine/ Tenofovir DF (Truvada)",
      "SPECIFIC USES": "HIV",
      "MOA": "competitively inhibits HIV-1 reverse transcriptase",
      "ADRS": "see above",
      "FACTS": "see above"
    },
    {
      "CATEGORY": "NRTIs (nucleoside reverse transcriptase inhibitors)",
      "DRUG NAME": "Emtricitabine/ Tenofovir AF (Descovy)",
      "SPECIFIC USES": "HIV",
      "MOA": "competitively inhibits HIV-1 reverse transcriptase",
      "ADRS": "see above",
      "FACTS": "see above"
    },
    {
      "CATEGORY": "NRTIs (nucleoside reverse transcriptase inhibitors)",
      "DRUG NAME": "Abacavir/Lamivudine (Epicom)",
      "SPECIFIC USES": "HIV",
      "MOA": "competitively inhibits HIV-1 reverse transcriptase",
      "ADRS": "see above",
      "FACTS": "see above"
    },
    {
      "CATEGORY": "NRTIs (nucleoside reverse transcriptase inhibitors)",
      "DRUG NAME": "Zidovudine/ Lamivudine (Combivir)",
      "SPECIFIC USES": "HIV",
      "MOA": "competitively inhibits HIV-1 reverse transcriptase",
      "ADRS": "see above",
      "FACTS": "see above"
    }
  ],
  "NNRTIs (Non-Nucleoside reverse transcriptase inhibitors": [
    {
      "CATEGORY": "NNRTIs (Non-Nucleoside reverse transcriptase inhibitors",
      "DRUG NAME": "Efavirenz (EFV/Sustiva)",
      "SPECIFIC USES": "HIV",
      "MOA": "noncompetitively binds reverse transcriptase",
      "DDI's": "metabolized by CYP3A4, inducer and inhibitor of CYP3A4",
      "ADRS": "CNS effects (somnolence, fatigue, psych changes, SI),\nrash,\nLFT's",
      "FACTS": "1st Gen NNRTI,\nC/I: undiagnosed or untreated psych disorders,\nok in pregnancy after 1st trimester",
      "DOSING": "take on empty stomach"
    },
    {
      "CATEGORY": "NNRTIs (Non-Nucleoside reverse transcriptase inhibitors",
      "DRUG NAME": "Nervirapine (Viramune)",
      "SPECIFIC USES": "HIV",
      "MOA": "noncompetitively binds reverse transcriptase",
      "DDI's": "metabolized by CYP3A4, inducer of CYP3A4",
      "ADRS": "rash,\nliver toxicity",
      "FACTS": "1st Gen NNRTI,\nDO NOT USE IN:\nfemale w/ CD4 >250cells\nmale w/ CD4 >400 cells",
      "DOSING": "200mg QD x 2wks;\n200mg q12h"
    },
    {
      "CATEGORY": "NNRTIs (Non-Nucleoside reverse transcriptase inhibitors",
      "DRUG NAME": "Etravirine (Intelence)",
      "SPECIFIC USES": "HIV",
      "MOA": "noncompetitively binds reverse transcriptase",
      "DDI's": "metabolized by CYP3A4, induces and inhibits CYP3A4",
      "ADRS": "rash,\nLFT's,\nminor CNS effects (less than efevirenz)",
      "FACTS": "active against K103N mutation,\nonly used in treatment experienced pt or if pt w/ K103N mutation",
      "DOSING": "200mg PO q12hrs"
    },
    {
      "CATEGORY": "NNRTIs (Non-Nucleoside reverse transcriptase inhibitors",
      "DRUG NAME": "Rilpivirine (Odefsey/Complera/Edurant)",
      "SPECIFIC USES": "HIV",
      "MOA": "noncompetitively binds reverse transcriptase",
      "DDI's": "metabolized by CYP3A4",
      "ADRS": "rash,\nLFT's,\nminor CNS effects (less than efevirenz and etravirine)",
      "FACTS": "DO NOT USE if baseline HIV VL >100K copies/mL,\nindicated for treatment niave pt,\nactive against K103N mutation",
      "DOSING": "25mg PO QD,\nMUST take w/ food (900kcals)"
    }
  ],
  "Protease Inhibitors\n(-navir)": [
    {
      "CATEGORY": "Protease Inhibitors\n(-navir)",
      "DRUG NAME": "Atazanavir (Reyataz)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit activation of immature proteins by blocking GAG-POL region of proteases (inhibiting cleavage of proteins)",
      "DDI's": "metabolized by CYP3A4,\nCYP3A4 inhibitor",
      "ADRS": "PR prolongation,\nhyperbilirubinemia,\nrash,\nLFT's,\nincreases BGs (diabetes),\nincreased CVD risk",
      "FACTS": "GI and Lipid neutral,\nmonitor EKG,\nif T. bili >2.9 d/c drug"
    },
    {
      "CATEGORY": "Protease Inhibitors\n(-navir)",
      "DRUG NAME": "Fosamprenavir (Lexiva)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit activation of immature proteins by blocking GAG-POL region of proteases (inhibiting cleavage of proteins)",
      "DDI's": "metabolized by CYP3A4,\nCYP3A4 inhibitor",
      "ADRS": "GI upset,\nrash,\nLFT's,\nincreases BG's (diabetes),\nincreased CVD risk,\nincreased TG & LDL,\nlipodystrophy",
      "FACTS": "caution w/ sulfa allergy"
    },
    {
      "CATEGORY": "Protease Inhibitors\n(-navir)",
      "DRUG NAME": "Darunavir (Prezista)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit activation of immature proteins by blocking GAG-POL region of proteases (inhibiting cleavage of proteins)",
      "DDI's": "metabolized by CYP3A4,\n3A4 inhbitor,\nautoinducer",
      "ADRS": "rash,\nLFTs,\nincreased BG's (diabetes),\nincreased CVD risk",
      "FACTS": "caution in sulfa allergy,\npreferred protease,\nMUST coadminister w/ ritonavir (due to autoinduction)"
    },
    {
      "CATEGORY": "Protease Inhibitors\n(-navir)",
      "DRUG NAME": "Indinavir (Crixivan)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit activation of immature proteins by blocking GAG-POL region of proteases (inhibiting cleavage of proteins)",
      "DDI's": "metabolized by CYP3A4,\nCYP3A4 inhibitor",
      "ADRS": "nephrolithiasis,\nhyperbilirubinemia,\nrash,\nLFT's,\nincreased CVD risk,\nincreased TG & LDL,\nincreased BG's (diabetes),\nlipodystrophy"
    },
    {
      "CATEGORY": "Protease Inhibitors\n(-navir)",
      "DRUG NAME": "Lopinavir/ritonavir (Kaletra)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit activation of immature proteins by blocking GAG-POL region of proteases (inhibiting cleavage of proteins)",
      "DDI's": "metabolized by CYP3A4,\nCYP3A4 inhibitor",
      "ADRS": "GI upset,\nrash,\nLFT's,\nincreases BG's (diabetes),\nincreased CVD risk,\nincreased TG & LDL,\nlipodystrophy",
      "FACTS": "only available as coformulation w/ ritonavir"
    },
    {
      "CATEGORY": "Protease Inhibitors\n(-navir)",
      "DRUG NAME": "Nelfinavir (Viracept)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit activation of immature proteins by blocking GAG-POL region of proteases (inhibiting cleavage of proteins)",
      "DDI's": "metabolized by CYP3A4,\nCYP3A4 inhibitor",
      "ADRS": "rash,\nLFT's,\nincreases BG's (diabetes),\nincreased CVD risk,\nincreased TG & LDL,\nlipodystrophy"
    },
    {
      "CATEGORY": "Protease Inhibitors\n(-navir)",
      "DRUG NAME": "Ritonavir (Norvir)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit activation of immature proteins by blocking GAG-POL region of proteases (inhibiting cleavage of proteins)",
      "DDI's": "most potent CYP3A4 inhibitor (booster)",
      "ADRS": "GI upset (diarrhea)",
      "FACTS": "give w/ food to avoid ADR"
    },
    {
      "CATEGORY": "Protease Inhibitors\n(-navir)",
      "DRUG NAME": "Saquinavir (Invirase)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit activation of immature proteins by blocking GAG-POL region of proteases (inhibiting cleavage of proteins)",
      "DDI's": "metabolized by CYP3A4,\nCYP3A4 inhibitor",
      "ADRS": "GI,\nCVD risk (black box warning),\nrash,\nLFT's,\nincreased BG's (diabetes),\nincreased TG & LDL,\nlipodystrophy",
      "FACTS": "sometimes given with ritonavir"
    },
    {
      "CATEGORY": "Protease Inhibitors\n(-navir)",
      "DRUG NAME": "Tipranavir (Aptivus)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit activation of immature proteins by blocking GAG-POL region of proteases (inhibiting cleavage of proteins)",
      "DDI's": "metabolized by CYP3A4,\ninducer of CYP3A4,\nautoinducer",
      "ADRS": "intracranial hemmhorage (black box warning),\nrash,\nLFT's,\nincreased BG's (diabetes),\nincreased CVD risk,\nincreased TG & LDL,\nlipodystrophy",
      "FACTS": "caution in sulfa allergy,\nMUST coadminister w/ ritonavir (4x normal amount to counter induction and autoinduction)"
    },
    {
      "CATEGORY": "Protease Inhibitors\n(-navir)",
      "DRUG NAME": "Atazanavir/COBI (Evotaz)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit activation of immature proteins by blocking GAG-POL region of proteases (inhibiting cleavage of proteins)",
      "DDI's": "see above",
      "ADRS": "see above"
    },
    {
      "CATEGORY": "Protease Inhibitors\n(-navir)",
      "DRUG NAME": "Darunavir/COBI (Prezcobix)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit activation of immature proteins by blocking GAG-POL region of proteases (inhibiting cleavage of proteins)",
      "DDI's": "see above",
      "ADRS": "see above"
    }
  ],
  "3A4 Booster": [
    {
      "CATEGORY": "3A4 Booster",
      "DRUG NAME": "COBI\nCobicistat (TyBost)",
      "SPECIFIC USES": "only used in combination w/ Atazanavir and Darunavir",
      "MOA": "CYP3A4 and CYP2D6 inhibitor",
      "DDI's": "same as ritonavir",
      "ADRS": "renal impairment,\nfanconi's syndrome",
      "FACTS": "DO NOT USE COBI + TDF if CrCl <70ml/min",
      "DOSING": "150mg PO QD"
    }
  ],
  "Fusion Inhibitor": [
    {
      "CATEGORY": "Fusion Inhibitor",
      "DRUG NAME": "Enfuvirtide (T20/Fuzeon)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit gp41 to prevent fusion of HIV to CD4 cell surface",
      "DDI's": "minimal",
      "ADRS": "GI,\ninjection site reactions (occur in all pt's, lasts 1-2 wks)",
      "FACTS": "only SQ product,\nrequires refrigeration",
      "DOSING": "90mg SQ q12hrs"
    }
  ],
  "Entry Inhibitor": [
    {
      "CATEGORY": "Entry Inhibitor",
      "DRUG NAME": "Maraviroc (MVC/Selzentry)",
      "SPECIFIC USES": "HIV",
      "MOA": "inhibit HIV coreceptor CCR5",
      "DDI's": "metabolized by CYP3A4",
      "ADRS": "LFT's,\nrash,\npyrexia,\northostasis",
      "FACTS": "dose adjustments for DDI's (CYP3A4),\nmust test for CCR5 tropism prior to use",
      "DOSING": "300mg PO q12hrs\nw/ 3A4 inhibitor: 150mg PO q 12hrs\nw/ 3A4 inducer: 600mg PO q12hrs"
    }
  ],
  "Integrase Inhibitors\nINRTIs\n(-gravir)": [
    {
      "CATEGORY": "Integrase Inhibitors\nINRTIs\n(-gravir)",
      "DRUG NAME": "Raltegravir (Isentress)",
      "SPECIFIC USES": "HIV",
      "MOA": "blocks catalytic activity of HIV integrase preventing integration of virus DNA into host",
      "DDI's": "eliminated by p-gp pump (rifampin)",
      "ADRS": "rash,\nLFTs,\nincreased CPK (muscle cramping),\npyrexia",
      "FACTS": "virus develops resistance to this quickly",
      "DOSING": "400mg PO q12hrs,\ndouble the dose when given w/ rifampin"
    },
    {
      "CATEGORY": "Integrase Inhibitors\nINRTIs\n(-gravir)",
      "DRUG NAME": "Elvitegravir (Stribild, Quad Pill/Genvoya)",
      "SPECIFIC USES": "HIV",
      "MOA": "blocks catalytic activity of HIV integrase preventing integration of virus DNA into host",
      "DDI's": "metabolized by CYP3A4,\nMANY DDI's (COBI)",
      "ADRS": "new/worsening renal function,\nbone mineral density loss,\nGI",
      "FACTS": "used for treatment naïve pt's,\ndo not use in pt CrCl <70ml/min (COBI/TDF),\n<30ml/min (COBI/TAF)",
      "DOSING": "daily w/ food,\nStribild:150mg/150mg COBI/300mg TDF/ 200mg emtricitabine \nGenvoya: 150mg/150mg COBI/10mg TAF/ 200mg emtrictabline"
    },
    {
      "CATEGORY": "Integrase Inhibitors\nINRTIs\n(-gravir)",
      "DRUG NAME": "Dolutegravir (Tivicay)",
      "SPECIFIC USES": "HIV",
      "MOA": "blocks catalytic activity of HIV integrase preventing integration of virus DNA into host",
      "DDI's": "major UGT-1A1 metabolism, \nminor CYP3A4 metabolism,\npolyvalent cations (Mg, Al, Fe, Ca)",
      "ADRS": "hypersensitivity,\nLFT's,\ninsomnia,\nhyperglycemia,\nhypertriglyceridemia",
      "FACTS": "take 2 hrs before or 6hrs after taking cations (antacids)",
      "DOSING": "treatment naïve: 50mg PO QD\ntreatment naïve but INSTI naïve: 50mg PO QD\ncoadministered w/ UGT1A/3A4 inducers: 50mg PO q12h\nINSTI experienced w/ INSTI resistance: 50mg PO q12h"
    },
    {
      "CATEGORY": "Integrase Inhibitors\nINRTIs\n(-gravir)",
      "DRUG NAME": "Raltegravir (Isentress)",
      "SPECIFIC USES": "HIV",
      "MOA": "blocks catalytic activity of HIV integrase preventing integration of virus DNA into host",
      "DDI's": "eliminated by p-gp pump (rifampin)",
      "ADRS": "rash,\nLFTs,\nincreased CPK (muscle cramping),\npyrexia",
      "FACTS": "virus develops resistance to this quickly",
      "DOSING": "400mg PO q12hrs,\ndouble the dose when given w/ rifampin"
    }
  ],
  "Fixed Dose Combinations:": [
    {
      "CATEGORY": "Fixed Dose Combinations:",
      "DRUG NAME": "Atripla",
      "SPECIFIC USES": "efavirenz",
      "DDI's": "Triumeq",
      "ADRS": "dolutegravir"
    },
    {
      "CATEGORY": "Fixed Dose Combinations:",
      "DRUG NAME": "Atripla",
      "SPECIFIC USES": "tenofovir DF",
      "DDI's": "Triumeq",
      "ADRS": "abacabir"
    },
    {
      "CATEGORY": "Fixed Dose Combinations:",
      "DRUG NAME": "Atripla",
      "SPECIFIC USES": "emtricitabine",
      "DDI's": "Triumeq",
      "ADRS": "lamivudine"
    }
  ],
  "Polyene Antibiotic": [
    {
      "CATEGORY": "Polyene Antibiotic",
      "DRUG NAME": "Nystatin",
      "SPECIFIC USES": "Non-systemic infections",
      "MOA": "Bind sterols in fungal membrane (ergostrol) causing content leakage and cell death",
      "COVERAGE": "Candida",
      "FACTS": "Poor oral absorption"
    },
    {
      "CATEGORY": "Polyene Antibiotic",
      "DRUG NAME": "Amphotericin B",
      "MOA": "Bind sterols in fungal membrane (ergostrol) causing content leakage and cell death",
      "COVERAGE": "Most molds & yeast\ndoes NOT cover: \nC. lusitanae, Fusarium, Tricosporon, Scedosporium",
      "ADRS": "Glomerular nephrotoxicity (dose dependent),\ntubular nephrotoxicity,\ndecreased EPO production,\nchills,\nfevers,\ntachypnea,\nhypotension",
      "FACTS": "multiple formulations (to decrease nephrotoxicity),\namphoteric (soluble in acidic and basic solution, water insoluble),\npoor penetration of CNS & bronchial secretions",
      "DOSING": "0.3-1 mg/kg daily,\nsupport w/ fluids, heparin (thrombophlebitis)"
    },
    {
      "CATEGORY": "Polyene Antibiotic",
      "DRUG NAME": "Natamycin",
      "SPECIFIC USES": "Not typically seen in U.S.",
      "MOA": "Bind sterols in fungal membrane (ergostrol) causing content leakage and cell death"
    },
    {
      "CATEGORY": "Polyene Antibiotic",
      "DRUG NAME": "Rimocidin",
      "SPECIFIC USES": "Non-systemic infections",
      "MOA": "Bind sterols in fungal membrane (ergostrol) causing content leakage and cell death"
    },
    {
      "CATEGORY": "Polyene Antibiotic",
      "DRUG NAME": "Filipin",
      "SPECIFIC USES": "Non-systemic infections",
      "MOA": "Bind sterols in fungal membrane (ergostrol) causing content leakage and cell death"
    },
    {
      "CATEGORY": "Polyene Antibiotic",
      "DRUG NAME": "Rimaricin",
      "SPECIFIC USES": "Non-systemic infections",
      "MOA": "Bind sterols in fungal membrane (ergostrol) causing content leakage and cell death"
    }
  ],
  "Imidazoles": [
    {
      "CATEGORY": "Imidazoles",
      "DRUG NAME": "Ketoconazole",
      "SPECIFIC USES": "Topical agents (tinea pedis, contact dermatitis, oropharyngeal candidiasis)",
      "MOA": "Inhibit alpha14 demethylase blocking synthesis of ergosterol (fungal membrane cannot form),\nblocks steroid synthesis in humans",
      "COVERAGE": "Candidia, blastomycosis, hisoplasmosis, coccidiodomycosis, paracoccidioidomycosis,\nNOT aspergillus",
      "ADRS": "Many\nsee slide 19",
      "FACTS": "Poor absorption in CNS and eye,\nneeds acidic environment for absorption",
      "DOSING": "200-400mg QD,\ndecrease dose for liver failure"
    },
    {
      "CATEGORY": "Imidazoles",
      "DRUG NAME": "Miconazole",
      "SPECIFIC USES": "Topical agents (tinea pedis, contact dermatitis, oropharyngeal candidiasis)",
      "MOA": "Inhibit alpha14 demethylase blocking synthesis of ergosterol (fungal membrane cannot form),\nblocks steroid synthesis in humans"
    },
    {
      "CATEGORY": "Imidazoles",
      "DRUG NAME": "Butoconazole",
      "SPECIFIC USES": "Topical agents (tinea pedis, contact dermatitis, oropharyngeal candidiasis)",
      "MOA": "Inhibit alpha14 demethylase blocking synthesis of ergosterol (fungal membrane cannot form),\nblocks steroid synthesis in humans"
    },
    {
      "CATEGORY": "Imidazoles",
      "DRUG NAME": "Clotrimazole",
      "SPECIFIC USES": "Topical agents (tinea pedis, contact dermatitis, oropharyngeal candidiasis)",
      "MOA": "Inhibit alpha14 demethylase blocking synthesis of ergosterol (fungal membrane cannot form),\nblocks steroid synthesis in humans"
    },
    {
      "CATEGORY": "Imidazoles",
      "DRUG NAME": "Econazole",
      "SPECIFIC USES": "Topical agents (tinea pedis, contact dermatitis, oropharyngeal candidiasis)",
      "MOA": "Inhibit alpha14 demethylase blocking synthesis of ergosterol (fungal membrane cannot form),\nblocks steroid synthesis in humans"
    },
    {
      "CATEGORY": "Imidazoles",
      "DRUG NAME": "Mebendazole",
      "SPECIFIC USES": "Topical agents (tinea pedis, contact dermatitis, oropharyngeal candidiasis)",
      "MOA": "Inhibit alpha14 demethylase blocking synthesis of ergosterol (fungal membrane cannot form),\nblocks steroid synthesis in humans",
      "FACTS": "Ineffective against fungus, \nantiparasitic"
    },
    {
      "CATEGORY": "Imidazoles",
      "DRUG NAME": "Oxiconazole",
      "SPECIFIC USES": "Topical agents (tinea pedis, contact dermatitis, oropharyngeal candidiasis)",
      "MOA": "Inhibit alpha14 demethylase blocking synthesis of ergosterol (fungal membrane cannot form),\nblocks steroid synthesis in humans"
    },
    {
      "CATEGORY": "Imidazoles",
      "DRUG NAME": "Sulconazole",
      "SPECIFIC USES": "Topical agents (tinea pedis, contact dermatitis, oropharyngeal candidiasis)",
      "MOA": "Inhibit alpha14 demethylase blocking synthesis of ergosterol (fungal membrane cannot form),\nblocks steroid synthesis in humans"
    },
    {
      "CATEGORY": "Imidazoles",
      "DRUG NAME": "Sertaconazole",
      "SPECIFIC USES": "Topical agents (tinea pedis, contact dermatitis, oropharyngeal candidiasis)",
      "MOA": "Inhibit alpha14 demethylase blocking synthesis of ergosterol (fungal membrane cannot form),\nblocks steroid synthesis in humans"
    },
    {
      "CATEGORY": "Imidazoles",
      "DRUG NAME": "Thiabendazole",
      "SPECIFIC USES": "Topical agents (tinea pedis, contact dermatitis, oropharyngeal candidiasis)",
      "MOA": "Inhibit alpha14 demethylase blocking synthesis of ergosterol (fungal membrane cannot form),\nblocks steroid synthesis in humans",
      "FACTS": "Ineffective against fungus, \nantiparasitic"
    }
  ],
  "Triazoles": [
    {
      "CATEGORY": "Triazoles",
      "DRUG NAME": "Fluconazole",
      "MOA": "Inhibit alpha14 sterol demethylase (blocks synthesis of ergosterol)",
      "COVERAGE": "Candidia (EXCEPT glabrata),\ncryptococcus, coccidioides, blastomyces, histoplasma",
      "DDI": "Minor inhibitor of 3A4,\nmoderate inhibitor of 2C9",
      "ADRS": "GI intolerance,\nelevated LFT's,\nrash",
      "FACTS": "80% excreted unchanged in urine",
      "DOSING": "PO and IV,\ntablet = suspension,\nCrCl >50mg/min, full dose\nCrCl <50ml/min, give 50% dose\ndialysis: replace full dose after each session"
    },
    {
      "CATEGORY": "Triazoles",
      "DRUG NAME": "Itraconaole",
      "MOA": "Inhibit alpha14 sterol demethylase (blocks synthesis of ergosterol)",
      "COVERAGE": "Candidia (EXCEPT glabrata),\naspergillus, cryptococcus, blastomyces, coccidioides, histoplasma",
      "DDI": "Metabolized by CYP3A4,\ninhibitor of 3A4",
      "ADRS": "C/I: pt w/ CHF (negative inotropic effects),\nQTc prolongation,\nhepatotoxicity,\nhypokalemia,\nrash,\nGI intolerance",
      "FACTS": "Poor CNS penetration",
      "DOSING": "PO and IV,\ntablet ≠ suspension (oral solution 60% more bioavailable),\ntablet w/ food,\nsuspension on empty stomach"
    },
    {
      "CATEGORY": "Triazoles",
      "DRUG NAME": "Posaconazole",
      "MOA": "Inhibit alpha14 sterol demethylase (blocks synthesis of ergosterol)",
      "COVERAGE": "All EXCEPT scedosporium",
      "DDI": "Moderate inhibitor of 3A4",
      "ADRS": "Hepatoxicity,\nQTc prolongation,\nGI intolerance",
      "FACTS": "Widely distributed in tissues",
      "DOSING": "PO and IV,\ntablet ≠ suspension,\ntake w/ high fat meal"
    },
    {
      "CATEGORY": "Triazoles",
      "DRUG NAME": "Voriconazole",
      "MOA": "Inhibit alpha14 sterol demethylase (blocks synthesis of ergosterol)",
      "COVERAGE": "All EXCEPT scedosporium and zygomycetes",
      "DDI": "Metabolized by 2C9 and 2C19 (minor: 3A4),\nWeak inhibitor: 2C9, 2C19\nModerate inhibitor: 3A4",
      "ADRS": "Peripheral edema,\nrash,\nN/V/D,\nhepatotoxicity,\nheadache,\nvisual/auditory disturbances,\nfever,\nSJS,\nliver failure,\nanaphylaxis,\nrenal failure,\nQTc prolongation",
      "FACTS": "Good CNS penetration",
      "DOSING": "PO, IV, and ophthalmic,\ndose: IV: 6mg/kg for 2 doses, 3-4mg/kg q12h\nPO: >40kg: 200-300mg q12h\n<40kg: 100-150mg q12h\ncirrhosis: IV: 6mg/kg for 2 doses, 2mg/kg q12h\nPO: >40kg: 100mg q12h\n<40kg: 50mg q12h\nrenal: CrCl <50ml/min use oral formulation"
    }
  ],
  "Echinocandins": [
    {
      "CATEGORY": "Echinocandins",
      "DRUG NAME": "Anidulafingin",
      "MOA": "Inhibit synthesis of glucan in cell wall via beta 1,3-D glucan synthase (cell rupture, cell death)",
      "COVERAGE": "All EXCEPT cryptococcus, histoplasma, fusarium, scedosporidium, zygomycetes",
      "DDI": "No clinically significant interactions",
      "ADRS": "infusion related reaction,\nGI intolerance,\nhypokalemia,\nhypomagnesemia,\nelevated LFT's",
      "DOSING": "200mg IV day 1, 100mg IV daily after"
    },
    {
      "CATEGORY": "Echinocandins",
      "DRUG NAME": "Caspofungin",
      "MOA": "Inhibit synthesis of glucan in cell wall via beta 1,3-D glucan synthase (cell rupture, cell death)",
      "COVERAGE": "All EXCEPT cryptococcus, histoplasma, fusarium, scedosporidium, zygomycetes",
      "DDI": "Not metabolized by CYP but CYP inducers reduce caspofungin levels,\ncyclosporine increases AUC of caspofungin,\ntacrolimus reduced when given w/ caspofungin",
      "ADRS": "infusion related reaction,\nGI intolerance,\nhypokalemia,\nhypomagnesemia,\nelevated LFT's",
      "FACTS": "higher frequency of liver abnormalities,\nhigher frequency of infusion related pain",
      "DOSING": "70mg IV day 1, 50mg IV daily after"
    },
    {
      "CATEGORY": "Echinocandins",
      "DRUG NAME": "Micafungin",
      "MOA": "Inhibit synthesis of glucan in cell wall via beta 1,3-D glucan synthase (cell rupture, cell death)",
      "COVERAGE": "All EXCEPT cryptococcus, histoplasma, fusarium, scedosporidium, zygomycetes",
      "DDI": "Minor substrate and weak inhibitor 3A4,\nNifedipine AUC and Cmax increase when given w/ micafungin,\nsirolimus concentrations increase when givevn w/ micafungin",
      "ADRS": "infusion related reaction,\nGI intolerance,\nhypokalemia,\nhypomagnesemia,\nelevated LFT's",
      "DOSING": "100mg IV daily,\nno loading dose"
    }
  ],
  "Allylamines": [
    {
      "CATEGORY": "Allylamines",
      "DRUG NAME": "Terbinafine (Lamisil)",
      "SPECIFIC USES": "Onychomycosis, NOT used for systemic infections",
      "MOA": "Inhibit squalene epoxidase (required for ergosterol synthesis)",
      "DOSING": "Oral and topical,\n2 months for fingernails, 3 months for toenails"
    },
    {
      "CATEGORY": "Allylamines",
      "DRUG NAME": "Amorolfine",
      "MOA": "Inhibit squalene epoxidase (required for ergosterol synthesis)"
    },
    {
      "CATEGORY": "Allylamines",
      "DRUG NAME": "Naftifine",
      "MOA": "Inhibit squalene epoxidase (required for ergosterol synthesis)"
    },
    {
      "CATEGORY": "Allylamines",
      "DRUG NAME": "Butenafine",
      "MOA": "Inhibit squalene epoxidase (required for ergosterol synthesis)"
    }
  ],
  "Other": [
    {
      "CATEGORY": "Other",
      "DRUG NAME": "Flucytosine",
      "MOA": "Converted and incorporated into fungal RNA leading to miscoding,\ninterferes w/ DNA synthesis",
      "COVERAGE": "Candida (except krusei), cryptococcus, aspergillus",
      "ADRS": "bone marrow suppression,\nhepatotoxicity,\nenterocolitis,\n*toxicities occur more in pt w/ renal impairment,\nC/I: pregnancy",
      "FACTS": "used as synergistic agent (amphotericin B), never used alone due to high resistance (loss of enzymes needed to convert flucytosine or loss of fungal membrane transporter)",
      "DOSING": "100-150mg/kg/day divided in 4 doses,\ndose adjust for renal insufficiency"
    },
    {
      "CATEGORY": "Other",
      "DRUG NAME": "Griseofulvin",
      "MOA": "Binds polymerized microtubules inhibiting fungal mitosis"
    },
    {
      "CATEGORY": "Other",
      "DRUG NAME": "Salicylic Acid",
      "DOSING": "topical"
    },
    {
      "CATEGORY": "Other",
      "DRUG NAME": "Tinactin or Tolnaftate"
    },
    {
      "CATEGORY": "Other",
      "DRUG NAME": "Potassium Iodide"
    }
  ],
  "Cytotoxic Chemotherapy": [
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "cisplatin",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "carboplatin",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "thrombocytopenia,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies",
      "FACTS": "similar to cisplatin in structure, but different ADRS"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "oxaliplatin",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "neuropathy,\nfeel like they can't breathe,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies",
      "FACTS": "modified cisplatin, different ADRS, acts on different types of cancer than cisplatin"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "cyclophosphamide",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "N/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "ifosfamide",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "N/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "carmustine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "lomustine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "procarbazine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "cusulfan",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "melphalan",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "chlorambucil",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "mechlorethamine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "temozolomide/\ndacarbazine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "streptozocin",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "thiotepa",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Antimetabolites",
      "DRUG NAME": "methotrexate",
      "MOA": "insert themselves in place of normal metabolite to build DNA and RNA (works in S phase)",
      "ADRS": "renal toxicity,\nmyelosuppression,\nalopecia,\nN/V/D,\nmucositis",
      "FACTS": "antifolate,\nfirst antimetabolite",
      "DOSING": "give w/ leucovorin (chemoprotective; limits renal toxicity)\nleucovorin MUST be given q6hrs"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "fluorouracil (5FU)",
      "SPECIFIC USES": "colorectal cancer",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "myelosuppression,\nalopecia,\nN/V/D,\nmucositis",
      "FACTS": "often given w/ leucovorin (in this case it increases toxicity of coadministered drug)"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "cytarabine",
      "SPECIFIC USES": "AML",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "cerebellar neurotoxicity (high dose),\nocular irritation\nmyelosuppression,\nalopecia,\nN/V/D,\nmucositis",
      "FACTS": "must do neuro exam before each dose, if fail exam stop drug until they recover from neuro deficits",
      "DOSING": "give w/ eye drops to help ocular irritation"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "capecitabine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hand-foot syndrome,\nmyelosuppression,\nalopecia,\nN/V/D,\nmucositis"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "mercptopurine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "myelosuppression,\nalopecia,\nN/V/D,\nmucositis"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "cladribine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "pentostatin",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "clorfarabine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "pralatrexate",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "pemetrexed",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "azcitidine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "decitabine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "gemcitabine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "thioguanine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "nelarabine",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Natural Product: Antitumor Antibiotics",
      "DRUG NAME": "anthracyclines (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone)",
      "MOA": "block DNA and RNA transcription",
      "ADRS": "cardiotoxicity (CHF),\nmyelosuppression,\nN/V,\nalopecia,\nstomatitis",
      "FACTS": "doxorubicin max lifetime dose: 450mg/m2\ngive dexrazoxane to prevent cardiotoxicity (binds ROS created by doxorubicin)"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "mitomycin",
      "MOA": "cross links DNA",
      "ADRS": "N/V,\nmyelosuppression,\nalopecia,\nstomatitis"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "dactinomycin",
      "MOA": "blocks RNA synthesis",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "bleomycin",
      "MOA": "inhibits DNA synthesis (S phase)",
      "ADRS": "pulmonary toxicity (fibrosis & pneumonitis),\nmyelosuppression,\nN/V,\nalopecia,\nstomatitis",
      "FACTS": "max lifetime dose: 400 units,\nif getting surgery tell anesthesiologist if on or previously on bleomycin"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Natural Product: Anti-Microtubule agents",
      "DRUG NAME": "taxanes \n(docetaxel, paclitaxel, cabazitaxel, nab-paclitaxel)",
      "MOA": "prevent microtubule disassembly",
      "ADRS": "docetaxel\nneuropathies,\nperipheral edema,\nhypersensitivity\npaclitaxel\nneuropathies,\nhypersensitivity rxns",
      "FACTS": "premedicate pt on paclitaxel with H1 and H2 blocker + steroid"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "vinca alkaloids\n(vinblastine, vincristine, vinorelbine)",
      "MOA": "prevent microtubule assembly",
      "ADRS": "vincristine\nneuropathies,\nconstipation,\njaw pain (children)",
      "FACTS": "DO NOT GIVE VINCRISTINE INTRATHECALLY (FATAL)"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Natural Product: Marine Based Products",
      "DRUG NAME": "eribulin",
      "MOA": "microtubule like agent",
      "ADRS": "fatigue,\nperipheral neuropathy,\nchemo induced N/V",
      "FACTS": "sea sponge"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "trabectedin",
      "MOA": "somewhat like an alkylating agent",
      "ADRS": "fatigue,\nhand-foot syndrome,\nchemo induced N/V,\nhepatic damage",
      "FACTS": "sea squirt"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Other Natural Products",
      "DRUG NAME": "Irinotecan",
      "MOA": "topoisomerase I inhibtors",
      "ADRS": "diarrhea (immediate cholinergic reaction)",
      "FACTS": "\"I ran to the can\""
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "topotecan",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "etoposide",
      "SPECIFIC USES": "lung cancer, pediatric cancer",
      "MOA": "topoisomerase II inhibitors",
      "ADRS": "secondary cancers (usually AML)"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "teniposide",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "asparaginase",
      "SPECIFIC USES": "ALL",
      "MOA": "enzyme",
      "ADRS": "hypersensitivity rxn,\npacreatitis,\ncoagulopathies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "pegasparagase",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Hormonal Treatment",
      "DRUG NAME": "tamoxifen",
      "SPECIFIC USES": "hormone receptor positive diseases pre and post menopausal",
      "MOA": "selective estrogen receptor modulator (SERM)",
      "ADRS": "cataracts,\nendometrial cancer,\nvenous thromboembolism",
      "FACTS": "decreases odds of recurrence by 39%,\nincreases 15 yr survival rate by 31%"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "letrozole",
      "SPECIFIC USES": "hormone receptor positive diseases preferably post menopausal",
      "MOA": "aromatase inhibitor",
      "ADRS": "osteoporosis,\nfractures,\narthralgias",
      "FACTS": "can be used pre-menopausal if in combination w/ ovarian suppression"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "anastrozole",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "exemestane",
      "MOA": "prevents cell division by cross linking DNA strands and decreasing synthesis (not specific to  a cell cycle phase)",
      "ADRS": "hearing loss (permanent),\nnephrotoxicity,\nN/V,\nmyelosuppression,\nalopecia,\nsterility/infertility,\nsecondary malignancies"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "LHRH agonists \n(leuprolide, goserelin, triptorelin)",
      "SPECIFIC USES": "prostate cancer, hormone positive breast cancer",
      "MOA": "inhibit release of LH and FSH (which inhibits production of testosterone) from pituitary by negative feedback",
      "ADRS": "tumor flare?"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "LHRH antagonists \n(degarelix)",
      "MOA": "directly inhibits release of LH and FSH"
    },
    {
      "CATEGORY": "Cytotoxic Chemotherapy",
      "SUBCATEGORY": "Alkylating Agents",
      "DRUG NAME": "Antiandrogens\n(bicalutamide, flutamide, nilutamide, enzalutamide, abiraterone)",
      "MOA": "blocks androgen receptor"
    }
  ],
  "Targeted Agents": [
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "bevacizumab",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "sunitinib",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "pazopanib",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "regorafenib",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "EGFR inhibitors",
      "DRUG NAME": "erlotinib",
      "SPECIFIC USES": "lung and colon cancer",
      "MOA": "block epidermal growth factor receptor (EGFR)",
      "ADRS": "acneiform rash",
      "FACTS": "rash may indicate effectiveness,\ntreat rash w/ tetracyclines, topical antibiotics"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "gefitinib",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "alectinib",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "cetuximab",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "panitumumab",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "mTOR inhibitors",
      "DRUG NAME": "everolimus",
      "MOA": "inhibit mammalian target of Rapamycin",
      "ADRS": "hyperglycemia,\nhyperlipidemia,\nmucosal sensitivity,\nulcers",
      "FACTS": "treat mucosal ulcers w/ magic mouthwash"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "sirolimus",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "temsirolimus",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "BCR-ABL mutation inhibition",
      "DRUG NAME": "imatinib",
      "MOA": "inhibit BCR-ABL mutation positive cancers",
      "DDI": "3A4 substrate and inhibitor",
      "ADRS": "edema (periorbital),\nN/V"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "dasatinib",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "DDI": "3A4 substrate  ",
      "ADRS": "neutropenia,\nedema,\nN/V"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "nilotinib",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "DDI": "3A4 substrate",
      "ADRS": "N/V,\nfatigue"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "ponatinib",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "cardiac issues,\nQTc prolongation"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "bosutinib",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "DDI": "3A4 substrate",
      "ADRS": "N/V/D"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "CD20",
      "DRUG NAME": "rituximab",
      "MOA": "target the CD20 on B cells",
      "ADRS": "infusion reactions,\nmyelosuppression"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "ofatumumab",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "obinutuzumab",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "HER2",
      "DRUG NAME": "trastuzumab",
      "SPECIFIC USES": "HER2 positive breast cancer",
      "MOA": "inhibit HER2",
      "ADRS": "cardiotoxicity  "
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "pertuzumab",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "lapatinib",
      "MOA": "blocks vascular endothelial growth factor (VEGF) receptor",
      "DDI": "interactions w/ 3A4 inducers and inhibitors",
      "ADRS": "N/V,\nfatigue,\ndiarrhea,\nhand-foot syndrome"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "Monoclonal antibodies",
      "DRUG NAME": "nilotinib",
      "ADRS": "QTc prolongation",
      "FACTS": "general mab ADRS:\nfatigue,\nhair thinning,\nN/V,\nmyelosuppression,\ndysphonia (voice changes),\nhair depigmentation"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "pazopanib",
      "ADRS": "QTc prolongation,\nhypothyroidism (irreversible)",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "brentuximab",
      "ADRS": "neuropathy ",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "vemurafenib",
      "ADRS": "colitis",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "bortezomib",
      "ADRS": "neuropathies",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "sunitinib",
      "ADRS": "hypothyroidism (irreversible)",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    },
    {
      "CATEGORY": "Targeted Agents",
      "SUBCATEGORY": "VEGF inhibitors",
      "DRUG NAME": "regorafenib",
      "ADRS": "hypertension,\nproteinuria,\nbleeding,\nimpaired wound healing",
      "FACTS": "hypertension may indicate effectiveness,\nhold prior to and following surgery,\ndon't cure cancer but extend life span"
    }
  ],
  "Immunological therapies": [
    {
      "CATEGORY": "Immunological therapies",
      "SUBCATEGORY": "Cancer Vaccine",
      "DRUG NAME": "Sipeulucel-T",
      "SPECIFIC USES": "prostate cancer ",
      "MOA": "take pt's T cells, modify them in a lab to be specific to kill cancer then reinfuse the cells into the pt"
    },
    {
      "CATEGORY": "Immunological therapies",
      "SUBCATEGORY": "PD-1 and PD-L1 inhibitors",
      "DRUG NAME": "pembrolizumab",
      "SPECIFIC USES": "melanoma",
      "MOA": "blocks binding of PD-1 on T cell to PD-L1 on cancer cell which would normally inhbit T cells (blocking binding activates T cells against cancer)",
      "ADRS": "fatigue,\nitching,\nrash"
    },
    {
      "CATEGORY": "Immunological therapies",
      "SUBCATEGORY": "Cancer Vaccine",
      "DRUG NAME": "nivolumab",
      "SPECIFIC USES": "melanoma, lung cancer",
      "MOA": "take pt's T cells, modify them in a lab to be specific to kill cancer then reinfuse the cells into the pt",
      "ADRS": "fatigue,\nmalaise"
    }
  ],
  "H1 Blockers": [
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Dimenhydrinate",
      "SPECIFIC USES": "motion sickness, insomnia",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "most metabolized by 2D6 and 3A4,\navoid use w/ alcohol, hyptonics, benzodiazepines, tricyclic antidepressants, acetylcholinesterase inhibitors, MAOIs",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "strong anticholinergic effects",
      "DOSING": "OTC"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Diphenhydamine",
      "SPECIFIC USES": "allergies, insomnia",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "most metabolized by 2D6 and 3A4,\navoid use w/ alcohol, hyptonics, benzodiazepines, tricyclic antidepressants, acetylcholinesterase inhibitors, MAOIs",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "strong anticholinergic effects",
      "DOSING": "OTC"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Cyclizine",
      "SPECIFIC USES": "motion sickness, vertigo",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "most metabolized by 2D6 and 3A4,\navoid use w/ alcohol, hyptonics, benzodiazepines, tricyclic antidepressants, acetylcholinesterase inhibitors, MAOIs",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "weak anticholinergic effects",
      "DOSING": "OTC"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Meclizine",
      "SPECIFIC USES": "motion sickness, vertigo",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "most metabolized by 2D6 and 3A4,\navoid use w/ alcohol, hyptonics, benzodiazepines, tricyclic antidepressants, acetylcholinesterase inhibitors, MAOIs",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "weak anticholinergic effects",
      "DOSING": "OTC, Rx"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Bromopheniramine",
      "SPECIFIC USES": "allergies ",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "most metabolized by 2D6 and 3A4,\navoid use w/ alcohol, hyptonics, benzodiazepines, tricyclic antidepressants, acetylcholinesterase inhibitors, MAOIs",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "weak anticholinergic effects",
      "DOSING": "OTC,\nusually only as combo"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Chlorpheniramine",
      "SPECIFIC USES": "allergies, insomnia",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "most metabolized by 2D6 and 3A4,\navoid use w/ alcohol, hyptonics, benzodiazepines, tricyclic antidepressants, acetylcholinesterase inhibitors, MAOIs",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "weak anticholinergic effects",
      "DOSING": "OTC"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Hydroxyzine HCl",
      "SPECIFIC USES": "allergies, urticaria",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "most metabolized by 2D6 and 3A4,\navoid use w/ alcohol, hyptonics, benzodiazepines, tricyclic antidepressants, acetylcholinesterase inhibitors, MAOIs",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "moderate anticholinergic effects",
      "DOSING": "Rx"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Hydroxyzine pamoate",
      "SPECIFIC USES": "insomnia, anxiety",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "most metabolized by 2D6 and 3A4,\navoid use w/ alcohol, hyptonics, benzodiazepines, tricyclic antidepressants, acetylcholinesterase inhibitors, MAOIs",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "moderate anticholinergic effects",
      "DOSING": "Rx"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Promethazine",
      "SPECIFIC USES": "alpha blocker, anti-emetic",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "most metabolized by 2D6 and 3A4,\navoid use w/ alcohol, hyptonics, benzodiazepines, tricyclic antidepressants, acetylcholinesterase inhibitors, MAOIs",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "strong anticholinergic effects",
      "DOSING": "Rx"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Cyproheptadine",
      "SPECIFIC USES": "serotonin block, weight gain (cancer &HIV)",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "most metabolized by 2D6 and 3A4,\navoid use w/ alcohol, hyptonics, benzodiazepines, tricyclic antidepressants, acetylcholinesterase inhibitors, MAOIs",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "weak anticholinergic effects",
      "DOSING": "Rx"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "2nd Generation",
      "DRUG NAME": "Azelastine",
      "SPECIFIC USES": "allergic symptoms",
      "MOA": "block H1 (limited access across BBB)",
      "ADRS": "somnolence (at high dose),\nconstipation,\nheadache",
      "FACTS": "better to use in elderly (no BBB penetration),\nfaster onset,\nless frequent dosing",
      "DOSING": "Rx, nasal spray"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Cetirizine",
      "SPECIFIC USES": "motion sickness, insomnia",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "p-gp substrate (careful w/ grapefruit juice)",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "strong anticholinergic effects",
      "DOSING": "OTC, oral"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Desloratidine",
      "SPECIFIC USES": "motion sickness, insomnia",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "metabolized by 3A4 & 2D6 (careful w/ erythromycin, ketoconzaole, clarithrymycin, cimetidine, & grapefruit juice)",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "strong anticholinergic effects",
      "DOSING": "Rx, oral"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Fexofenadine",
      "SPECIFIC USES": "motion sickness, insomnia",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "NOT metabolized by liver",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "strong anticholinergic effects",
      "DOSING": "OTC, oral"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Levocetirizine",
      "SPECIFIC USES": "motion sickness, insomnia",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "p-gp substrate (careful w/ grapefruit juice)",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "strong anticholinergic effects",
      "DOSING": "OTC, oral"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Loratidine",
      "SPECIFIC USES": "motion sickness, insomnia",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "DDI": "metabolized by 3A4 & 2D6 (careful w/ erythromycin, ketoconzaole, clarithrymycin, cimetidine, & grapefruit juice)",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "strong anticholinergic effects",
      "DOSING": "OTC, oral"
    },
    {
      "CATEGORY": "H1 Blockers",
      "SUBCATEGORY": "1st Generation",
      "DRUG NAME": "Olopatidine",
      "SPECIFIC USES": "motion sickness, insomnia",
      "MOA": "block H1 receptors (bronchodilation, stop itching, reduce pain, reduce inflammation, reduce allergic response, anti-emetic, increase appetite)\nanticholinergic effects",
      "ADRS": "constipation,\ncognitive impairment,\nsleepiness,\ndrowsiness,\nhypotension,\ndizziness,\nreflex tachycardia,\ndry mouth,\nincreased urinary retention",
      "FACTS": "strong anticholinergic effects",
      "DOSING": "Rx, nasal spray"
    }
  ],
  "H2 Blockers": [
    {
      "CATEGORY": "H2 Blockers",
      "DRUG NAME": "Ranitidine",
      "SPECIFIC USES": "mild-moderate, infrequent episodic heartburn,\nGERD,\npeptic ulcer disease",
      "MOA": "block H2 receptor (decrease acid secretion from parietal cells of stomach)",
      "DDI": "careful w/ drugs that depend on acid for proper absorption (ketoconazole, itraconazole, calcium carbonate, iron salts, protease inhibitors)",
      "ADRS": "headache,\ndizziness,\nfatigue,\nconsfusion,\ndose related gynecomastia (cimetidine only),\ntolerance can develop w/ daily use",
      "FACTS": "well absorbed,\nwell tolerated,\nself treatment should be limited to no more than twice a day for 2 weeks,\nbest if only taken PRN,\nonset of action: 30-45 min,\nduration of relief: 4-10hrs",
      "DOSING": "available OTC and Rx (OTC usually half Rx doses)"
    },
    {
      "CATEGORY": "H2 Blockers",
      "DRUG NAME": "Cimedtidine",
      "SPECIFIC USES": "mild-moderate, infrequent episodic heartburn,\nGERD,\npeptic ulcer disease",
      "MOA": "block H2 receptor (decrease acid secretion from parietal cells of stomach)",
      "DDI": "inhibits 3A4, 2D6, 1A2, & 2C9 (careful w/ warfarin, phenytoin, amiodarone, antidepressants, cyclosporine, theophylline),\ncareful w/ drugs that depend on acid for proper absorption (ketoconazole, itraconazole, calcium carbonate, iron salts, protease inhibitors)",
      "ADRS": "headache,\ndizziness,\nfatigue,\nconsfusion,\ndose related gynecomastia (cimetidine only),\ntolerance can develop w/ daily use",
      "FACTS": "well absorbed,\nwell tolerated,\nself treatment should be limited to no more than twice a day for 2 weeks,\nbest if only taken PRN,\nonset of action: 30-45 min,\nduration of relief: 4-10hrs",
      "DOSING": "available OTC and Rx (OTC usually half Rx doses)"
    },
    {
      "CATEGORY": "H2 Blockers",
      "DRUG NAME": "Nizatidine",
      "SPECIFIC USES": "mild-moderate, infrequent episodic heartburn,\nGERD,\npeptic ulcer disease",
      "MOA": "block H2 receptor (decrease acid secretion from parietal cells of stomach)",
      "DDI": "careful w/ drugs that depend on acid for proper absorption (ketoconazole, itraconazole, calcium carbonate, iron salts, protease inhibitors)",
      "ADRS": "headache,\ndizziness,\nfatigue,\nconsfusion,\ndose related gynecomastia (cimetidine only),\ntolerance can develop w/ daily use",
      "FACTS": "well absorbed,\nwell tolerated,\nself treatment should be limited to no more than twice a day for 2 weeks,\nbest if only taken PRN,\nonset of action: 30-45 min,\nduration of relief: 4-10hrs",
      "DOSING": "available OTC and Rx (OTC usually half Rx doses)"
    },
    {
      "CATEGORY": "H2 Blockers",
      "DRUG NAME": "Famotidine",
      "SPECIFIC USES": "mild-moderate, infrequent episodic heartburn,\nGERD,\npeptic ulcer disease",
      "MOA": "block H2 receptor (decrease acid secretion from parietal cells of stomach)",
      "DDI": "careful w/ drugs that depend on acid for proper absorption (ketoconazole, itraconazole, calcium carbonate, iron salts, protease inhibitors)",
      "ADRS": "headache,\ndizziness,\nfatigue,\nconsfusion,\ndose related gynecomastia (cimetidine only),\ntolerance can develop w/ daily use",
      "FACTS": "well absorbed,\nwell tolerated,\nself treatment should be limited to no more than twice a day for 2 weeks,\nbest if only taken PRN,\nonset of action: 30-45 min,\nduration of relief: 4-10hrs",
      "DOSING": "available OTC and Rx (OTC usually half Rx doses)"
    }
  ],
  "Anti-Emetic": [
    {
      "CATEGORY": "Anti-Emetic",
      "SUBCATEGORY": "D2 Receptor Antagonists",
      "DRUG NAME": "Compazine (prochlorperazine)",
      "SPECIFIC USES": "anti-emetic,\nmotion sickness (blocks H1)",
      "MOA": "blocks D2 and H1,\nimproved GI motility,\nLES tone",
      "ADRS": "movement disorders,\nprolactin release,\nsedation,\nhypotension"
    },
    {
      "CATEGORY": "Anti-Emetic",
      "SUBCATEGORY": "D2 Receptor Antagonists",
      "DRUG NAME": "Tigan (Trimethobenzamide)",
      "SPECIFIC USES": "anti-emetic,\nmotion sickness (blocks H1)",
      "MOA": "blocks D2 and H1,\nimproved GI motility,\nLES tone",
      "ADRS": "movement disorders,\nprolactin release,\nsedation,\nhypotension"
    },
    {
      "CATEGORY": "Anti-Emetic",
      "SUBCATEGORY": "D2 Receptor Antagonists",
      "DRUG NAME": "Phenergan (promethazine)",
      "SPECIFIC USES": "anti-emetic,\nmotion sickness (blocks H1)",
      "MOA": "blocks D2 and H1,\nimproved GI motility,\nLES tone",
      "ADRS": "movement disorders,\nprolactin release,\nsedation,\nhypotension"
    },
    {
      "CATEGORY": "Anti-Emetic",
      "SUBCATEGORY": "5HT-3 Receptor Antagonists\n(-setron)",
      "DRUG NAME": "Zofran (ondansetron)",
      "SPECIFIC USES": "anti-emetic,\nCINV",
      "MOA": "block 5HT-3 receptors in gut"
    },
    {
      "CATEGORY": "Anti-Emetic",
      "SUBCATEGORY": "D2 Receptor Antagonists",
      "DRUG NAME": "Granisetron",
      "SPECIFIC USES": "anti-emetic,\nmotion sickness (blocks H1)",
      "MOA": "blocks D2 and H1,\nimproved GI motility,\nLES tone"
    },
    {
      "CATEGORY": "Anti-Emetic",
      "SUBCATEGORY": "D2 Receptor Antagonists",
      "DRUG NAME": "Dolasetron",
      "SPECIFIC USES": "anti-emetic,\nmotion sickness (blocks H1)",
      "MOA": "blocks D2 and H1,\nimproved GI motility,\nLES tone"
    },
    {
      "CATEGORY": "Anti-Emetic",
      "SUBCATEGORY": "D2 Receptor Antagonists",
      "DRUG NAME": "Palonesetron",
      "SPECIFIC USES": "anti-emetic,\nmotion sickness (blocks H1)",
      "MOA": "blocks D2 and H1,\nimproved GI motility,\nLES tone"
    },
    {
      "CATEGORY": "Anti-Emetic",
      "DRUG NAME": "Reglan (metoclopramide)",
      "SPECIFIC USES": "Anti-emetic,\nGERD (adjunct agent)",
      "MOA": "D2 & 5HT-3 receptor blocker,\nprokinetic activity",
      "FACTS": "less effective than individual D2 or 5HT-3 blockers"
    },
    {
      "CATEGORY": "Anti-Emetic",
      "DRUG NAME": "Emend (aprepitant/fosaprepitant)",
      "SPECIFIC USES": "PREVENT CINV",
      "MOA": "neurokinin-1 receptor blocker (blocks substance p release in gut)",
      "FACTS": "only used to PRETREAT cancer pt before getting chemo"
    },
    {
      "CATEGORY": "Anti-Emetic",
      "DRUG NAME": "Marinol (dronabinol)",
      "SPECIFIC USES": "CINV,\nanorexia or AIDS related wasting",
      "MOA": "cannabinoid receptor agonist (primarily CB1 in CTZ)",
      "ADRS": "tachycardia,\npalpitations,\neuphoria,\naltered sense of reality,\nxerostomia,\nhunger",
      "FACTS": "withdrawal (insomnia, irritability) \nsimilar effects to marijuana use"
    },
    {
      "CATEGORY": "Anti-Emetic",
      "DRUG NAME": "Cesamet (nabilone)",
      "SPECIFIC USES": "anti-emetic,\nmotion sickness (blocks H1)",
      "MOA": "blocks D2 and H1,\nimproved GI motility,\nLES tone",
      "ADRS": "movement disorders,\nprolactin release,\nsedation,\nhypotension"
    }
  ],
  "Constipation": [
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "Psyllium",
      "SPECIFIC USES": "laxative"
    },
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "Methylcellulose",
      "SPECIFIC USES": "laxative"
    },
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "glycerin",
      "SPECIFIC USES": "laxative"
    },
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "PEG 3350",
      "SPECIFIC USES": "laxative"
    },
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "polycarbophil",
      "SPECIFIC USES": "laxative"
    },
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "milk of magnesia",
      "SPECIFIC USES": "laxative"
    },
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "magnesium citrate",
      "SPECIFIC USES": "laxative"
    },
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "senna",
      "SPECIFIC USES": "laxative"
    },
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "bisacodyl",
      "SPECIFIC USES": "laxative"
    },
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "docusate",
      "SPECIFIC USES": "stool softener"
    },
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "mineral oil",
      "SPECIFIC USES": "lubricant"
    },
    {
      "CATEGORY": "Constipation",
      "SUBCATEGORY": "Mu Antagonist",
      "DRUG NAME": "methylnaltrexone",
      "SPECIFIC USES": "OIC (opioid induced constipation)"
    },
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "naloxegol",
      "SPECIFIC USES": "laxative"
    },
    {
      "CATEGORY": "Constipation",
      "DRUG NAME": "alvimopan",
      "SPECIFIC USES": "laxative"
    }
  ],
  "Diarrhea": [
    {
      "CATEGORY": "Diarrhea",
      "DRUG NAME": "Pepto-Bismol (bismuth sabsalicylate)",
      "ADRS": "malnutrition",
      "FACTS": "can turn tongue and stool black but it's not a serious thing, it will go away upon d/c"
    },
    {
      "CATEGORY": "Diarrhea",
      "DRUG NAME": "Imodium (loperamide)",
      "ADRS": "malnutrition",
      "FACTS": "OTC"
    },
    {
      "CATEGORY": "Diarrhea",
      "DRUG NAME": "Lomotil (diphenoxylate/atropine)",
      "ADRS": "malnutrition",
      "FACTS": "Rx"
    },
    {
      "CATEGORY": "Diarrhea",
      "SUBCATEGORY": "Bile acid Sequestrants",
      "DRUG NAME": "cholestyramine",
      "ADRS": "malnutrition"
    },
    {
      "CATEGORY": "Diarrhea",
      "DRUG NAME": "colestipol",
      "ADRS": "malnutrition"
    },
    {
      "CATEGORY": "Diarrhea",
      "DRUG NAME": "colesevelam",
      "ADRS": "malnutrition"
    }
  ],
  "IBS (irritable bowel syndrome)": [
    {
      "CATEGORY": "IBS (irritable bowel syndrome)",
      "SUBCATEGORY": "IBS-C",
      "DRUG NAME": "Amitiza (lubiprostone)",
      "SPECIFIC USES": "IBS-C,\nOIC",
      "MOA": "activates chloride channel, increased fluid secretion into small intestine, more stools"
    },
    {
      "CATEGORY": "IBS (irritable bowel syndrome)",
      "SUBCATEGORY": "IBS-C",
      "DRUG NAME": "Linzess (linaclotide)",
      "SPECIFIC USES": "IBS-C",
      "MOA": "guanylate cyclase agonist, prokinetic"
    },
    {
      "CATEGORY": "IBS (irritable bowel syndrome)",
      "SUBCATEGORY": "IBS-D",
      "DRUG NAME": "Xifaxan (rifaximin)",
      "SPECIFIC USES": "IBS-D,\ntravelers diarrhea",
      "FACTS": "minimal systemic bioavailability w/ PO"
    },
    {
      "CATEGORY": "IBS (irritable bowel syndrome)",
      "SUBCATEGORY": "IBS-C",
      "DRUG NAME": "Viberzi (eluxadoline)",
      "MOA": "Mu/kappa opioid agonist, delta opioid antagonist"
    },
    {
      "CATEGORY": "IBS (irritable bowel syndrome)",
      "SUBCATEGORY": "IBS-C",
      "DRUG NAME": "Lotronex (alosetron)",
      "SPECIFIC USES": "women w/ IBS-D",
      "MOA": "5HT-3 receptor antagonist",
      "FACTS": "withdrawn from market in 2000 for ischemic colitis, reintroduced in 2002"
    }
  ],
  "Peptic Ulcer Disease": [
    {
      "CATEGORY": "Peptic Ulcer Disease",
      "SUBCATEGORY": "Stomach Protection",
      "DRUG NAME": "Cytotec (misoprostol)",
      "SPECIFIC USES": "ulcer treatment/prophylaxis,\npromote pregnancy termination,\nallow easier delivery",
      "MOA": "prostaglandin E analog (increase PGE1/PGE2), increase mucus production",
      "ADRS": "diarrhea,\nuterine contractions",
      "FACTS": "multiple daily doses"
    },
    {
      "CATEGORY": "Peptic Ulcer Disease",
      "SUBCATEGORY": "Stomach Protection",
      "DRUG NAME": "Carafate (sucralfate)",
      "SPECIFIC USES": "treatment of ulcers",
      "MOA": "forms viscous adhesive coating by binding charged proteins in ulcer",
      "DDI": "many",
      "ADRS": "constipation,\naccumulation in renal insufficiency",
      "FACTS": "aluminum sucrose sulfate; activated by stomach acid"
    },
    {
      "CATEGORY": "Peptic Ulcer Disease",
      "SUBCATEGORY": "H2 receptor antagonists (H2RAs)\n[-tidine]",
      "DRUG NAME": "Zantac (ranitidine)",
      "SPECIFIC USES": "treatment of ulcers,\nGERD",
      "MOA": "reversible binding of H2,\nreduce nocturnal and post prandial acid secretion",
      "ADRS": "potential to build tolerance,\nabrupt d/c can lead to rebound acididty",
      "DOSING": "heartburn/GERD take 30-60 min before meals PRN or for 2-4 wks,\nPUD: 4-8 wks"
    },
    {
      "CATEGORY": "Peptic Ulcer Disease",
      "SUBCATEGORY": "Stomach Protection",
      "DRUG NAME": "Pepcid (famotidine)",
      "SPECIFIC USES": "ulcer treatment/prophylaxis,\npromote pregnancy termination,\nallow easier delivery",
      "MOA": "prostaglandin E analog (increase PGE1/PGE2), increase mucus production",
      "ADRS": "diarrhea,\nuterine contractions"
    },
    {
      "CATEGORY": "Peptic Ulcer Disease",
      "SUBCATEGORY": "Stomach Protection",
      "DRUG NAME": "Axid (nizatidine)",
      "SPECIFIC USES": "ulcer treatment/prophylaxis,\npromote pregnancy termination,\nallow easier delivery",
      "MOA": "prostaglandin E analog (increase PGE1/PGE2), increase mucus production",
      "ADRS": "diarrhea,\nuterine contractions"
    },
    {
      "CATEGORY": "Peptic Ulcer Disease",
      "SUBCATEGORY": "Stomach Protection",
      "DRUG NAME": "Tagamet (cimetidine)",
      "SPECIFIC USES": "ulcer treatment/prophylaxis,\npromote pregnancy termination,\nallow easier delivery",
      "MOA": "prostaglandin E analog (increase PGE1/PGE2), increase mucus production",
      "DDI": "CYP3A4 inhibitor",
      "ADRS": "diarrhea,\nuterine contractions",
      "FACTS": "anti androgen effects"
    },
    {
      "CATEGORY": "Peptic Ulcer Disease",
      "SUBCATEGORY": "Proton Pump Inhibitors (PPIs)\n[-prazole]",
      "DRUG NAME": "Prilosec (omeprazole)",
      "SPECIFIC USES": "treatment of ulcers,\nGERD,\nNOT for PRN use",
      "MOA": "irreversibly bind H+/K+ ATPase pump,\nreduce acid production",
      "DDI": "clopidogrel 2C19 (cardiac events)",
      "ADRS": "osteoporosis, fractures,\nc. diff,\nlow Mg/B12,\npneumonia,\ndementia,\nCKD,\nCAD",
      "FACTS": "delayed onset,\nlong term therapy proving to be dangerous,\ntaper off",
      "DOSING": "heartburn: 30-60 min before meal (except rabeprazole & dexlansoprazole) for 2wks,\nGERD: 4wks,\nPUD: 4-8wks"
    },
    {
      "CATEGORY": "Peptic Ulcer Disease",
      "SUBCATEGORY": "Stomach Protection",
      "DRUG NAME": "Nexium (esomeprazole)",
      "SPECIFIC USES": "ulcer treatment/prophylaxis,\npromote pregnancy termination,\nallow easier delivery",
      "MOA": "prostaglandin E analog (increase PGE1/PGE2), increase mucus production",
      "ADRS": "diarrhea,\nuterine contractions",
      "FACTS": "multiple daily doses"
    },
    {
      "CATEGORY": "Peptic Ulcer Disease",
      "SUBCATEGORY": "Stomach Protection",
      "DRUG NAME": "Prevacid (lansoprazole)",
      "SPECIFIC USES": "ulcer treatment/prophylaxis,\npromote pregnancy termination,\nallow easier delivery",
      "MOA": "prostaglandin E analog (increase PGE1/PGE2), increase mucus production",
      "ADRS": "diarrhea,\nuterine contractions",
      "FACTS": "multiple daily doses"
    },
    {
      "CATEGORY": "Peptic Ulcer Disease",
      "SUBCATEGORY": "Stomach Protection",
      "DRUG NAME": "Protonix (pantoprazole)",
      "SPECIFIC USES": "ulcer treatment/prophylaxis,\npromote pregnancy termination,\nallow easier delivery",
      "MOA": "prostaglandin E analog (increase PGE1/PGE2), increase mucus production",
      "ADRS": "diarrhea,\nuterine contractions",
      "FACTS": "multiple daily doses"
    },
    {
      "CATEGORY": "Peptic Ulcer Disease",
      "SUBCATEGORY": "Stomach Protection",
      "DRUG NAME": "Aciphex (rabeprazole)",
      "SPECIFIC USES": "ulcer treatment/prophylaxis,\npromote pregnancy termination,\nallow easier delivery",
      "MOA": "prostaglandin E analog (increase PGE1/PGE2), increase mucus production",
      "ADRS": "diarrhea,\nuterine contractions",
      "FACTS": "multiple daily doses"
    },
    {
      "CATEGORY": "Peptic Ulcer Disease",
      "SUBCATEGORY": "Stomach Protection",
      "DRUG NAME": "Dexilant (dexlansoprazole)",
      "SPECIFIC USES": "ulcer treatment/prophylaxis,\npromote pregnancy termination,\nallow easier delivery",
      "MOA": "prostaglandin E analog (increase PGE1/PGE2), increase mucus production",
      "ADRS": "diarrhea,\nuterine contractions",
      "FACTS": "multiple daily doses"
    }
  ],
  "GERD": [
    {
      "CATEGORY": "GERD",
      "SUBCATEGORY": "Antacids",
      "DRUG NAME": "Calcium",
      "SPECIFIC USES": "GERD, intermittent symptomatic relief",
      "MOA": "neutralize acid and raise gastric pH",
      "DDI": "Chelation (fluoroquinolones, TCAs, levothyroxine),\nreduced absorption caused by increased pH (azole antifungals, bisphosphonates, iron)",
      "ADRS": "constipation "
    },
    {
      "CATEGORY": "GERD",
      "SUBCATEGORY": "Antacids",
      "DRUG NAME": "Magnesium  ",
      "SPECIFIC USES": "GERD, intermittent symptomatic relief",
      "MOA": "neutralize acid and raise gastric pH",
      "DDI": "Chelation (fluoroquinolones, TCAs, levothyroxine),\nreduced absorption caused by increased pH (azole antifungals, bisphosphonates, iron)",
      "ADRS": "diarrhea,\naccumulation in renal insufficiency"
    },
    {
      "CATEGORY": "GERD",
      "SUBCATEGORY": "Antacids",
      "DRUG NAME": "Aluminum",
      "SPECIFIC USES": "GERD, intermittent symptomatic relief",
      "MOA": "neutralize acid and raise gastric pH",
      "DDI": "Chelation (fluoroquinolones, TCAs, levothyroxine),\nreduced absorption caused by increased pH (azole antifungals, bisphosphonates, iron)",
      "ADRS": "constipation,\naccumulation in renal insufficiency"
    }
  ],
  "Inflammitory Bowel Disease (IBD)": [
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Rowasa (Mesalamine (5-ASA))",
      "SPECIFIC USES": "rectum, sigmoid colon",
      "MOA": "scavenger of free radicals,\nblocks production and chemotaxis of leukotrienes & prostaglandins",
      "ADRS": "headache,\nnausea,\nabdominal pain,\nGI upset",
      "DOSING": "enema"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Cansa (Mesalamine (5-ASA))",
      "SPECIFIC USES": "rectum ",
      "MOA": "scavenger of free radicals,\nblocks production and chemotaxis of leukotrienes & prostaglandins",
      "ADRS": "headache,\nnausea,\nabdominal pain,\nGI upset",
      "DOSING": "suppository"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Lialda (Mesalamine)",
      "SPECIFIC USES": "rectum, sigmoid colon, left colon, right colon",
      "MOA": "scavenger of free radicals,\nblocks production and chemotaxis of leukotrienes & prostaglandins",
      "ADRS": "headache,\nnausea,\nabdominal pain,\nGI upset",
      "DOSING": "PO extended release"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Apriso (Mesalamine)",
      "SPECIFIC USES": "rectum, sigmoid colon",
      "MOA": "scavenger of free radicals,\nblocks production and chemotaxis of leukotrienes & prostaglandins",
      "ADRS": "headache,\nnausea,\nabdominal pain,\nGI upset",
      "DOSING": "PO extended release"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Asacol (Mesalamine)",
      "SPECIFIC USES": "rectum, sigmoid colon, left colon, right colon, terminal ileum",
      "MOA": "scavenger of free radicals,\nblocks production and chemotaxis of leukotrienes & prostaglandins",
      "ADRS": "headache,\nnausea,\nabdominal pain,\nGI upset",
      "DOSING": "PO extended release"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Delzicol (Mesalamine)",
      "SPECIFIC USES": "rectum, sigmoid colon",
      "MOA": "scavenger of free radicals,\nblocks production and chemotaxis of leukotrienes & prostaglandins",
      "ADRS": "headache,\nnausea,\nabdominal pain,\nGI upset",
      "DOSING": "PO extended release"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Pentasa (Mesalamine)",
      "SPECIFIC USES": "rectum, sigmoid colon, left colon, right colon, terminal ileum, ileum, jejunum, duodenum",
      "MOA": "scavenger of free radicals,\nblocks production and chemotaxis of leukotrienes & prostaglandins",
      "ADRS": "headache,\nnausea,\nabdominal pain,\nGI upset",
      "DOSING": "PO extended release"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Sulfasalazine",
      "SPECIFIC USES": "rectum, sigmoid colon, left colon, right colon",
      "MOA": "scavenger of free radicals,\nblocks production and chemotaxis of leukotrienes & prostaglandins",
      "ADRS": "orange/yellow skin/urine discoloration,\nphotosensitivity,\nhemolytic anemia (w/ G6PD deficiency),\nfolic acid malabsorption",
      "FACTS": "C/I: sulfa and salicylate allergies,\nprodrug of mesalamine",
      "DOSING": "PO  "
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Balsalazide",
      "SPECIFIC USES": "rectum, sigmoid colon",
      "MOA": "scavenger of free radicals,\nblocks production and chemotaxis of leukotrienes & prostaglandins",
      "FACTS": "prodrug of mesalamine",
      "DOSING": "PO  "
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Olsalazine",
      "SPECIFIC USES": "rectum, sigmoid colon",
      "MOA": "scavenger of free radicals,\nblocks production and chemotaxis of leukotrienes & prostaglandins",
      "FACTS": "prodrug of mesalamine",
      "DOSING": "PO"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Corticosteroids",
      "DRUG NAME": "Budesonide",
      "SPECIFIC USES": "mild/moderate CD in ascending/right colon or ileum,\ninduce remission in UC"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Hydrocortisone",
      "SPECIFIC USES": "CD or UC in rectum (enema),\nrelapses (PO/IV)",
      "DOSING": "enema, PO/IV"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Prednisone",
      "SPECIFIC USES": "relapses ",
      "DOSING": "PO/IV"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Methylprednisolone",
      "SPECIFIC USES": "rectum, sigmoid colon",
      "DOSING": "enema"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Immunomodulators",
      "DRUG NAME": "Azathioprine (AZA)/ \n6-mercaptopurine (6-MP)",
      "SPECIFIC USES": "maintenance of CD & UC,\nNOT used for induction",
      "MOA": "inhibits T lymphocytes (AZA),\ninhibits DNA synthesis (6-MP)",
      "ADRS": "bone marrow suppression,\nhepatotoxicity,\npancreatitis,\ninfections,\nrisk of lymphoma",
      "FACTS": "used in combo w/ steroids when initiating treatment due to delayed onset (3 months to 1 year)"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Methotrexate (MTX)",
      "SPECIFIC USES": "induction or maintenance of CD",
      "MOA": "inhibit dihydrofolate reductase and DNA synthesis",
      "ADRS": "myelosupression,\nnausea,\nhepatotoxicity",
      "FACTS": "avoid live vaccines,\nmay need to administer w/ folic acid"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Cyclosporine",
      "SPECIFIC USES": "severe, refractory cases",
      "MOA": "calcineurin inhibitor",
      "ADRS": "nephrotoxicity,\ntremor,\nhypertension,\nhyperlipidemia",
      "DOSING": "induction: IV\nmaintenance: PO w/ AZA/6-MP"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "TNF inhibitors",
      "DRUG NAME": "Remicade (infliximab)",
      "SPECIFIC USES": "moderate/severe UC or CD,\nfistulizing CD",
      "ADRS": "hepatoxicity,\ninfections,\npsoriasis,\ndemyelinating disorders,\nneutropenia,\npancytopenia,\nantibodies can form over time,\nincreased lymphoma risk",
      "FACTS": "only used when conventional therapies fail,\nget baseline CXR/PPD and LFTs,\ncaution in moderate/severe heart failure",
      "DOSING": "IV"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Humira (adalimumab)",
      "SPECIFIC USES": "moderate/severe UC or CD",
      "ADRS": "headache,\nnausea,\nabdominal pain,\nGI upset",
      "DOSING": "SQ"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Cimzia (certolizumab)",
      "SPECIFIC USES": "moderate/severe UC or CD",
      "ADRS": "headache,\nnausea,\nabdominal pain,\nGI upset",
      "DOSING": "SQ"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Simponi (golimumab)",
      "SPECIFIC USES": "moderate/severe UC",
      "ADRS": "headache,\nnausea,\nabdominal pain,\nGI upset",
      "DOSING": "SQ"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Anti-⍶4 integrin",
      "DRUG NAME": "Entyvio (vedolizumab)",
      "SPECIFIC USES": "moderate/severe UC or CD when conventional therapies fail",
      "MOA": "Anti-⍶4 integrin",
      "ADRS": "hepatotoxicity,\nacute hypersensitivity infusion rxns,\ninfections,\nfatigue,\ndepression",
      "FACTS": "less pronounced ADRS than Tysabri,\nminimal PML concern (no cases yet)",
      "DOSING": "IV"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "SUBCATEGORY": "Aminosalicylates",
      "DRUG NAME": "Tysabri (natalizumab)",
      "SPECIFIC USES": "moderate/severe CD when conventional therapies fail (LAST LINE)",
      "MOA": "scavenger of free radicals,\nblocks production and chemotaxis of leukotrienes & prostaglandins",
      "ADRS": "hepatotoxicity,\nacute hypersensitivity infusion rxns,\ninfections,\nfatigue,\ndepression,\nPML (progressive multifocal leukoencephalopathy)",
      "FACTS": "PML risk increases w/ each infusion",
      "DOSING": "IV"
    },
    {
      "CATEGORY": "Inflammitory Bowel Disease (IBD)",
      "DRUG NAME": "Stelara (ustekinumab)",
      "SPECIFIC USES": "moderate/severe CD when conventional therapies fail,\nmoderate/severe plaque psoriasis,\ntreatment of active psoriatic arthritis",
      "MOA": "IL-12 and IL-23 blocker",
      "ADRS": "immunosuppression",
      "DOSING": "induction: weight based IV over 1hr\n8wks after induction: 90mg SQ q8wks"
    }
  ],
  "Short Acting Beta Agonists (SABA)": [
    {
      "CATEGORY": "Short Acting Beta Agonists (SABA)",
      "DRUG NAME": "Albuterol",
      "SPECIFIC USES": "acute asthma attack, exercise enduced asthma",
      "MOA": "stimulate beta-2 receptor in lungs, increase cAMP, bronchodilation",
      "ADRS": "mouth irritation, \ncough,\nat high doses:\nskeletal muscle tremor,\ntachycardia,\narrhythmia,\ntolerance",
      "DOSING": "onset: 15 min,\nduration: 3-4 hrs,\ninhaled product"
    },
    {
      "CATEGORY": "Short Acting Beta Agonists (SABA)",
      "DRUG NAME": "Levalbuterol",
      "SPECIFIC USES": "acute asthma attack, exercise enduced asthma",
      "MOA": "stimulate beta-2 receptor in lungs, increase cAMP, bronchodilation",
      "ADRS": "mouth irritation, \ncough,\nat high doses:\nskeletal muscle tremor,\ntachycardia,\narrhythmia,\ntolerance",
      "FACTS": "racemic mixture of albuterol made to counter cardiac ADRS",
      "DOSING": "onset: 15 min,\nduration: 3-4 hrs,\ninhaled product"
    }
  ],
  "Long Acting Beta Agonists (LABA)": [
    {
      "CATEGORY": "Long Acting Beta Agonists (LABA)",
      "DRUG NAME": "Salmeterol (Serevent)",
      "SPECIFIC USES": "monotherapy for COPD,\nasthma (administered w/ inhaled corticosteroid)",
      "MOA": "stimulate beta-2 receptor in lungs, increase cAMP, bronchodilation",
      "ADRS": "mouth irritation, \ncough,\nat high doses:\nskeletal muscle tremor,\ntachycardia,\narrhythmia,\ntolerance",
      "DOSING": "tolerance less of an issue since dosing is daily (harder to over use)"
    },
    {
      "CATEGORY": "Long Acting Beta Agonists (LABA)",
      "DRUG NAME": "Formoterol (Foradil)",
      "SPECIFIC USES": "monotherapy for COPD,\nasthma (administered w/ inhaled corticosteroid)",
      "MOA": "stimulate beta-2 receptor in lungs, increase cAMP, bronchodilation",
      "ADRS": "mouth irritation, \ncough,\nat high doses:\nskeletal muscle tremor,\ntachycardia,\narrhythmia,\ntolerance",
      "DOSING": "tolerance less of an issue since dosing is daily (harder to over use)"
    },
    {
      "CATEGORY": "Long Acting Beta Agonists (LABA)",
      "DRUG NAME": "Indacaterol (Arcapta)",
      "SPECIFIC USES": "monotherapy for COPD,\nasthma (administered w/ inhaled corticosteroid)",
      "MOA": "stimulate beta-2 receptor in lungs, increase cAMP, bronchodilation",
      "ADRS": "mouth irritation, \ncough,\nat high doses:\nskeletal muscle tremor,\ntachycardia,\narrhythmia,\ntolerance",
      "DOSING": "tolerance less of an issue since dosing is daily (harder to over use)"
    },
    {
      "CATEGORY": "Long Acting Beta Agonists (LABA)",
      "DRUG NAME": "Olodaterol (Striverdi Respimat)",
      "SPECIFIC USES": "monotherapy for COPD,\nasthma (administered w/ inhaled corticosteroid)",
      "MOA": "stimulate beta-2 receptor in lungs, increase cAMP, bronchodilation",
      "ADRS": "mouth irritation, \ncough,\nat high doses:\nskeletal muscle tremor,\ntachycardia,\narrhythmia,\ntolerance",
      "DOSING": "tolerance less of an issue since dosing is daily (harder to over use)"
    },
    {
      "CATEGORY": "Long Acting Beta Agonists (LABA)",
      "DRUG NAME": "Bilanerol (Breo Ellipta)",
      "SPECIFIC USES": "monotherapy for COPD,\nasthma (administered w/ inhaled corticosteroid)",
      "MOA": "stimulate beta-2 receptor in lungs, increase cAMP, bronchodilation",
      "ADRS": "mouth irritation, \ncough,\nat high doses:\nskeletal muscle tremor,\ntachycardia,\narrhythmia,\ntolerance",
      "DOSING": "tolerance less of an issue since dosing is daily (harder to over use)"
    }
  ],
  "Muscarinic Antagonists": [
    {
      "CATEGORY": "Muscarinic Antagonists",
      "DRUG NAME": "Ipratropium (Atrovent)",
      "SPECIFIC USES": "COPD",
      "MOA": "block muscarinic receptors, block Ach actions in airway (vasoconstriction)\n(no effects on inflammation)",
      "ADRS": "dry mouth,\ndry eyes,\nbitter metallic taste,\nconstipation,\nurinary retention"
    },
    {
      "CATEGORY": "Muscarinic Antagonists",
      "DRUG NAME": "Aclidinium (Tudorza Pressair)",
      "SPECIFIC USES": "COPD",
      "MOA": "block muscarinic receptors, block Ach actions in airway (vasoconstriction)\n(no effects on inflammation)",
      "ADRS": "dry mouth,\ndry eyes,\nbitter metallic taste,\nconstipation,\nurinary retention"
    },
    {
      "CATEGORY": "Muscarinic Antagonists",
      "DRUG NAME": "Umeclindinium (Incruze Elipta)",
      "SPECIFIC USES": "COPD",
      "MOA": "block muscarinic receptors, block Ach actions in airway (vasoconstriction)\n(no effects on inflammation)",
      "ADRS": "dry mouth,\ndry eyes,\nbitter metallic taste,\nconstipation,\nurinary retention"
    },
    {
      "CATEGORY": "Muscarinic Antagonists",
      "DRUG NAME": "Tiotropium (Spiriva)",
      "SPECIFIC USES": "COPD, moderate to severe asthma",
      "MOA": "block muscarinic receptors, block Ach actions in airway (vasoconstriction)\n(no effects on inflammation)",
      "ADRS": "dry mouth,\ndry eyes,\nbitter metallic taste,\nconstipation,\nurinary retention",
      "FACTS": "add-on treatment for pt >12 yrs old w/ history of exacerbation despite conventional therapy"
    }
  ],
  "Methylxanthine Derivative": [
    {
      "CATEGORY": "Methylxanthine Derivative",
      "DRUG NAME": "Theophylline (Theo-Dur)",
      "MOA": "non-selectively inhibits PDE, increased cAMP, bronchodilation,\nblock adenosine receptors in CNS",
      "DDI": "metabolized by 1A2",
      "ADRS": "GI distress,\ntremor,\ninsomnia,\noverdose (severe N/V, hypotension, agitation, arrhythmias, cardiac arrest, seizures),\nsystemic effects (insomnia, seizure, alertness, cardiac stimulation, smooth muscle relaxant, weak diuretic, enhanced gastric acid secretion)",
      "FACTS": "duration: 12hrs,\nrequires high concentration to be effective,\nclearance mediated by age, smoking status, and other drugs (smokers clear faster, younger pt clear faster),\nmonitor therapeutic level (range: 10-20 mcg/ml)",
      "DOSING": "PO"
    }
  ],
  "PDE-4 Inhibitors": [
    {
      "CATEGORY": "PDE-4 Inhibitors",
      "DRUG NAME": "Roflumilast (Daliresp)",
      "SPECIFIC USES": "severe COPD",
      "MOA": "inhibit PDE-4, increase cAMP, brochodilation",
      "DDI": "metabolized by 3A4",
      "ADRS": "diarrhea, \nnausea,\nabdominal pain,\nheadache,\ndyspepsia,\npsychiatric events,\nweight loss",
      "FACTS": "always used in combination w/ at least 1 other long-acting bronchodilatior for COPD",
      "DOSING": "PO once daily"
    }
  ],
  "Corticosteroids": [
    {
      "CATEGORY": "Corticosteroids",
      "SUBCATEGORY": "Inhaled",
      "DRUG NAME": "Beclomethasone (Qvar)",
      "SPECIFIC USES": "prophylaxis only,\npersistent asthma,\nPO/IV reserved for acute exacerbation",
      "MOA": "inhibit inflammitory cell migration & activation,\ninhibit cytokine & mediator release,\nupregulate B2 receptors,\ninhibit IgE synthesis\n(takes 4-6 wks for clinical effect)",
      "ADRS": "thrush (counsel to rinse mouth after each use),\ndysphonia,\nsore throat,\ncough",
      "DOSING": "ok to use in kids (stunts growth but is not progressive; 1.2cm shorter)"
    },
    {
      "CATEGORY": "Corticosteroids",
      "SUBCATEGORY": "Inhaled",
      "DRUG NAME": "Budesonide (Pulmicort)",
      "SPECIFIC USES": "prophylaxis only,\npersistent asthma,\nPO/IV reserved for acute exacerbation",
      "MOA": "inhibit inflammitory cell migration & activation,\ninhibit cytokine & mediator release,\nupregulate B2 receptors,\ninhibit IgE synthesis\n(takes 4-6 wks for clinical effect)",
      "ADRS": "thrush (counsel to rinse mouth after each use),\ndysphonia,\nsore throat,\ncough",
      "FACTS": "safest in pregnancy",
      "DOSING": "ok to use in kids (stunts growth but is not progressive; 1.2cm shorter)"
    },
    {
      "CATEGORY": "Corticosteroids",
      "SUBCATEGORY": "Inhaled",
      "DRUG NAME": "Fluticasone propionate (Flovent)",
      "SPECIFIC USES": "prophylaxis only,\npersistent asthma,\nPO/IV reserved for acute exacerbation",
      "MOA": "inhibit inflammitory cell migration & activation,\ninhibit cytokine & mediator release,\nupregulate B2 receptors,\ninhibit IgE synthesis\n(takes 4-6 wks for clinical effect)",
      "ADRS": "thrush (counsel to rinse mouth after each use),\ndysphonia,\nsore throat,\ncough",
      "FACTS": "most potent",
      "DOSING": "ok to use in kids (stunts growth but is not progressive; 1.2cm shorter)"
    },
    {
      "CATEGORY": "Corticosteroids",
      "SUBCATEGORY": "Inhaled",
      "DRUG NAME": "Fluticasone furorate (Arnuity)",
      "SPECIFIC USES": "prophylaxis only,\npersistent asthma,\nPO/IV reserved for acute exacerbation",
      "MOA": "inhibit inflammitory cell migration & activation,\ninhibit cytokine & mediator release,\nupregulate B2 receptors,\ninhibit IgE synthesis\n(takes 4-6 wks for clinical effect)",
      "ADRS": "thrush (counsel to rinse mouth after each use),\ndysphonia,\nsore throat,\ncough",
      "DOSING": "ok to use in kids (stunts growth but is not progressive; 1.2cm shorter)"
    },
    {
      "CATEGORY": "Corticosteroids",
      "SUBCATEGORY": "Inhaled",
      "DRUG NAME": "Mometasone (Asmanex)",
      "SPECIFIC USES": "prophylaxis only,\npersistent asthma,\nPO/IV reserved for acute exacerbation",
      "MOA": "inhibit inflammitory cell migration & activation,\ninhibit cytokine & mediator release,\nupregulate B2 receptors,\ninhibit IgE synthesis\n(takes 4-6 wks for clinical effect)",
      "ADRS": "thrush (counsel to rinse mouth after each use),\ndysphonia,\nsore throat,\ncough",
      "DOSING": "ok to use in kids (stunts growth but is not progressive; 1.2cm shorter)"
    },
    {
      "CATEGORY": "Corticosteroids",
      "SUBCATEGORY": "Inhaled",
      "DRUG NAME": "Fluisolide (Aerospan)",
      "SPECIFIC USES": "prophylaxis only,\npersistent asthma,\nPO/IV reserved for acute exacerbation",
      "MOA": "inhibit inflammitory cell migration & activation,\ninhibit cytokine & mediator release,\nupregulate B2 receptors,\ninhibit IgE synthesis\n(takes 4-6 wks for clinical effect)",
      "ADRS": "thrush (counsel to rinse mouth after each use),\ndysphonia,\nsore throat,\ncough",
      "DOSING": "ok to use in kids (stunts growth but is not progressive; 1.2cm shorter)"
    },
    {
      "CATEGORY": "Corticosteroids",
      "SUBCATEGORY": "Inhaled",
      "DRUG NAME": "Ciclesonide (Alvesco)",
      "SPECIFIC USES": "prophylaxis only,\npersistent asthma,\nPO/IV reserved for acute exacerbation",
      "MOA": "inhibit inflammitory cell migration & activation,\ninhibit cytokine & mediator release,\nupregulate B2 receptors,\ninhibit IgE synthesis\n(takes 4-6 wks for clinical effect)",
      "ADRS": "thrush (counsel to rinse mouth after each use),\ndysphonia,\nsore throat,\ncough",
      "DOSING": "ok to use in kids (stunts growth but is not progressive; 1.2cm shorter)"
    },
    {
      "CATEGORY": "Corticosteroids",
      "SUBCATEGORY": "PO/IV",
      "DRUG NAME": "Prednisone (Deltasone)",
      "SPECIFIC USES": "prophylaxis only,\npersistent asthma,\nPO/IV reserved for acute exacerbation",
      "MOA": "inhibit inflammitory cell migration & activation,\ninhibit cytokine & mediator release,\nupregulate B2 receptors,\ninhibit IgE synthesis\n(takes 4-6 wks for clinical effect)",
      "ADRS": "adrenal suppression,\nCushing's syndrome,\ngrowth retardation,\nosteoporosis,\nglucose intolerance,\nincreased risk of infection,\nmood changes,\nweight gain,\nedema",
      "DOSING": "ok to use in kids (stunts growth but is not progressive; 1.2cm shorter)"
    },
    {
      "CATEGORY": "Corticosteroids",
      "SUBCATEGORY": "Inhaled",
      "DRUG NAME": "Prenisolone (Prelone)",
      "SPECIFIC USES": "prophylaxis only,\npersistent asthma,\nPO/IV reserved for acute exacerbation",
      "MOA": "inhibit inflammitory cell migration & activation,\ninhibit cytokine & mediator release,\nupregulate B2 receptors,\ninhibit IgE synthesis\n(takes 4-6 wks for clinical effect)",
      "ADRS": "thrush (counsel to rinse mouth after each use),\ndysphonia,\nsore throat,\ncough",
      "DOSING": "ok to use in kids (stunts growth but is not progressive; 1.2cm shorter)"
    },
    {
      "CATEGORY": "Corticosteroids",
      "SUBCATEGORY": "Inhaled",
      "DRUG NAME": "Methylprednisolone (Medrol, Solumedrol)",
      "SPECIFIC USES": "prophylaxis only,\npersistent asthma,\nPO/IV reserved for acute exacerbation",
      "MOA": "inhibit inflammitory cell migration & activation,\ninhibit cytokine & mediator release,\nupregulate B2 receptors,\ninhibit IgE synthesis\n(takes 4-6 wks for clinical effect)",
      "ADRS": "thrush (counsel to rinse mouth after each use),\ndysphonia,\nsore throat,\ncough",
      "DOSING": "ok to use in kids (stunts growth but is not progressive; 1.2cm shorter)"
    },
    {
      "CATEGORY": "Corticosteroids",
      "SUBCATEGORY": "Inhaled",
      "DRUG NAME": "Hydrocortisone (Hydrocortone)",
      "SPECIFIC USES": "prophylaxis only,\npersistent asthma,\nPO/IV reserved for acute exacerbation",
      "MOA": "inhibit inflammitory cell migration & activation,\ninhibit cytokine & mediator release,\nupregulate B2 receptors,\ninhibit IgE synthesis\n(takes 4-6 wks for clinical effect)",
      "ADRS": "thrush (counsel to rinse mouth after each use),\ndysphonia,\nsore throat,\ncough",
      "DOSING": "ok to use in kids (stunts growth but is not progressive; 1.2cm shorter)"
    }
  ],
  "Leukotriene Antagonists": [
    {
      "CATEGORY": "Leukotriene Antagonists",
      "SUBCATEGORY": "Lipoxygenase inhibitors",
      "DRUG NAME": "Zileuton (Zyflo)",
      "MOA": "inhibit actions of 5-lipoxygenase (inhibits synthesis of leukotrienes)",
      "ADRS": "headache,\ninsomnia,\nsomnolence,\nGI upset,\nhepatotoxicity (do not use if LFT's >3x normal upper limit)",
      "FACTS": "females >65 and pt w/ pre-existing LFT elevation at highest risk for hepatotoxicity"
    },
    {
      "CATEGORY": "Leukotriene Antagonists",
      "SUBCATEGORY": "Leukotriene Receptor Antagonists",
      "DRUG NAME": "Montelukast (Singulair)",
      "SPECIFIC USES": "asthma,\nallergic symptoms,\nexercise induced bronchospasm,\nurticaria (hives)",
      "MOA": "competitively blocks actions of leukotrienes at LTD4 receptor",
      "ADRS": "headache,\nneuropsychiatric events (black box warning)",
      "DOSING": "PO"
    },
    {
      "CATEGORY": "Leukotriene Antagonists",
      "SUBCATEGORY": "Lipoxygenase inhibitors",
      "DRUG NAME": "Zafirlukast (Accolate)",
      "MOA": "inhibit actions of 5-lipoxygenase (inhibits synthesis of leukotrienes)",
      "DDI": "warfarin",
      "ADRS": "headache,\nneuropsychiatric events (black box warning),\nhepatotoxicity",
      "DOSING": "PO"
    }
  ],
  "Mast Cell Stabilizers": [
    {
      "CATEGORY": "Mast Cell Stabilizers",
      "DRUG NAME": "Cromolyn sodium (Intal)",
      "SPECIFIC USES": "mild to moderate asthma",
      "MOA": "block influx of Ca preventing mast cell degranulation (prevent inflammatory mediators)",
      "ADRS": "mild throat irritation,\ncough,\nbad taste in mouth",
      "FACTS": "clinical improvement in 2-6 wks,\nnot used much",
      "DOSING": "nebulizer only,\n4 times a day dosing"
    },
    {
      "CATEGORY": "Mast Cell Stabilizers",
      "DRUG NAME": "Nedocromil Sodium (Tilade)",
      "SPECIFIC USES": "mild to moderate asthma",
      "MOA": "block influx of Ca preventing mast cell degranulation (prevent inflammatory mediators)",
      "ADRS": "mild throat irritation,\ncough,\nbad taste in mouth",
      "FACTS": "clinical improvement in 2-6 wks,\nnot used much",
      "DOSING": "nebulizer only,\n4 times a day dosing"
    }
  ],
  "Immunotherapy": [
    {
      "CATEGORY": "Immunotherapy",
      "SUBCATEGORY": "Anti IgE Agents",
      "DRUG NAME": "Omalizumab (Xolair)",
      "SPECIFIC USES": "allergic asthma in pt >12 yrs old",
      "MOA": "inhibits binding of IgE to mast cells and basophils (inhibits release of inflammitory mediators)",
      "ADRS": "injection site reactions,\nanaphylaxis,\narthralgia,\nheadache,\npharyngitis,\nsinusitis,\nmalignancies?",
      "FACTS": "clinical improvement can take up to 12 wks,\nadminister dose in providers office to watch for possible anaphylaxis (within 1-2 hrs after dose)",
      "DOSING": "dose based/adjusted for IgE level and body weight"
    },
    {
      "CATEGORY": "Immunotherapy",
      "SUBCATEGORY": "IL-5 Antagonists",
      "DRUG NAME": "Mepolizumab",
      "SPECIFIC USES": "maintenance of severe asthma for pt w/ continued exacerbations,\nnot used as monotherapy",
      "MOA": "reduce amount of eosinophils in blood (reduces proinflammitory effects)",
      "ADRS": "injection site reactions,\nheadache,\nanaphylaxis,\nmalignancy,\nmuscle & face pain",
      "FACTS": "administer dose in office to watch for anaphylaxis",
      "DOSING": "SQ q4wks"
    },
    {
      "CATEGORY": "Immunotherapy",
      "SUBCATEGORY": "Anti IgE Agents",
      "DRUG NAME": "Reslizumab",
      "SPECIFIC USES": "allergic asthma in pt >12 yrs old",
      "MOA": "inhibits binding of IgE to mast cells and basophils (inhibits release of inflammitory mediators)",
      "ADRS": "injection site reactions,\nanaphylaxis,\narthralgia,\nheadache,\npharyngitis,\nsinusitis,\nmalignancies?",
      "FACTS": "clinical improvement can take up to 12 wks,\nadminister dose in providers office to watch for possible anaphylaxis (within 1-2 hrs after dose)",
      "DOSING": "IV q4wks"
    }
  ],
  "Acne Therapy": [
    {
      "CATEGORY": "Acne Therapy",
      "SUBCATEGORY": "Topical Retinoids (vitamin A derivatives)",
      "DRUG NAME": "Adapalene (Differin)"
    },
    {
      "CATEGORY": "Acne Therapy",
      "SUBCATEGORY": "Topical Retinoids (vitamin A derivatives)",
      "DRUG NAME": "Tretinoin "
    },
    {
      "CATEGORY": "Acne Therapy",
      "SUBCATEGORY": "Topical Retinoids (vitamin A derivatives)",
      "DRUG NAME": "Tazarotene"
    },
    {
      "CATEGORY": "Acne Therapy",
      "SUBCATEGORY": "Topical Retinoids (vitamin A derivatives)",
      "DRUG NAME": "Bexarotene"
    },
    {
      "CATEGORY": "Acne Therapy",
      "DRUG NAME": "Benzoyl peroxide",
      "SPECIFIC USES": "OTC cleansers/creams",
      "ADRS": "stains clothes/sheets orange, \nphotosensitivity (avoid sun exposure)"
    },
    {
      "CATEGORY": "Acne Therapy",
      "DRUG NAME": "Salicylic acid",
      "SPECIFIC USES": "OTC cleansers, facial pads"
    },
    {
      "CATEGORY": "Acne Therapy",
      "DRUG NAME": "Azelaic acid"
    },
    {
      "CATEGORY": "Acne Therapy",
      "DRUG NAME": "Isotretinoin",
      "ADRS": "arthralgias, \nlipid/sugar elevations,\nhearing loss (maybe permanent),\nagitation/mood swings,\nteratogenic",
      "DOSING": "PO"
    },
    {
      "CATEGORY": "Acne Therapy",
      "SUBCATEGORY": "Antibiotics",
      "DRUG NAME": "Clindamycin",
      "SPECIFIC USES": "active agains P. acnes",
      "DOSING": "usually topical, sometimes given PO"
    },
    {
      "CATEGORY": "Acne Therapy",
      "SUBCATEGORY": "Topical Retinoids (vitamin A derivatives)",
      "DRUG NAME": "Tetracyclines"
    },
    {
      "CATEGORY": "Acne Therapy",
      "SUBCATEGORY": "Topical Retinoids (vitamin A derivatives)",
      "DRUG NAME": "Erythromycin"
    },
    {
      "CATEGORY": "Acne Therapy",
      "SUBCATEGORY": "Androgen related",
      "DRUG NAME": "Oral Contraceptives"
    },
    {
      "CATEGORY": "Acne Therapy",
      "SUBCATEGORY": "Topical Retinoids (vitamin A derivatives)",
      "DRUG NAME": "Spironolactone",
      "MOA": "aldosterone antagonist, androgen blocker"
    }
  ],
  "Eczema": [
    {
      "CATEGORY": "Eczema",
      "SUBCATEGORY": "Antihistamines"
    },
    {
      "CATEGORY": "Eczema",
      "SUBCATEGORY": "Topical/systemic steroids",
      "FACTS": "take a few weeks to manifest results"
    },
    {
      "CATEGORY": "Eczema",
      "SUBCATEGORY": "Topical/systemic immune suppressants",
      "DRUG NAME": "tacrolimus"
    }
  ],
  "Psoriasis": [
    {
      "CATEGORY": "Psoriasis",
      "SUBCATEGORY": "topical treatments",
      "DRUG NAME": "steroids",
      "SPECIFIC USES": "High potency: severe dermatoses over non-facial areas (palms and soles),\nMedium potency: mild-moderate non-facial and non-intertriginous dermatoses,\nlow potency: eyelid and genital dermatoses, larger skin areas"
    },
    {
      "CATEGORY": "Psoriasis",
      "SUBCATEGORY": "topical treatments",
      "DRUG NAME": "retinoids"
    },
    {
      "CATEGORY": "Psoriasis",
      "SUBCATEGORY": "topical treatments",
      "DRUG NAME": "vitamin D analogs"
    },
    {
      "CATEGORY": "Psoriasis",
      "SUBCATEGORY": "systemic medications",
      "DRUG NAME": "biologics"
    },
    {
      "CATEGORY": "Psoriasis",
      "SUBCATEGORY": "topical treatments",
      "DRUG NAME": "steroids"
    },
    {
      "CATEGORY": "Psoriasis",
      "SUBCATEGORY": "light therapy"
    }
  ],
  "Topical Antibiotics": [
    {
      "CATEGORY": "Topical Antibiotics",
      "DRUG NAME": "Bacitracin",
      "SPECIFIC USES": "gram positive organisms (strep and staph)",
      "FACTS": "commonly in triple antibiotic ointment (neosporin)"
    },
    {
      "CATEGORY": "Topical Antibiotics",
      "DRUG NAME": "Mupirocin (Bactroban)",
      "SPECIFIC USES": "strep, staph, MRSA",
      "FACTS": "intranasal use for MRSA",
      "DOSING": "Rx cream/ointment"
    }
  ],
  "Sunscreens": [
    {
      "CATEGORY": "Sunscreens"
    }
  ],
  "SSRI's": [
    {
      "CATEGORY": "SSRI's",
      "DRUG NAME": "fluoxetine",
      "SPECIFIC USES": "Major Depressive Disorder,\nanxiety disorders (GAD, OCD, panic disorder, PTSD)",
      "ACTIONS": "presynaptic inhibition of serotonin reuptake pump,\n↑5-HT in synapse results in neuronal adaptation (not immediate effect)",
      "ADRS": "diarrhea (5-HT4),\nN/V (5-HT3),\nheadache (5-HT1),\nsomnolence/messed up sleep cycle (5-HT2),\n*sexual dysfunction/loss of libido (5-HT2),\nweight gain (rare) \n(5-HTc),\nelongated QTc"
    },
    {
      "CATEGORY": "SSRI's",
      "DRUG NAME": "paroxetine",
      "SPECIFIC USES": "Major Depressive Disorder,\nanxiety disorders (GAD, OCD, panic disorder, PTSD)",
      "ACTIONS": "presynaptic inhibition of serotonin reuptake pump,\n↑5-HT in synapse results in neuronal adaptation (not immediate effect)",
      "ADRS": "diarrhea (5-HT4),\nN/V (5-HT3),\nheadache (5-HT1),\nsomnolence/messed up sleep cycle (5-HT2),\n*sexual dysfunction/loss of libido (5-HT2),\nweight gain (rare) \n(5-HTc),\nelongated QTc",
      "FACTS": "slight anticholinergic effect (higher risk of weight gain),\nhigh risk of sexual dysfunction/decreased libido"
    },
    {
      "CATEGORY": "SSRI's",
      "DRUG NAME": "sertraline",
      "SPECIFIC USES": "Major Depressive Disorder,\nanxiety disorders (GAD, OCD, panic disorder, PTSD)",
      "ACTIONS": "presynaptic inhibition of serotonin reuptake pump,\n↑5-HT in synapse results in neuronal adaptation (not immediate effect)",
      "ADRS": "diarrhea (5-HT4),\nN/V (5-HT3),\nheadache (5-HT1),\nsomnolence/messed up sleep cycle (5-HT2),\n*sexual dysfunction/loss of libido (5-HT2),\nweight gain (rare) \n(5-HTc),\nelongated QTc"
    },
    {
      "CATEGORY": "SSRI's",
      "DRUG NAME": "fluvoxamine",
      "SPECIFIC USES": "Major Depressive Disorder,\nanxiety disorders (GAD, OCD, panic disorder, PTSD)",
      "ACTIONS": "presynaptic inhibition of serotonin reuptake pump,\n↑5-HT in synapse results in neuronal adaptation (not immediate effect)",
      "ADRS": "diarrhea (5-HT4),\nN/V (5-HT3),\nheadache (5-HT1),\nsomnolence/messed up sleep cycle (5-HT2),\n*sexual dysfunction/loss of libido (5-HT2),\nweight gain (rare) \n(5-HTc),\nelongated QTc"
    },
    {
      "CATEGORY": "SSRI's",
      "DRUG NAME": "citalopram",
      "SPECIFIC USES": "Major Depressive Disorder,\nanxiety disorders (GAD, OCD, panic disorder, PTSD)",
      "ACTIONS": "presynaptic inhibition of serotonin reuptake pump,\n↑5-HT in synapse results in neuronal adaptation (not immediate effect)",
      "ADRS": "diarrhea (5-HT4),\nN/V (5-HT3),\nheadache (5-HT1),\nsomnolence/messed up sleep cycle (5-HT2),\n*sexual dysfunction/loss of libido (5-HT2),\nweight gain (rare) \n(5-HTc),\nelongated QTc"
    },
    {
      "CATEGORY": "SSRI's",
      "DRUG NAME": "escitalopram",
      "SPECIFIC USES": "Major Depressive Disorder,\nanxiety disorders (GAD, OCD, panic disorder, PTSD)",
      "ACTIONS": "presynaptic inhibition of serotonin reuptake pump,\n↑5-HT in synapse results in neuronal adaptation (not immediate effect)",
      "ADRS": "diarrhea (5-HT4),\nN/V (5-HT3),\nheadache (5-HT1),\nsomnolence/messed up sleep cycle (5-HT2),\n*sexual dysfunction/loss of libido (5-HT2),\nweight gain (rare) \n(5-HTc),\nelongated QTc"
    }
  ],
  "SSRI & Serotonin receptor modulators": [
    {
      "CATEGORY": "SSRI & Serotonin receptor modulators",
      "DRUG NAME": "vilazodone",
      "SPECIFIC USES": "Major Depressive Disorder,\nanxiety disorders (GAD, OCD, panic disorder, PTSD)",
      "ACTIONS": "serotonin reuptake pump inhibitor, serotonin 1a partial agonist (has same clinical effect as SSRI's)",
      "ADRS": "nausea,\ndiarrhea,\ndizziness,\nsexual dysfuntion/loss of libido"
    },
    {
      "CATEGORY": "SSRI & Serotonin receptor modulators",
      "DRUG NAME": "vortioxetine",
      "SPECIFIC USES": "Major Depressive Disorder,\nanxiety disorders (GAD, OCD, panic disorder, PTSD)",
      "ACTIONS": "serotonin reuptake pump inhibitor, serotonin 1a agonist,\nserotonin 7 antagonist (has same clinical effect as SSRI's)",
      "ADRS": "N/V,\nheadache,\ndizziness,\nsexual dysfunction",
      "FACTS": "NO weight gain,\nNO vital sign changes"
    }
  ],
  "SNRI": [
    {
      "CATEGORY": "SNRI",
      "DRUG NAME": "venlafaxine",
      "SPECIFIC USES": "depression/anxiety",
      "ACTIONS": "↑5HT, NE, and dopamine (dose dependent),\nmoderate histamine 1 blocker",
      "ADRS": "nausea,\nheadache,\ninsomnia,\n↑BP (3-15mmHg systolic)",
      "FACTS": "generic available"
    },
    {
      "CATEGORY": "SNRI",
      "DRUG NAME": "duloxetine",
      "SPECIFIC USES": "depression/anxiety,\nneuropathy",
      "ACTIONS": "blocks reuptake of NE and 5HT",
      "ADRS": "headache,\nnausea,\nsexual dysfunction,\ninsomnia,\nurinary hesitation,\nmild HR & BP ↑,\nhepatotoxic (rare)",
      "FACTS": "generic available"
    },
    {
      "CATEGORY": "SNRI",
      "DRUG NAME": "desvenlafaxine",
      "SPECIFIC USES": "depression/anxiety",
      "ACTIONS": "↑5HT, NE, and dopamine (dose dependent),\nmoderate histamine 1 blocker",
      "ADRS": "nausea,\nheadache,\ninsomnia,\n↑BP (more than venlafaxine)",
      "FACTS": "metabolite of venlafaxine"
    },
    {
      "CATEGORY": "SNRI",
      "DRUG NAME": "levomilnacipran",
      "SPECIFIC USES": "depression/anxiety",
      "ACTIONS": "blocks reuptake of NE and 5HT (less 5HT effect, same NE effect as other SNRI's)",
      "ADRS": "nausea,\nconstipation,\nheadache,\ntachycardia,\nsexual dysfunction,\nurinary hesitation,\nslight ↑BP,\nslight ↑LFT's"
    }
  ],
  "TCA's": [
    {
      "CATEGORY": "TCA's",
      "DRUG NAME": "imipramine",
      "SPECIFIC USES": "depression/anxiety",
      "ACTIONS": "blocks reuptake of 5HT & NE,\nantimuscarinic,\nhistamine 1 blocker,\nalpha 1 blocker,\nNa channel blocker",
      "ADRS": "constipation,\nblurred vision,\ndry mouth,\nsedation,\nheadache,\nsexual dysfunction,\ncognitive impairment,\northostasis,\nphotosensitivity,\nlowers seizure threshold,\nhyperglycemia,\narrhythmias,\ntachycardia,\ndeadly in overdose",
      "FACTS": "work as well as SNRI's but are poorly tolerated and high risk"
    },
    {
      "CATEGORY": "TCA's",
      "DRUG NAME": "amitriptyline",
      "SPECIFIC USES": "depression/anxiety",
      "ACTIONS": "blocks reuptake of 5HT & NE,\nantimuscarinic,\nhistamine 1 blocker,\nalpha 1 blocker,\nNa channel blocker",
      "ADRS": "constipation,\nblurred vision,\ndry mouth,\nsedation,\nheadache,\nsexual dysfunction,\ncognitive impairment,\northostasis,\nphotosensitivity,\nlowers seizure threshold,\nhyperglycemia,\narrhythmias,\ntachycardia,\ndeadly in overdose",
      "FACTS": "work as well as SNRI's but are poorly tolerated and high risk"
    },
    {
      "CATEGORY": "TCA's",
      "DRUG NAME": "desipramine",
      "SPECIFIC USES": "depression/anxiety",
      "ACTIONS": "blocks reuptake of 5HT & NE,\nantimuscarinic,\nhistamine 1 blocker,\nalpha 1 blocker,\nNa channel blocker",
      "ADRS": "constipation,\nblurred vision,\ndry mouth,\nsedation,\nheadache,\nsexual dysfunction,\ncognitive impairment,\northostasis,\nphotosensitivity,\nlowers seizure threshold,\nhyperglycemia,\narrhythmias,\ntachycardia,\ndeadly in overdose",
      "FACTS": "work as well as SNRI's but are poorly tolerated and high risk"
    },
    {
      "CATEGORY": "TCA's",
      "DRUG NAME": "nortriptyline",
      "SPECIFIC USES": "depression/anxiety",
      "ACTIONS": "blocks reuptake of 5HT & NE,\nantimuscarinic,\nhistamine 1 blocker,\nalpha 1 blocker,\nNa channel blocker",
      "ADRS": "constipation,\nblurred vision,\ndry mouth,\nsedation,\nheadache,\nsexual dysfunction,\ncognitive impairment,\northostasis,\nphotosensitivity,\nlowers seizure threshold,\nhyperglycemia,\narrhythmias,\ntachycardia,\ndeadly in overdose",
      "FACTS": "work as well as SNRI's but are poorly tolerated and high risk"
    },
    {
      "CATEGORY": "TCA's",
      "DRUG NAME": "clomipramine",
      "SPECIFIC USES": "depression/anxiety",
      "ACTIONS": "blocks reuptake of 5HT & NE,\nantimuscarinic,\nhistamine 1 blocker,\nalpha 1 blocker,\nNa channel blocker",
      "ADRS": "constipation,\nblurred vision,\ndry mouth,\nsedation,\nheadache,\nsexual dysfunction,\ncognitive impairment,\northostasis,\nphotosensitivity,\nlowers seizure threshold,\nhyperglycemia,\narrhythmias,\ntachycardia,\ndeadly in overdose",
      "FACTS": "work as well as SNRI's but are poorly tolerated and high risk"
    }
  ],
  "MAOI": [
    {
      "CATEGORY": "MAOI",
      "DRUG NAME": "selegiline",
      "SPECIFIC USES": "parkinsons",
      "ACTIONS": "inhibit dopamine breakdown (MAO-B [selective for dopamine])",
      "DDI's": "foods w/ high tyramine content,\nSSRI's and MAOI's",
      "ADRS": "serotonin syndrome (if used w/ SSRI's or other MAOI's)",
      "FACTS": "minor effects as monotherapy,\nused w/ sinemet"
    },
    {
      "CATEGORY": "MAOI",
      "DRUG NAME": "rasagiline",
      "SPECIFIC USES": "parkinsons",
      "ACTIONS": "inhibit dopamine breakdown (MAO-B [selective for dopamine])",
      "DDI's": "foods w/ high tyramine content,\nSSRI's and MAOI's",
      "ADRS": "serotonin syndrome (if used w/ SSRI's or other MAOI's)",
      "FACTS": "more potent,\nused w/ sinemet"
    }
  ],
  "mood stabilizer": [
    {
      "CATEGORY": "mood stabilizer",
      "DRUG NAME": "lithium",
      "SPECIFIC USES": "bipolar disorder,\nadjunt treatment in MDD,\nmania,\ndepressed episodes",
      "ACTIONS": "reduce suicidal ideations,\nstabilize mood (not well understood MOA),\nneuroprotective effects?",
      "DDI's": "NSAIDs,\nthiazide diuretics,\nACE inhibitors,\ncalcium channel blockers \n(all increase lithium levels)",
      "ADRS": "sedation,\ncognitive difficulties,\ndry mouth,\nhand tremor,\nincreased appetite,\nweight gain,\npolydipsia,\npolyuria,\nnausea,\ndiarrhea,\nacne,\npsoriasis,\nnephrogenic diabetes insipidus,\nrenal failure,\nhypothyroidism,\nmild leukocytosis,\n↑free Ca levels,\nSA node blockade",
      "FACTS": "very narrow therapeutic index (easily toxic),\ntherapeutic range: 0.5-1.2 mEq/L,\ntoxicity effects vary based on lithium levels (see chart in slides),\nmonitor lithium levels, thryroid function, renal function,\nteratogenic (Ebstein's anomaly: malformation of tricuspid valve)"
    }
  ],
  "anxiolytics": [
    {
      "CATEGORY": "anxiolytics",
      "SUB-CATEGORY": "antidepressants",
      "DRUG NAME": "see other chart",
      "SPECIFIC USES": "anxiety conditions & agitation",
      "ACTIONS": "see other chart",
      "DDI's": "see other chart",
      "ADRS": "see other chart",
      "FACTS": "see other chart"
    },
    {
      "CATEGORY": "anxiolytics",
      "DRUG NAME": "buspirone",
      "SPECIFIC USES": "anxiety conditions & agitation",
      "FACTS": "non-sedating anxiolytic,\nnot often used",
      "FACTS 2": "more info on next chart"
    },
    {
      "CATEGORY": "anxiolytics",
      "SUB-CATEGORY": "barbiturates",
      "SPECIFIC USES": "anxiety conditions & agitation",
      "FACTS": "lethal in overdose,\nmodern use is rare,\nless seletively anxiolytic"
    },
    {
      "CATEGORY": "anxiolytics",
      "SUB-CATEGORY": "benzodiazepines",
      "DRUG NAME": "triazolam",
      "SPECIFIC USES": "acute anxiety,\nchronic use debated,\ninsomnia",
      "ACTIONS": "enhance GABA effect by binding benzo receptor on GABAA(allow Cl influx to inhibit neuron firing),\n",
      "DDI's": "CNS depressants (alcohol, opiates, barbiturates) --> respiratory depression",
      "ADRS": "sedation (tolerance in 2 weeks),\ncognitive impairment,\nataxia/incoordination,\nrespiratory depression,\nanterograde amnesia,\nparadoxical agitation (rare),\nraises seizure threshold,\noverdose (hypotension, respiratory depression, coma)",
      "FACTS": "cross tolerance w/ alcohol,\nrapid dose escalation can induce tolerance,\npotential for abuse,\nacute withdrawal symptoms worse w/ short half-life benzos,\nDO NOT USE IN: liver disease, hx substance abuse, severe respiratory distress, performing hazardous tasks,\navoid in pregnancy/lactation"
    },
    {
      "CATEGORY": "anxiolytics",
      "SUB-CATEGORY": "antidepressants",
      "DRUG NAME": "clonazepam",
      "SPECIFIC USES": "anxiety conditions & agitation",
      "ACTIONS": "see other chart",
      "DDI's": "see other chart",
      "ADRS": "see other chart",
      "FACTS": "see other chart",
      "FACTS 2": "high potency"
    },
    {
      "CATEGORY": "anxiolytics",
      "SUB-CATEGORY": "antidepressants",
      "DRUG NAME": "alprazoplam",
      "SPECIFIC USES": "anxiety conditions & agitation",
      "ACTIONS": "see other chart",
      "DDI's": "see other chart",
      "ADRS": "see other chart",
      "FACTS": "see other chart",
      "FACTS 2": "short half life,\nhigh potency,\nfast acting"
    },
    {
      "CATEGORY": "anxiolytics",
      "SUB-CATEGORY": "antidepressants",
      "DRUG NAME": "lorazepam",
      "SPECIFIC USES": "anxiety conditions & agitation",
      "ACTIONS": "see other chart",
      "DDI's": "see other chart",
      "ADRS": "see other chart",
      "FACTS": "see other chart",
      "FACTS 2": "phase II metabolism,\nshort half life"
    },
    {
      "CATEGORY": "anxiolytics",
      "SUB-CATEGORY": "antidepressants",
      "DRUG NAME": "diazepam",
      "SPECIFIC USES": "anxiety conditions & agitation",
      "ACTIONS": "see other chart",
      "DDI's": "see other chart",
      "ADRS": "see other chart",
      "FACTS": "see other chart",
      "FACTS 2": "rapid acting"
    },
    {
      "CATEGORY": "anxiolytics",
      "SUB-CATEGORY": "antidepressants",
      "DRUG NAME": "oxazepam",
      "SPECIFIC USES": "anxiety conditions & agitation",
      "ACTIONS": "see other chart",
      "DDI's": "see other chart",
      "ADRS": "see other chart",
      "FACTS": "see other chart",
      "FACTS 2": "phase II metabolism,\nshort half life"
    },
    {
      "CATEGORY": "anxiolytics",
      "SUB-CATEGORY": "antidepressants",
      "DRUG NAME": "chlordiazepoxide",
      "SPECIFIC USES": "anxiety conditions & agitation",
      "ACTIONS": "see other chart",
      "DDI's": "see other chart",
      "ADRS": "see other chart",
      "FACTS": "see other chart"
    }
  ],
  "benzodiazepine antagonist": [
    {
      "CATEGORY": "benzodiazepine antagonist",
      "DRUG NAME": "flumazenil",
      "SPECIFIC USES": "purely benzodiazepine overdose",
      "ACTIONS": "competative inhibition of GABA receptor",
      "DDI's": "do not use if overdose is caused by other drugs in combination w/ benzo's; can result in uncontrolled seizure",
      "ADRS": "withdrawal symptoms",
      "FACTS": "short half life (may require multiple doses to counter benzo overdose since half life is shorter than all benzo's)"
    }
  ],
  "Non-Biologic (First-Line treatment; target T & B cells)": [
    {
      "CATEGORY": "Non-Biologic (First-Line treatment; target T & B cells)",
      "DRUG NAME": "methotrexate",
      "SPECIFIC USES": "rheumatoid arthritis (RA), \ncancer",
      "ACTIONS": "reduced purine biosynthesis,\nselectively inhibits replication of B & T cells,\ninhibits cytokines,\n↑IL-4 secretion",
      "ADRS": "↓immune response,\nmyelosuppression,\nGI toxicity (nausea, mucosal ulcers),\npulmonary toxicity,\nhepatotoxicity (monitor LFT q 3 mon.),\nthrombocytopenia",
      "FACTS": "preferred DMARD treatment,\ngiven w/ folic acid (counter GI ADRS),\nantineoplastic at high dose,\nC/I: pregnancy (d/c 3 months before conception) & breastfeeding,\n4-8 wks for effect"
    },
    {
      "CATEGORY": "Non-Biologic (First-Line treatment; target T & B cells)",
      "DRUG NAME": "leflunomide",
      "SPECIFIC USES": "RA",
      "ACTIONS": "inhibit autoimmune T cell proliferation & production of autoantibodies",
      "ADRS": "alopecia,\nhematologic toxicity,\ndiarrhea,\nsevere hepatotoxicity",
      "FACTS": "C/I: pregnancy & breastfeeding,\n4-12 wks for effect,\ncomparible efficacy to methotrexate"
    },
    {
      "CATEGORY": "Non-Biologic (First-Line treatment; target T & B cells)",
      "DRUG NAME": "sulfasalazine",
      "SPECIFIC USES": "RA",
      "DRUG-DRUG INTERACTIONS": "Sulfa Allergies",
      "ACTIONS": "unknown MOA",
      "ADRS": "GI effects,\nlupus-like syndrome,\nheadache,\nfever,\nrash,\nhepatotoxicity",
      "FACTS": "8-12 wks for effect,\n\"probably\" safe in pregnancy,\nC/I: breastfeeding"
    },
    {
      "CATEGORY": "Non-Biologic (First-Line treatment; target T & B cells)",
      "DRUG NAME": "hydroxychloroquine",
      "SPECIFIC USES": "RA,\nantimalarial",
      "ACTIONS": "IL-1 release inhibition?,\nMOA largely unknown",
      "ADRS": "dose dependent occular toxicity,\nmyopathy,\nGI effects (dyspepsia, nausea),\nCNS effects (nightmares)",
      "FACTS": "max effects seen after 3-6 months"
    },
    {
      "CATEGORY": "Non-Biologic (First-Line treatment; target T & B cells)",
      "DRUG NAME": "azathioprine",
      "FACTS": "NOT RECOMMENDED FOR USE IN RA"
    },
    {
      "CATEGORY": "Non-Biologic (First-Line treatment; target T & B cells)",
      "DRUG NAME": "cyclosporine",
      "SPECIFIC USES": "rheumatoid arthritis (RA), \ncancer",
      "ACTIONS": "reduced purine biosynthesis,\nselectively inhibits replication of B & T cells,\ninhibits cytokines,\n↑IL-4 secretion",
      "ADRS": "↓immune response,\nmyelosuppression,\nGI toxicity (nausea, mucosal ulcers),\npulmonary toxicity,\nhepatotoxicity (monitor LFT q 3 mon.),\nthrombocytopenia",
      "FACTS": "preferred DMARD treatment,\ngiven w/ folic acid (counter GI ADRS),\nantineoplastic at high dose,\nC/I: pregnancy (d/c 3 months before conception) & breastfeeding,\n4-8 wks for effect"
    }
  ],
  "Biologic": [
    {
      "CATEGORY": "Biologic",
      "SUB-CATEGORY": "TNF inhibitors (first line)",
      "DRUG NAME": "etanercept",
      "SPECIFIC USES": "RA",
      "DRUG-DRUG INTERACTIONS": "anakinra,\nabatacecpt",
      "ACTIONS": "soluble TNF receptor blocker",
      "ADRS": "↑susceptibility to infections,\ninjection site reactions,\n↑ risk of colon cancer?,\nnew/worsening HF",
      "FACTS": "lowest infeciton risk"
    },
    {
      "CATEGORY": "Biologic",
      "SUB-CATEGORY": "TNF inhibitors (first line)",
      "DRUG NAME": "adalimumab",
      "SPECIFIC USES": "RA",
      "DRUG-DRUG INTERACTIONS": "anakinra,\nabatacecpt",
      "ACTIONS": "human anti-TNF antibody",
      "ADRS": "↑susceptibility to infections,\ninjection site reactions,\n↑ risk of colon cancer?,\nnew/worsening HF"
    },
    {
      "CATEGORY": "Biologic",
      "SUB-CATEGORY": "TNF inhibitors (first line)",
      "DRUG NAME": "infliximab",
      "SPECIFIC USES": "RA",
      "DRUG-DRUG INTERACTIONS": "anakinra,\nabatacecpt",
      "ACTIONS": "chimeric anti-TNF antibody",
      "ADRS": "↑susceptibility to infections,\ninjection site reactions,\n↑ risk of colon cancer?,\nnew/worsening HF",
      "FACTS": "given IV"
    },
    {
      "CATEGORY": "Biologic",
      "SUB-CATEGORY": "TNF inhibitors (first line)",
      "DRUG NAME": "certolizumab pegol",
      "SPECIFIC USES": "RA",
      "DRUG-DRUG INTERACTIONS": "anakinra,\nabatacecpt",
      "ACTIONS": "pegyated humanized Fab fragment of TNF-alpha antibody",
      "ADRS": "↑susceptibility to infections,\ninjection site reactions,\n↑ risk of colon cancer?,\nnew/worsening HF",
      "FACTS": "highest infection risk"
    },
    {
      "CATEGORY": "Biologic",
      "SUB-CATEGORY": "TNF inhibitors (first line)",
      "DRUG NAME": "golimumab",
      "SPECIFIC USES": "RA",
      "DRUG-DRUG INTERACTIONS": "anakinra,\nabatacecpt",
      "ACTIONS": "human anti-TNF antibody",
      "ADRS": "↑susceptibility to infections,\ninjection site reactions,\n↑ risk of colon cancer?,\nnew/worsening HF"
    },
    {
      "CATEGORY": "Biologic",
      "SUB-CATEGORY": "Non-TNF inhibitors",
      "DRUG NAME": "anakinra",
      "SPECIFIC USES": "RA",
      "DRUG-DRUG INTERACTIONS": "do not use w/ TNF inhibitors",
      "ACTIONS": "IL-1 receptor antagonist",
      "ADRS": "↑susceptibility to infections (check PPD before use, do not give live vaccines),\ninjection site reactions,\n↑ risk of colon cancer?",
      "FACTS": "least effective"
    },
    {
      "CATEGORY": "Biologic",
      "SUB-CATEGORY": "TNF inhibitors (first line)",
      "DRUG NAME": "rituximab",
      "SPECIFIC USES": "RA",
      "DRUG-DRUG INTERACTIONS": "anakinra,\nabatacecpt",
      "ACTIONS": "B cell depeletion",
      "ADRS": "↑susceptibility to infections,\ninjection site reactions,\n↑ risk of colon cancer?,\nnew/worsening HF",
      "FACTS": "black box warning: fatal infusion related reactions, tumor lysis syndrome, severe mucocutaneous reactions"
    },
    {
      "CATEGORY": "Biologic",
      "SUB-CATEGORY": "TNF inhibitors (first line)",
      "DRUG NAME": "abatacept",
      "SPECIFIC USES": "RA",
      "DRUG-DRUG INTERACTIONS": "anakinra,\nabatacecpt",
      "ACTIONS": "T cell co-stimulation blocker,\ninhibits T cells",
      "ADRS": "↑susceptibility to infections,\ninjection site reactions,\n↑ risk of colon cancer?,\nnew/worsening HF"
    },
    {
      "CATEGORY": "Biologic",
      "SUB-CATEGORY": "TNF inhibitors (first line)",
      "DRUG NAME": "toclizumab",
      "SPECIFIC USES": "RA",
      "DRUG-DRUG INTERACTIONS": "anakinra,\nabatacecpt",
      "ACTIONS": "anti IL-6 receptor antibody",
      "ADRS": "↑susceptibility to infections,\ninjection site reactions,\n↑ risk of colon cancer?,\nnew/worsening HF"
    }
  ],
  "uricostatic": [
    {
      "CATEGORY": "uricostatic",
      "DRUG NAME": "allopurinol",
      "SPECIFIC USES": "recurrent gout attacks,\nfor underexcretors and overproducers",
      "ACTIONS": "xanthine oxidase inhibitor",
      "ADRS": "GI intolerance,\nrash,\nbone marrow dysfunction,\nhepatotoxicity,\nrenal damage",
      "FACTS": "evaluate renal function prior to use,\npurine inhibitor,\nfirst line gout prevention"
    },
    {
      "CATEGORY": "uricostatic",
      "DRUG NAME": "febuxostat",
      "SPECIFIC USES": "recurrent gout attacks,\nfor underexcretors and overproducers",
      "ACTIONS": "xanthine oxidase inhibitor",
      "ADRS": "LFT abnormalities,\nheadache,\nGI upset",
      "FACTS": "expensive,\nmore effective than allopurinol?,\nmore selective; nonpurine inhibitor,\nprecipitate cardiovascular event?"
    }
  ],
  "uricosuric": [
    {
      "CATEGORY": "uricosuric",
      "DRUG NAME": "probenecid",
      "SPECIFIC USES": "recurrent gout attacks,\nfor underexcretors",
      "DRUG-DRUG INTERACTIONS": "penicillins, cephalosporins, methotrexate (use same transporter)",
      "ACTIONS": "blocks transporter responsible for reabsorption and secretion of uric acid in proximal tubule",
      "ADRS": "uric acid kidney stones,\nGI intolerance (dyspepsia, acid reflux)",
      "FACTS": "not effective in mild renal insufficiency,\nuseful in underexcretors,\nstart at low dose to prevent gouty attack"
    }
  ],
  "IL-1 inhibitors": [
    {
      "CATEGORY": "IL-1 inhibitors",
      "DRUG NAME": "anakinra",
      "SPECIFIC USES": "acute gout attacks ",
      "ACTIONS": "inhibits IL-1"
    },
    {
      "CATEGORY": "IL-1 inhibitors",
      "DRUG NAME": "canakinumab",
      "SPECIFIC USES": "acute gout attacks ",
      "ACTIONS": "inhibits IL-1"
    },
    {
      "CATEGORY": "IL-1 inhibitors",
      "DRUG NAME": "rilonacept",
      "SPECIFIC USES": "acute gout attacks ",
      "ACTIONS": "inhibits IL-1"
    }
  ],
  "Statins (HMG-CoA Reductase Inhibitors)": [
    {
      "CATEGORY": "Statins (HMG-CoA Reductase Inhibitors)",
      "DRUG NAME": "fluvastatin",
      "SPECIFIC USES/FACTS": "secondary prevention (pt w/ ASCVD),\nprimary prevention (LDL ≥ 190, diabetic w/ LDL 70-190, 10yr ASCVD risk w/ LDL 70-190)",
      "DRUG-DRUG INTERACTIONS": "2C9 inhibitors",
      "ACTIONS": "↓ hepatic VLDL synthesis, \n↑ uptake of VLDL/IDL remnants, \n↑ HDL synthesis, \n↑ plaque stability, \n↓ endothelial dysfunction, \n↓ platelet activation, \n↓ vascular inflammation",
      "ADRS": "myalgia/myopathy/rhabdomyolysis,\nhepatic dysfunction, \nheadache,\nconstipation,\nteratogenic,\nnew onset diabetes"
    },
    {
      "CATEGORY": "Statins (HMG-CoA Reductase Inhibitors)",
      "DRUG NAME": "lovastatin",
      "SPECIFIC USES/FACTS": "secondary prevention (pt w/ ASCVD),\nprimary prevention (LDL ≥ 190, diabetic w/ LDL 70-190, 10yr ASCVD risk w/ LDL 70-190)",
      "DRUG-DRUG INTERACTIONS": "3A4 inhibitors",
      "ACTIONS": "↓ hepatic VLDL synthesis, \n↑ uptake of VLDL/IDL remnants, \n↑ HDL synthesis, \n↑ plaque stability, \n↓ endothelial dysfunction, \n↓ platelet activation, \n↓ vascular inflammation",
      "ADRS": "myalgia/myopathy/rhabdomyolysis,\nhepatic dysfunction, \nheadache,\nconstipation,\nteratogenic,\nnew onset diabetes"
    },
    {
      "CATEGORY": "Statins (HMG-CoA Reductase Inhibitors)",
      "DRUG NAME": "pravastatin",
      "SPECIFIC USES/FACTS": "secondary prevention (pt w/ ASCVD),\nprimary prevention (LDL ≥ 190, diabetic w/ LDL 70-190, 10yr ASCVD risk w/ LDL 70-190)",
      "ACTIONS": "↓ hepatic VLDL synthesis, \n↑ uptake of VLDL/IDL remnants, \n↑ HDL synthesis, \n↑ plaque stability, \n↓ endothelial dysfunction, \n↓ platelet activation, \n↓ vascular inflammation",
      "ADRS": "myalgia/myopathy/rhabdomyolysis,\nhepatic dysfunction, \nheadache,\nconstipation,\nteratogenic,\nnew onset diabetes"
    },
    {
      "CATEGORY": "Statins (HMG-CoA Reductase Inhibitors)",
      "DRUG NAME": "simvastatin",
      "SPECIFIC USES/FACTS": "secondary prevention (pt w/ ASCVD),\nprimary prevention (LDL ≥ 190, diabetic w/ LDL 70-190, 10yr ASCVD risk w/ LDL 70-190)",
      "DRUG-DRUG INTERACTIONS": "3A4 inhibitors",
      "ACTIONS": "↓ hepatic VLDL synthesis, \n↑ uptake of VLDL/IDL remnants, \n↑ HDL synthesis, \n↑ plaque stability, \n↓ endothelial dysfunction, \n↓ platelet activation, \n↓ vascular inflammation",
      "ADRS": "myalgia/myopathy/rhabdomyolysis,\nhepatic dysfunction, \nheadache,\nconstipation,\nteratogenic,\nnew onset diabetes"
    },
    {
      "CATEGORY": "Statins (HMG-CoA Reductase Inhibitors)",
      "DRUG NAME": "pitavastatin",
      "SPECIFIC USES/FACTS": "secondary prevention (pt w/ ASCVD),\nprimary prevention (LDL ≥ 190, diabetic w/ LDL 70-190, 10yr ASCVD risk w/ LDL 70-190)",
      "ACTIONS": "↓ hepatic VLDL synthesis, \n↑ uptake of VLDL/IDL remnants, \n↑ HDL synthesis, \n↑ plaque stability, \n↓ endothelial dysfunction, \n↓ platelet activation, \n↓ vascular inflammation",
      "ADRS": "myalgia/myopathy/rhabdomyolysis,\nhepatic dysfunction, \nheadache,\nconstipation,\nteratogenic,\nnew onset diabetes"
    },
    {
      "CATEGORY": "Statins (HMG-CoA Reductase Inhibitors)",
      "DRUG NAME": "atorvastatin",
      "SPECIFIC USES/FACTS": "secondary prevention (pt w/ ASCVD),\nprimary prevention (LDL ≥ 190, diabetic w/ LDL 70-190, 10yr ASCVD risk w/ LDL 70-190)",
      "DRUG-DRUG INTERACTIONS": "3A4 inhibitors",
      "ACTIONS": "↓ hepatic VLDL synthesis, \n↑ uptake of VLDL/IDL remnants, \n↑ HDL synthesis, \n↑ plaque stability, \n↓ endothelial dysfunction, \n↓ platelet activation, \n↓ vascular inflammation",
      "ADRS": "myalgia/myopathy/rhabdomyolysis,\nhepatic dysfunction, \nheadache,\nconstipation,\nteratogenic,\nnew onset diabetes"
    },
    {
      "CATEGORY": "Statins (HMG-CoA Reductase Inhibitors)",
      "DRUG NAME": "rosuvastatin",
      "SPECIFIC USES/FACTS": "secondary prevention (pt w/ ASCVD),\nprimary prevention (LDL ≥ 190, diabetic w/ LDL 70-190, 10yr ASCVD risk w/ LDL 70-190)",
      "ACTIONS": "↓ hepatic VLDL synthesis, \n↑ uptake of VLDL/IDL remnants, \n↑ HDL synthesis, \n↑ plaque stability, \n↓ endothelial dysfunction, \n↓ platelet activation, \n↓ vascular inflammation",
      "ADRS": "myalgia/myopathy/rhabdomyolysis,\nhepatic dysfunction, \nheadache,\nconstipation,\nteratogenic,\nnew onset diabetes"
    }
  ],
  "Bile Acid Sequestrants (BAS)": [
    {
      "CATEGORY": "Bile Acid Sequestrants (BAS)",
      "DRUG NAME": "cholestyramine",
      "SPECIFIC USES/FACTS": "↓ LDL",
      "DRUG-DRUG INTERACTIONS": "Vitamins A,D,E,K (↓ absorption),\nWarfarin, levothyroxine, digoxin, statins (give 1hr before/4 hrs after BAS)",
      "ACTIONS": "↓ LDL [stops bile acid reabsorption forcing synthesis of new ones (requires LDL to make)]",
      "ADRS": "bloating,\nconstipation,\nabdominal pain,\nabnormal taste"
    },
    {
      "CATEGORY": "Bile Acid Sequestrants (BAS)",
      "DRUG NAME": "colestipol",
      "SPECIFIC USES/FACTS": "↓ LDL",
      "DRUG-DRUG INTERACTIONS": "Vitamins A,D,E,K (↓ absorption),\nWarfarin, levothyroxine, digoxin, statins (give 1hr before/4 hrs after BAS)",
      "ACTIONS": "↓ LDL [stops bile acid reabsorption forcing synthesis of new ones (requires LDL to make)]",
      "ADRS": "bloating,\nconstipation,\nabdominal pain,\nabnormal taste"
    },
    {
      "CATEGORY": "Bile Acid Sequestrants (BAS)",
      "DRUG NAME": "colesevelam",
      "SPECIFIC USES/FACTS": "↓ LDL",
      "DRUG-DRUG INTERACTIONS": "Vitamins A,D,E,K (↓ absorption),\nWarfarin, levothyroxine, digoxin, statins (give 1hr before/4 hrs after BAS)",
      "ACTIONS": "↓ LDL [stops bile acid reabsorption forcing synthesis of new ones (requires LDL to make)]",
      "ADRS": "bloating,\nconstipation,\nabdominal pain,\nabnormal taste"
    }
  ],
  "Vitamin B3": [
    {
      "CATEGORY": "Vitamin B3",
      "DRUG NAME": "niacin",
      "SPECIFIC USES/FACTS": "2nd line for ↓LDL",
      "ACTIONS": "↓ VLDL synthesis (↓LDL),\n↑LPL activity,\n↑HDL (↓ catabolic rate of HDL)",
      "ADRS": "flushing,\nnausea,\nabdominal pain,\nteratogenic,\n↑uric acid & glucose"
    }
  ],
  "Cholesterol Absorption Inhibitor": [
    {
      "CATEGORY": "Cholesterol Absorption Inhibitor",
      "DRUG NAME": "ezetimibe",
      "SPECIFIC USES/FACTS": "w/ statin,\nacute coronary syndrome,\n3rd line for ↓LDL",
      "DRUG-DRUG INTERACTIONS": "BAS (↓absoption)",
      "ACTIONS": "↑ LDL receptors in liver",
      "ADRS": "diarrhea,\nsinusitis,\nheadache,\nteratogenic"
    }
  ],
  "Fibric Acid Derivatives (Fibrates)": [
    {
      "CATEGORY": "Fibric Acid Derivatives (Fibrates)",
      "DRUG NAME": "gemfibrozil",
      "SPECIFIC USES/FACTS": "pt w/ high TG",
      "DRUG-DRUG INTERACTIONS": "CAN BE USED W/ STATIN",
      "ACTIONS": "↓VLDL synthesis,\n↑LPL activity,\n↑ TG clearance",
      "ADRS": "myopathy,\nnausea/GI upset,\nskin rash,\n↑transaminases,\nteratogenic"
    },
    {
      "CATEGORY": "Fibric Acid Derivatives (Fibrates)",
      "DRUG NAME": "fenofibrate",
      "SPECIFIC USES/FACTS": "pt w/ high TG",
      "DRUG-DRUG INTERACTIONS": "CAN BE USED W/ STATIN",
      "ACTIONS": "↓VLDL synthesis,\n↑LPL activity,\n↑ TG clearance",
      "ADRS": "myopathy,\nnausea/GI upset,\nskin rash,\n↑transaminases,\nteratogenic"
    }
  ],
  "Omega-3 Fatty Acids": [
    {
      "CATEGORY": "Omega-3 Fatty Acids",
      "SPECIFIC USES/FACTS": "↓TG,\nrequires 3-15g/day",
      "ACTIONS": "↓TG (inhibit hepaitic secretion, promote metabolism)",
      "ADRS": "fishy taste,\nburping,\nantiplatelet effects (high dose)"
    }
  ],
  "Proprotein convertase subtilisin-kexin type-9 (PCSK-9) Inhibitors": [
    {
      "CATEGORY": "Proprotein convertase subtilisin-kexin type-9 (PCSK-9) Inhibitors",
      "DRUG NAME": "alirocumab",
      "SPECIFIC USES/FACTS": "↓LDL",
      "ACTIONS": "↑LDL receptors",
      "ADRS": "headache,\narthralgia,\nmyalgia,\nlimb pain,\nfatigue,\ninjection site reactions,\nneurocognitive deficits,\nvery expensive $$$"
    },
    {
      "CATEGORY": "Proprotein convertase subtilisin-kexin type-9 (PCSK-9) Inhibitors",
      "DRUG NAME": "evolucumab",
      "SPECIFIC USES/FACTS": "↓LDL",
      "ACTIONS": "↑LDL receptors",
      "ADRS": "headache,\narthralgia,\nmyalgia,\nlimb pain,\nfatigue,\ninjection site reactions,\nneurocognitive deficits,\nvery expensive $$$"
    },
    {
      "CATEGORY": "Proprotein convertase subtilisin-kexin type-9 (PCSK-9) Inhibitors",
      "DRUG NAME": "bococizumab",
      "SPECIFIC USES/FACTS": "↓LDL",
      "DRUG-DRUG INTERACTIONS": "stage 3 clinical trial",
      "ACTIONS": "↑LDL receptors",
      "ADRS": "headache,\narthralgia,\nmyalgia,\nlimb pain,\nfatigue,\ninjection site reactions,\nneurocognitive deficits,\nvery expensive $$$"
    }
  ],
  "Nitrates": [
    {
      "CATEGORY": "Nitrates",
      "DRUG NAME": "isosorbide dinitrate",
      "SPECIFIC USES/FACTS": "angina",
      "ACTIONS": "smooth muscle relaxation (vasodilation),\n↓preload,\n↓afterload",
      "ADRS": "headache, dizziness, flushing, sweating, rash, hypotension, reflex tachycardia, methemoglobinemia, PDE-5 interactions"
    },
    {
      "CATEGORY": "Nitrates",
      "DRUG NAME": "nitroglycerin",
      "SPECIFIC USES/FACTS": "angina",
      "ACTIONS": "smooth muscle relaxation (vasodilation),\n↓preload,\n↓afterload",
      "ADRS": "headache, dizziness, flushing, sweating, rash, hypotension, reflex tachycardia, methemoglobinemia, PDE-5 interactions"
    },
    {
      "CATEGORY": "Nitrates",
      "DRUG NAME": "isosorbide mononitrate",
      "SPECIFIC USES/FACTS": "angina",
      "ACTIONS": "smooth muscle relaxation (vasodilation),\n↓preload,\n↓afterload",
      "ADRS": "headache, dizziness, flushing, sweating, rash, hypotension, reflex tachycardia, methemoglobinemia, PDE-5 interactions"
    }
  ],
  "PDE-5 Inhibitors": [
    {
      "CATEGORY": "PDE-5 Inhibitors",
      "DRUG NAME": "sildenafil",
      "SPECIFIC USES/FACTS": "ED, \nBPH,\npulmonary arterial hypertension",
      "ACTIONS": "smooth muscle relaxation/vasodilation (increased cGMP)",
      "ADRS": "nitrate interactions,\nseeing blue/green halos"
    },
    {
      "CATEGORY": "PDE-5 Inhibitors",
      "DRUG NAME": "tadalafil",
      "SPECIFIC USES/FACTS": "ED, \nBPH,\npulmonary arterial hypertension",
      "ACTIONS": "smooth muscle relaxation/vasodilation (increased cGMP)",
      "ADRS": "nitrate interactions,\nseeing blue/green halos"
    },
    {
      "CATEGORY": "PDE-5 Inhibitors",
      "DRUG NAME": "vardenafil",
      "SPECIFIC USES/FACTS": "ED, \nBPH,\npulmonary arterial hypertension",
      "ACTIONS": "smooth muscle relaxation/vasodilation (increased cGMP)",
      "ADRS": "nitrate interactions,\nseeing blue/green halos"
    },
    {
      "CATEGORY": "PDE-5 Inhibitors",
      "DRUG NAME": "avanafil",
      "SPECIFIC USES/FACTS": "ED, \nBPH,\npulmonary arterial hypertension",
      "ACTIONS": "smooth muscle relaxation/vasodilation (increased cGMP)",
      "ADRS": "nitrate interactions,\nseeing blue/green halos"
    }
  ],
  "Direct Vasodilators": [
    {
      "CATEGORY": "Direct Vasodilators",
      "SUBCATEGORY": "Alpha-1 Blockers"
    },
    {
      "CATEGORY": "Direct Vasodilators",
      "SUBCATEGORY": "CCB's"
    },
    {
      "CATEGORY": "Direct Vasodilators",
      "DRUG NAME": "hydralazine",
      "SPECIFIC USES/FACTS": "hypertension,\nheart failure",
      "ACTIONS": "↓ BP,\n↓ vascular resistance,\nvasodilation of arterial smooth m.",
      "ADRS": "headache, flushing, dizziness, palpitations, angina, sinus tachycardia, hypotension, peripheral edema, fluid retention"
    },
    {
      "CATEGORY": "Direct Vasodilators",
      "SUBCATEGORY": "Alpha-1 Blockers",
      "DRUG NAME": "minoxidil",
      "SPECIFIC USES/FACTS": "severe, drug-resistant hypertension",
      "ACTIONS": "↓ BP,\n↓ vascular resistance,\nvasodilation of arterial smooth m.",
      "ADRS": "hypotension, hypertrichosis, sinus tachycardia, angina, headache, peripheral edema, fluid retention"
    },
    {
      "CATEGORY": "Direct Vasodilators",
      "SUBCATEGORY": "Alpha-1 Blockers",
      "DRUG NAME": "nitroprusside",
      "SPECIFIC USES/FACTS": "hypertensive emergency, acute CHF",
      "ACTIONS": "liberate NO,\n↓preload & afterload",
      "ADRS": "hypotension, methemoglobinemia, cyanide toxicity"
    }
  ],
  "Positive Cardiac Inotropes": [
    {
      "CATEGORY": "Positive Cardiac Inotropes",
      "SUBCATEGORY": "Vasopressor",
      "DRUG NAME": "epinephrine/norepi"
    },
    {
      "CATEGORY": "Positive Cardiac Inotropes",
      "SUBCATEGORY": "Vasopressor",
      "DRUG NAME": "dobutamine"
    },
    {
      "CATEGORY": "Positive Cardiac Inotropes",
      "SUBCATEGORY": "Vasopressor",
      "DRUG NAME": "isoproterenol"
    },
    {
      "CATEGORY": "Positive Cardiac Inotropes",
      "SUBCATEGORY": "Vasopressor",
      "DRUG NAME": "dopamine"
    },
    {
      "CATEGORY": "Positive Cardiac Inotropes",
      "SUBCATEGORY": "PDE-3 Inhibitor",
      "DRUG NAME": "milrinone",
      "SPECIFIC USES/FACTS": "short term for acute decompensated HF",
      "ACTIONS": "↑ cAMP in cardiac tissue, ↑contraction",
      "ADRS": "hepatotoxicity, throbocytopenia, arrhythmias, headache"
    },
    {
      "CATEGORY": "Positive Cardiac Inotropes",
      "SUBCATEGORY": "Cardiac Glycoside",
      "DRUG NAME": "digoxin",
      "SPECIFIC USES/FACTS": "CHF, rate control in A Fib",
      "ACTIONS": "↑intracellular Na, ↑ intracellular Ca, ↑contraction",
      "ADRS": "digitalis toxicity,\nhyperkalemia, arrhythmias, AV block, EKG changes, xanthopsia"
    }
  ],
  "Loop Diuretics": [
    {
      "CATEGORY": "Loop Diuretics",
      "DRUG NAME": "furosemide",
      "SPECIFIC USES/FACTS": "hypertension,\nCHF,\nedema,\npulmonary edema,\ngood in renal disease",
      "ACTIONS": "inhibit Na/K/Cl symporter (more ions in lumen),\nmore Mg and Ca in lumen",
      "ADRS": "hypokalemia,\nhypocalcemia,\nhypomagnesemia,\nhypovolemia,\nhypotension,\nototoxicity",
      "FACTS": "Sulfa in all except ethacrynic acid, only need to avoid w/ sulfa anaphalyxis"
    },
    {
      "CATEGORY": "Loop Diuretics",
      "DRUG NAME": "torsemide",
      "SPECIFIC USES/FACTS": "hypertension,\nCHF,\nedema,\npulmonary edema,\ngood in renal disease",
      "ACTIONS": "inhibit Na/K/Cl symporter (more ions in lumen),\nmore Mg and Ca in lumen",
      "ADRS": "hypokalemia,\nhypocalcemia,\nhypomagnesemia,\nhypovolemia,\nhypotension,\nototoxicity",
      "FACTS": "Sulfa in all except ethacrynic acid, only need to avoid w/ sulfa anaphalyxis"
    },
    {
      "CATEGORY": "Loop Diuretics",
      "DRUG NAME": "bumetanide",
      "SPECIFIC USES/FACTS": "hypertension,\nCHF,\nedema,\npulmonary edema,\ngood in renal disease",
      "ACTIONS": "inhibit Na/K/Cl symporter (more ions in lumen),\nmore Mg and Ca in lumen",
      "ADRS": "hypokalemia,\nhypocalcemia,\nhypomagnesemia,\nhypovolemia,\nhypotension,\nototoxicity",
      "FACTS": "Sulfa in all except ethacrynic acid, only need to avoid w/ sulfa anaphalyxis"
    },
    {
      "CATEGORY": "Loop Diuretics",
      "DRUG NAME": "ethacrynic acid",
      "SPECIFIC USES/FACTS": "hypertension,\nCHF,\nedema,\npulmonary edema,\ngood in renal disease",
      "ACTIONS": "inhibit Na/K/Cl symporter (more ions in lumen),\nmore Mg and Ca in lumen",
      "ADRS": "hypokalemia,\nhypocalcemia,\nhypomagnesemia,\nhypovolemia,\nhypotension,\nototoxicity",
      "FACTS": "Sulfa in all except ethacrynic acid, only need to avoid w/ sulfa anaphalyxis"
    }
  ],
  "Thiazide Diuretics": [
    {
      "CATEGORY": "Thiazide Diuretics",
      "DRUG NAME": "hydrochlorothiaide",
      "SPECIFIC USES/FACTS": "hypertension,\nCHF,\nedema",
      "ACTIONS": "inhibit Na/Cl symporter (more Na Cl in lumen)",
      "ADRS": "hypokalemia,\nhypercalecemia,\nhypomagnesemia,\nhyperglycemia,\nhypovolemia,\nhypotension",
      "FACTS": "Sulfa in all , only need to avoid w/ sulfa anaphalyxis"
    },
    {
      "CATEGORY": "Thiazide Diuretics",
      "DRUG NAME": "chlorthalidone",
      "SPECIFIC USES/FACTS": "hypertension,\nCHF,\nedema",
      "ACTIONS": "inhibit Na/Cl symporter (more Na Cl in lumen)",
      "ADRS": "hypokalemia,\nhypercalecemia,\nhypomagnesemia,\nhyperglycemia,\nhypovolemia,\nhypotension",
      "FACTS": "Sulfa in all , only need to avoid w/ sulfa anaphalyxis"
    },
    {
      "CATEGORY": "Thiazide Diuretics",
      "DRUG NAME": "indapamide",
      "SPECIFIC USES/FACTS": "hypertension,\nCHF,\nedema",
      "ACTIONS": "inhibit Na/Cl symporter (more Na Cl in lumen)",
      "ADRS": "hypokalemia,\nhypercalecemia,\nhypomagnesemia,\nhyperglycemia,\nhypovolemia,\nhypotension",
      "FACTS": "Sulfa in all , only need to avoid w/ sulfa anaphalyxis"
    },
    {
      "CATEGORY": "Thiazide Diuretics",
      "DRUG NAME": "chlorothiazide",
      "SPECIFIC USES/FACTS": "hypertension,\nCHF,\nedema",
      "ACTIONS": "inhibit Na/Cl symporter (more Na Cl in lumen)",
      "ADRS": "hypokalemia,\nhypercalecemia,\nhypomagnesemia,\nhyperglycemia,\nhypovolemia,\nhypotension",
      "FACTS": "Sulfa in all , only need to avoid w/ sulfa anaphalyxis"
    },
    {
      "CATEGORY": "Thiazide Diuretics",
      "DRUG NAME": "metolazone",
      "SPECIFIC USES/FACTS": "ok to use in kidney disease",
      "ACTIONS": "inhibit Na/Cl symporter (more Na Cl in lumen)",
      "ADRS": "hypokalemia,\nhypercalecemia,\nhypomagnesemia,\nhyperglycemia,\nhypovolemia,\nhypotension",
      "FACTS": "Sulfa in all , only need to avoid w/ sulfa anaphalyxis"
    }
  ],
  "Potassium-Sparing Diuretics": [
    {
      "CATEGORY": "Potassium-Sparing Diuretics",
      "SUBCATEGORY": "aldosterone antagonists",
      "DRUG NAME": "spironolactone",
      "SPECIFIC USES/FACTS": "hypertension,\nCHF,\nMI",
      "ACTIONS": "reduce Na/H2O absorption, increase K absorption",
      "ADRS": "hyperkalemia,\nimpotence (steroid related)",
      "DDI's": "DDI's E >>S"
    },
    {
      "CATEGORY": "Potassium-Sparing Diuretics",
      "SUBCATEGORY": "aldosterone antagonists",
      "DRUG NAME": "eplerenone",
      "SPECIFIC USES/FACTS": "hypertension,\nCHF,\nMI",
      "ACTIONS": "reduce Na/H2O absorption, increase K absorption",
      "ADRS": "hyperkalemia,\nimpotence (steroid related)",
      "DDI's": "DDI's E >>S"
    },
    {
      "CATEGORY": "Potassium-Sparing Diuretics",
      "SUBCATEGORY": "Na Channel Blockers",
      "DRUG NAME": "amiloride",
      "SPECIFIC USES/FACTS": "block Na Channel ",
      "ACTIONS": "Inc. Na in lumen,\nDec. K in lumen",
      "ADRS": "hyperkalemia "
    },
    {
      "CATEGORY": "Potassium-Sparing Diuretics",
      "SUBCATEGORY": "aldosterone antagonists",
      "DRUG NAME": "triamterene",
      "SPECIFIC USES/FACTS": "hypertension,\nCHF,\nMI",
      "ACTIONS": "reduce Na/H2O absorption, increase K absorption",
      "ADRS": "hyperkalemia,\nimpotence (steroid related)"
    }
  ],
  "Angiotensin Converting Enzyme (ACE) Inhibitors": [
    {
      "CATEGORY": "Angiotensin Converting Enzyme (ACE) Inhibitors",
      "DRUG NAME": "lisinopril",
      "SPECIFIC USES/FACTS": "hypertension/post MI,\nleft ventricular systolic dysfunction/ systolic heart failure,\nchronic kidney disease (CKD)",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "dry cough,\nhyperkalemia,\nacute renal failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "Can cause acute renal failure when starting therapy or when changing doses. Has reduced efficacy in African Americans b/c pts have low renin hypertension"
    },
    {
      "CATEGORY": "Angiotensin Converting Enzyme (ACE) Inhibitors",
      "DRUG NAME": "enalapril/enalaprilat",
      "SPECIFIC USES/FACTS": "hypertension/post MI,\nleft ventricular systolic dysfunction/ systolic heart failure,\nchronic kidney disease (CKD)",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "dry cough,\nhyperkalemia,\nacute renal failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "Can cause acute renal failure when starting therapy or when changing doses. Has reduced efficacy in African Americans b/c pts have low renin hypertension"
    },
    {
      "CATEGORY": "Angiotensin Converting Enzyme (ACE) Inhibitors",
      "DRUG NAME": "quinapril",
      "SPECIFIC USES/FACTS": "hypertension/post MI,\nleft ventricular systolic dysfunction/ systolic heart failure,\nchronic kidney disease (CKD)",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "dry cough,\nhyperkalemia,\nacute renal failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "Can cause acute renal failure when starting therapy or when changing doses. Has reduced efficacy in African Americans b/c pts have low renin hypertension"
    },
    {
      "CATEGORY": "Angiotensin Converting Enzyme (ACE) Inhibitors",
      "DRUG NAME": "captopril",
      "SPECIFIC USES/FACTS": "hypertension/post MI,\nleft ventricular systolic dysfunction/ systolic heart failure,\nchronic kidney disease (CKD)",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "dry cough,\nhyperkalemia,\nacute renal failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "Can cause acute renal failure when starting therapy or when changing doses. Has reduced efficacy in African Americans b/c pts have low renin hypertension"
    },
    {
      "CATEGORY": "Angiotensin Converting Enzyme (ACE) Inhibitors",
      "DRUG NAME": "ramipril",
      "SPECIFIC USES/FACTS": "hypertension/post MI,\nleft ventricular systolic dysfunction/ systolic heart failure,\nchronic kidney disease (CKD)",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "dry cough,\nhyperkalemia,\nacute renal failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "Can cause acute renal failure when starting therapy or when changing doses. Has reduced efficacy in African Americans b/c pts have low renin hypertension"
    },
    {
      "CATEGORY": "Angiotensin Converting Enzyme (ACE) Inhibitors",
      "DRUG NAME": "benazopril",
      "SPECIFIC USES/FACTS": "hypertension/post MI,\nleft ventricular systolic dysfunction/ systolic heart failure,\nchronic kidney disease (CKD)",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "dry cough,\nhyperkalemia,\nacute renal failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "Can cause acute renal failure when starting therapy or when changing doses. Has reduced efficacy in African Americans b/c pts have low renin hypertension"
    },
    {
      "CATEGORY": "Angiotensin Converting Enzyme (ACE) Inhibitors",
      "DRUG NAME": "fosinopril",
      "SPECIFIC USES/FACTS": "hypertension/post MI,\nleft ventricular systolic dysfunction/ systolic heart failure,\nchronic kidney disease (CKD)",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "dry cough,\nhyperkalemia,\nacute renal failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "Can cause acute renal failure when starting therapy or when changing doses. Has reduced efficacy in African Americans b/c pts have low renin hypertension"
    },
    {
      "CATEGORY": "Angiotensin Converting Enzyme (ACE) Inhibitors",
      "DRUG NAME": "moexipril",
      "SPECIFIC USES/FACTS": "hypertension/post MI,\nleft ventricular systolic dysfunction/ systolic heart failure,\nchronic kidney disease (CKD)",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "dry cough,\nhyperkalemia,\nacute renal failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "Can cause acute renal failure when starting therapy or when changing doses. Has reduced efficacy in African Americans b/c pts have low renin hypertension"
    },
    {
      "CATEGORY": "Angiotensin Converting Enzyme (ACE) Inhibitors",
      "DRUG NAME": "perindopril",
      "SPECIFIC USES/FACTS": "hypertension/post MI,\nleft ventricular systolic dysfunction/ systolic heart failure,\nchronic kidney disease (CKD)",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "dry cough,\nhyperkalemia,\nacute renal failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "Can cause acute renal failure when starting therapy or when changing doses. Has reduced efficacy in African Americans b/c pts have low renin hypertension"
    },
    {
      "CATEGORY": "Angiotensin Converting Enzyme (ACE) Inhibitors",
      "DRUG NAME": "trandolapril",
      "SPECIFIC USES/FACTS": "hypertension/post MI,\nleft ventricular systolic dysfunction/ systolic heart failure,\nchronic kidney disease (CKD)",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "dry cough,\nhyperkalemia,\nacute renal failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "Can cause acute renal failure when starting therapy or when changing doses. Has reduced efficacy in African Americans b/c pts have low renin hypertension"
    }
  ],
  "Angiotensin Receptor Blockers (ARB's)": [
    {
      "CATEGORY": "Angiotensin Receptor Blockers (ARB's)",
      "DRUG NAME": "losartan",
      "SPECIFIC USES/FACTS": "hypertension/post MI/heart failure,\nCKD,\nintolerance to ACEI,\ngout?",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "hyperkalemia,\nacute kidney failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "If pt is on ARB and also has gout may favor losartan as it has a seconrdary uric acid lowering benefit.  Has reduced efficacy in African Americans b/c pts have low renin hypertension."
    },
    {
      "CATEGORY": "Angiotensin Receptor Blockers (ARB's)",
      "DRUG NAME": "valsartan",
      "SPECIFIC USES/FACTS": "hypertension/post MI/heart failure,\nCKD,\nintolerance to ACEI,\ngout?",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "hyperkalemia,\nacute kidney failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "If pt is on ARB and also has gout may favor losartan as it has a seconrdary uric acid lowering benefit.  Has reduced efficacy in African Americans b/c pts have low renin hypertension."
    },
    {
      "CATEGORY": "Angiotensin Receptor Blockers (ARB's)",
      "DRUG NAME": "olmesartan",
      "SPECIFIC USES/FACTS": "hypertension/post MI/heart failure,\nCKD,\nintolerance to ACEI,\ngout?",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "hyperkalemia,\nacute kidney failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "If pt is on ARB and also has gout may favor losartan as it has a seconrdary uric acid lowering benefit.  Has reduced efficacy in African Americans b/c pts have low renin hypertension."
    },
    {
      "CATEGORY": "Angiotensin Receptor Blockers (ARB's)",
      "DRUG NAME": "irbesartan",
      "SPECIFIC USES/FACTS": "hypertension/post MI/heart failure,\nCKD,\nintolerance to ACEI,\ngout?",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "hyperkalemia,\nacute kidney failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "If pt is on ARB and also has gout may favor losartan as it has a seconrdary uric acid lowering benefit.  Has reduced efficacy in African Americans b/c pts have low renin hypertension."
    },
    {
      "CATEGORY": "Angiotensin Receptor Blockers (ARB's)",
      "DRUG NAME": "candesartan",
      "SPECIFIC USES/FACTS": "hypertension/post MI/heart failure,\nCKD,\nintolerance to ACEI,\ngout?",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "hyperkalemia,\nacute kidney failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "If pt is on ARB and also has gout may favor losartan as it has a seconrdary uric acid lowering benefit.  Has reduced efficacy in African Americans b/c pts have low renin hypertension."
    },
    {
      "CATEGORY": "Angiotensin Receptor Blockers (ARB's)",
      "DRUG NAME": "telmisartan",
      "SPECIFIC USES/FACTS": "hypertension/post MI/heart failure,\nCKD,\nintolerance to ACEI,\ngout?",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "hyperkalemia,\nacute kidney failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "If pt is on ARB and also has gout may favor losartan as it has a seconrdary uric acid lowering benefit.  Has reduced efficacy in African Americans b/c pts have low renin hypertension."
    },
    {
      "CATEGORY": "Angiotensin Receptor Blockers (ARB's)",
      "DRUG NAME": "eprosartan",
      "SPECIFIC USES/FACTS": "hypertension/post MI/heart failure,\nCKD,\nintolerance to ACEI,\ngout?",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "hyperkalemia,\nacute kidney failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "If pt is on ARB and also has gout may favor losartan as it has a seconrdary uric acid lowering benefit.  Has reduced efficacy in African Americans b/c pts have low renin hypertension."
    },
    {
      "CATEGORY": "Angiotensin Receptor Blockers (ARB's)",
      "DRUG NAME": "azilsartan",
      "SPECIFIC USES/FACTS": "hypertension/post MI/heart failure,\nCKD,\nintolerance to ACEI,\ngout?",
      "ACTIONS": "↓TPR/BP,\n↓ Na/H2O retention,\n↓ H2O ingestion,\n↓arterial pressure,\n↑compliance of large arteries,\n↓ proteinuria",
      "ADRS": "hyperkalemia,\nacute kidney failure/injury,\nangioedema,\nteratogenic,\nhypotension",
      "Facts": "If pt is on ARB and also has gout may favor losartan as it has a seconrdary uric acid lowering benefit.  Has reduced efficacy in African Americans b/c pts have low renin hypertension."
    }
  ],
  "Angiotensin receptor-neprilysin inhibitor (ARNI)": [
    {
      "CATEGORY": "Angiotensin receptor-neprilysin inhibitor (ARNI)",
      "DRUG NAME": "Entresto (sacubitril/valsartan",
      "SPECIFIC USES/FACTS": "CHF w/ reduced ejection fraction",
      "ACTIONS": "vasodilation,\nnatriuresis,\ndiuresis,\ninhibited pathogenic GF/fibrosis,\nADR effects"
    }
  ],
  "Calcium Channel Blockers": [
    {
      "CATEGORY": "Calcium Channel Blockers",
      "SUBCATEGORY": "Non-Dihydropyridines (Non-DHP's)",
      "DRUG NAME": "verapamil",
      "SPECIFIC USES/FACTS": "atrial fibrillation/flutter,\nparoxysmal supraventricular tachycardia,\nhypertension (DHP preferred),\nmyocardial ischemia/angina",
      "ACTIONS": "peripheral & coronary vasodilation,\nnegative inotrope, chronotrope, dromotrope,\nregulate O2 supply/demand",
      "ADRS": "constipation,\narrhythmias,\nheadache,\ndizziness,\nperipheral edema,\nAV block,\nhypotension,\nsinus bradycardia"
    },
    {
      "CATEGORY": "Calcium Channel Blockers",
      "SUBCATEGORY": "Non-Dihydropyridines (Non-DHP's)",
      "DRUG NAME": "diltiazem",
      "SPECIFIC USES/FACTS": "atrial fibrillation/flutter,\nparoxysmal supraventricular tachycardia,\nhypertension (DHP preferred),\nmyocardial ischemia/angina",
      "ACTIONS": "peripheral & coronary vasodilation,\nnegative inotrope, chronotrope, dromotrope,\nregulate O2 supply/demand",
      "ADRS": "constipation,\narrhythmias,\nhypotension,\nperipheral edema,\nsinus bradycardia,\nheadache,\nAV block,\nrhinitis"
    },
    {
      "CATEGORY": "Calcium Channel Blockers",
      "SUBCATEGORY": "Dihydropyridines (DHP's)",
      "DRUG NAME": "amlodipine",
      "SPECIFIC USES/FACTS": "hypertension,\nmyocaridal ischemia/angina (Non-DHP preferred)",
      "ACTIONS": "peripheral vasodilation",
      "ADRS": "peripheral edema,\nflushing,\npalpitations,\nreflex tachycardia,\nhypotension,\ndizziness,\nfatigue,\nexacerbation of angina,\nprecipitating arrhythmias"
    },
    {
      "CATEGORY": "Calcium Channel Blockers",
      "SUBCATEGORY": "Non-Dihydropyridines (Non-DHP's)",
      "DRUG NAME": "nifedipine",
      "SPECIFIC USES/FACTS": "atrial fibrillation/flutter,\nparoxysmal supraventricular tachycardia,\nhypertension (DHP preferred),\nmyocardial ischemia/angina",
      "ACTIONS": "peripheral & coronary vasodilation,\nnegative inotrope, chronotrope, dromotrope,\nregulate O2 supply/demand",
      "ADRS": "constipation,\narrhythmias,\nheadache,\ndizziness,\nperipheral edema,\nAV block,\nhypotension,\nsinus bradycardia"
    },
    {
      "CATEGORY": "Calcium Channel Blockers",
      "SUBCATEGORY": "Non-Dihydropyridines (Non-DHP's)",
      "DRUG NAME": "nicardipine",
      "SPECIFIC USES/FACTS": "atrial fibrillation/flutter,\nparoxysmal supraventricular tachycardia,\nhypertension (DHP preferred),\nmyocardial ischemia/angina",
      "ACTIONS": "peripheral & coronary vasodilation,\nnegative inotrope, chronotrope, dromotrope,\nregulate O2 supply/demand",
      "ADRS": "constipation,\narrhythmias,\nheadache,\ndizziness,\nperipheral edema,\nAV block,\nhypotension,\nsinus bradycardia"
    },
    {
      "CATEGORY": "Calcium Channel Blockers",
      "SUBCATEGORY": "Non-Dihydropyridines (Non-DHP's)",
      "DRUG NAME": "felodipine",
      "SPECIFIC USES/FACTS": "atrial fibrillation/flutter,\nparoxysmal supraventricular tachycardia,\nhypertension (DHP preferred),\nmyocardial ischemia/angina",
      "ACTIONS": "peripheral & coronary vasodilation,\nnegative inotrope, chronotrope, dromotrope,\nregulate O2 supply/demand",
      "ADRS": "constipation,\narrhythmias,\nheadache,\ndizziness,\nperipheral edema,\nAV block,\nhypotension,\nsinus bradycardia"
    },
    {
      "CATEGORY": "Calcium Channel Blockers",
      "SUBCATEGORY": "Non-Dihydropyridines (Non-DHP's)",
      "DRUG NAME": "isradipine",
      "SPECIFIC USES/FACTS": "atrial fibrillation/flutter,\nparoxysmal supraventricular tachycardia,\nhypertension (DHP preferred),\nmyocardial ischemia/angina",
      "ACTIONS": "peripheral & coronary vasodilation,\nnegative inotrope, chronotrope, dromotrope,\nregulate O2 supply/demand",
      "ADRS": "constipation,\narrhythmias,\nheadache,\ndizziness,\nperipheral edema,\nAV block,\nhypotension,\nsinus bradycardia"
    },
    {
      "CATEGORY": "Calcium Channel Blockers",
      "SUBCATEGORY": "Non-Dihydropyridines (Non-DHP's)",
      "DRUG NAME": "nimodipine",
      "SPECIFIC USES/FACTS": "atrial fibrillation/flutter,\nparoxysmal supraventricular tachycardia,\nhypertension (DHP preferred),\nmyocardial ischemia/angina",
      "ACTIONS": "peripheral & coronary vasodilation,\nnegative inotrope, chronotrope, dromotrope,\nregulate O2 supply/demand",
      "ADRS": "constipation,\narrhythmias,\nheadache,\ndizziness,\nperipheral edema,\nAV block,\nhypotension,\nsinus bradycardia"
    },
    {
      "CATEGORY": "Calcium Channel Blockers",
      "SUBCATEGORY": "Non-Dihydropyridines (Non-DHP's)",
      "DRUG NAME": "nisoldipine",
      "SPECIFIC USES/FACTS": "atrial fibrillation/flutter,\nparoxysmal supraventricular tachycardia,\nhypertension (DHP preferred),\nmyocardial ischemia/angina",
      "ACTIONS": "peripheral & coronary vasodilation,\nnegative inotrope, chronotrope, dromotrope,\nregulate O2 supply/demand",
      "ADRS": "constipation,\narrhythmias,\nheadache,\ndizziness,\nperipheral edema,\nAV block,\nhypotension,\nsinus bradycardia"
    },
    {
      "CATEGORY": "Calcium Channel Blockers",
      "SUBCATEGORY": "Non-Dihydropyridines (Non-DHP's)",
      "DRUG NAME": "clevidipine",
      "SPECIFIC USES/FACTS": "atrial fibrillation/flutter,\nparoxysmal supraventricular tachycardia,\nhypertension (DHP preferred),\nmyocardial ischemia/angina",
      "ACTIONS": "peripheral & coronary vasodilation,\nnegative inotrope, chronotrope, dromotrope,\nregulate O2 supply/demand",
      "ADRS": "constipation,\narrhythmias,\nheadache,\ndizziness,\nperipheral edema,\nAV block,\nhypotension,\nsinus bradycardia"
    }
  ],
  "Pro-GH ": [
    {
      "CATEGORY": "Pro-GH ",
      "SUB-CATEGORY": "recombinant GHRH",
      "DRUG NAME": "tesamorelin",
      "SPECIFIC USES": "replacement therapy (short children, GH deficiency),\nmuscle wasting in HIV pt,\nshort bowel syndrome w/ TPN (nutritional support)",
      "ACTIONS": "↑gluconeogenesis,\nstimulate bone growth,\n↑lipolysis,\n↑muscle mass,\nstimulate organ growth (except brain),\n↓body fat",
      "ADRS": "arthralgia, \nmusculoskeletal pain,\nmetabolic complications,\nperipheral edema,\ninjection site pain,\nflu-like symptoms,\nhematologic effects,\nhypoglycemia (mecasermin only)"
    },
    {
      "CATEGORY": "Pro-GH ",
      "SUB-CATEGORY": "recombinant human GH",
      "DRUG NAME": "somatropin",
      "SPECIFIC USES": "replacement therapy (short children, GH deficiency),\nmuscle wasting in HIV pt,\nshort bowel syndrome w/ TPN (nutritional support)",
      "ACTIONS": "↑gluconeogenesis,\nstimulate bone growth,\n↑lipolysis,\n↑muscle mass,\nstimulate organ growth (except brain),\n↓body fat",
      "ADRS": "arthralgia, \nmusculoskeletal pain,\nmetabolic complications,\nperipheral edema,\ninjection site pain,\nflu-like symptoms,\nhematologic effects,\nhypoglycemia (mecasermin only)"
    },
    {
      "CATEGORY": "Pro-GH ",
      "SUB-CATEGORY": "recombinant IGF-1",
      "DRUG NAME": "mecasermin",
      "SPECIFIC USES": "severe GH resistance,\nIGF-1 deficiency for long term treatment of growth failure",
      "ACTIONS": "↑gluconeogenesis,\nstimulate bone growth,\n↑lipolysis,\n↑muscle mass,\nstimulate organ growth (except brain),\n↓body fat",
      "ADRS": "arthralgia, \nmusculoskeletal pain,\nmetabolic complications,\nperipheral edema,\ninjection site pain,\nflu-like symptoms,\nhematologic effects,\nhypoglycemia (mecasermin only)"
    }
  ],
  "Anti-GH": [
    {
      "CATEGORY": "Anti-GH",
      "SUB-CATEGORY": "somatostatin analogs",
      "DRUG NAME": "octreotide",
      "SPECIFIC USES": "pituitary tumor,\nexcess GH,\ngigantism,\nacromegaly,\nhypertension,\nglucose intolerance,\nsleep apnea",
      "ACTIONS": "inhibits GHRH release",
      "ADRS": "nausea/vomiting,\nflatulence,\nabdominal cramps,\nfatty diarrhea,\ninjection site pain,\nneurologic complications,\nhyperglycemia (rare),\n↑morbidity due to CV disease & upper airway obstruction",
      "FACTS": "more commonly used"
    },
    {
      "CATEGORY": "Anti-GH",
      "SUB-CATEGORY": "somatostatin analogs",
      "DRUG NAME": "lanreotide",
      "SPECIFIC USES": "pituitary tumor,\nexcess GH,\ngigantism,\nacromegaly,\nhypertension,\nglucose intolerance,\nsleep apnea",
      "ACTIONS": "inhibits GHRH release",
      "ADRS": "nausea/vomiting,\nflatulence,\nabdominal cramps,\nfatty diarrhea,\ninjection site pain,\nneurologic complications,\nhyperglycemia (rare),\n↑morbidity due to CV disease & upper airway obstruction",
      "FACTS": "more selective, but more expensive"
    },
    {
      "CATEGORY": "Anti-GH",
      "SUB-CATEGORY": "GH antagonist",
      "DRUG NAME": "pegvisomant",
      "SPECIFIC USES": "pituitary tumor,\nexcess GH,\ngigantism,\nacromegaly,\nhypertension,\nglucose intolerance,\nsleep apnea",
      "ACTIONS": "blocks GH binding",
      "ADRS": "chest pain,\nperipheral edema,\ninjection site reaction,\nnausea,\nflu-like syndrome,\nelevated liver enzymes,\npotential antibody formation,\nGH deficient state,\n↑morbidity due to CV disease & upper airway obstruction"
    }
  ],
  "NSAIDs": [
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "aspirin (ASA)",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children",
      "FACTS": "used only in low dose (75-325mg),\nhigh dose has similar effect to NSAIDs but causes too many ADRS,\nC/I: hemophelia"
    },
    {
      "CATEGORY": "NSAIDs",
      "SUB-CATEGORY": "COX-2 Inhibitor",
      "DRUG NAME": "celecoxib",
      "SPECIFIC USES": "osteoarthritis, RA, moderate pain, other NSAID intolerance",
      "ACTIONS": "COX-2 inhibitor (↓PGI2, ↓PGE2 in inflamed areas)",
      "ADRS": "↑cardiovascular events, fewer GI ADRS than general COX inhibitors",
      "FACTS": "sulfa allergy?,\nblack box warning: ↑ risk for MI/stroke"
    },
    {
      "CATEGORY": "NSAIDs",
      "SUB-CATEGORY": "Slightly more selective for COX-2",
      "DRUG NAME": "diclofenac",
      "SPECIFIC USES": "pain relief,\ntreat PDA in premature infants",
      "DRUG-DRUG INTERACTIONS": "shouldn't be used w/ aspirin due to increased GI upset",
      "ACTIONS": "non-selective COX inhibitor (↓TXA2, ↓PGI2, ↓PGE2),\n↓platelet aggregation,\nvasoconstriction,\ntemp. control,\n↓mucous secretion in stomach,\n↓inflammation,\n↓pain perception",
      "ADRS": "headaches,\ntinnitus,\ndizziness,\nhypertension,\nedema,\nfluid retention,\nabdominal pain,\ndysplasia,\nn/v,\nGI ulcers/bleeding,\nthrombocytopenia,\nneutropenia,\naplastic anemia,\nliver failure,\nasthma,\nrenal insufficiency,\nhyperkalemia,\nproeinuria,\nhypersensitivity reactions can occur"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "meloxicam",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "etodolac",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "SUB-CATEGORY": "non-selective COX-1 and COX-2 inhibitors",
      "DRUG NAME": "ketorolac (toradol)",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "ibuprofen",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "nabumetone",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "naproxen",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "bromfenac",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "indomethacin",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "fenoprofen",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "flubiprofen",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "ketoprofen",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "mefanamic acid",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "oxaprozin",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "piroxicam",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "sulindac",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    },
    {
      "CATEGORY": "NSAIDs",
      "DRUG NAME": "tolmetin",
      "SPECIFIC USES": "arterial thrombosis,\ncardioprotection",
      "ACTIONS": "reduces TXA2 effects on platelets, inhibits platelets",
      "ADRS": "GI bleed/ulcers,\niron deficiency anemia,\nReye's syndrome (liver failure, encephalopathy) if w/ viral infection in children"
    }
  ],
  "Weak COX-1 and COX-2 inhibitor": [
    {
      "CATEGORY": "Weak COX-1 and COX-2 inhibitor",
      "DRUG NAME": "acetaminophen (APAP)",
      "SPECIFIC USES": "pain relief, fever reducer",
      "ACTIONS": "analgesic,\nantipyretic (temp control),\n?↓serotonin pathways,\n?changing NO pathway,\n↑NAPQI concentration",
      "ADRS": "↓GI/platelet/renal ADRS than NSAIDs,\nAPAP toxicity (large dose depletes GSH so NAPQI can't be detoxified; hepatic necrosis)[treat w/ mucomist (n-acetylcysteine (NAC))]"
    }
  ],
  "HYPERthyroid Drugs": [
    {
      "CATEGORY": "HYPERthyroid Drugs",
      "SUB-CATEGORY": "thioamides",
      "DRUG NAME": "methimazole",
      "SPECIFIC USES": "hyperthyroidism",
      "ACTIONS": "inhibit iodine incorporation into thyroglobulin",
      "ADRS": "hepatotoxic (less risk than PTU)",
      "FACTS": "drug of choice,\nfaster onset,\ndaily dosing,\npreferred after 1st trimester of pregnancy,\nsafe in lactation"
    },
    {
      "CATEGORY": "HYPERthyroid Drugs",
      "SUB-CATEGORY": "thioamides",
      "DRUG NAME": "propylthiouracil (PTU)",
      "SPECIFIC USES": "hyperthyroidism, \nthyroid storm,\nintolerance of methimazole",
      "ACTIONS": "inhibit iodine incorporation into thyroglobulin,\nblocks peripheral conversion of T4 to T3",
      "ADRS": "agranulocytosis,\nhepatotoxic",
      "FACTS": "preferred in 1st trimester of pregnancy,\nsafe in lactation (Drug of Choice)"
    },
    {
      "CATEGORY": "HYPERthyroid Drugs",
      "DRUG NAME": "sodium iodide (I-131)",
      "SPECIFIC USES": "measure thyroid function,\nthyroid cancer (thyroid ablasion)",
      "ACTIONS": "mimics iodide; gets taken up by thyroglobulin",
      "ADRS": "permanent hypothyroidism",
      "FACTS": "takes 4-8 wks for symptomatic relief (w/ ablasion)"
    },
    {
      "CATEGORY": "HYPERthyroid Drugs",
      "SUB-CATEGORY": "potassium iodide",
      "DRUG NAME": "SSKI",
      "SPECIFIC USES": "thyroid storm,\npre-op thyroidectomy",
      "ACTIONS": "saturate thyroglobin w/ iodine so it stops putting out T3/T4",
      "FACTS": "will cause initial spike in T3/T4, must give with thiamide to prevent fatal hyper thyroidism"
    },
    {
      "CATEGORY": "HYPERthyroid Drugs",
      "SUB-CATEGORY": "thioamides",
      "DRUG NAME": "Lugols solution",
      "SPECIFIC USES": "hyperthyroidism",
      "ACTIONS": "inhibit iodine incorporation into thyroglobulin",
      "ADRS": "hepatotoxic (less risk than PTU)",
      "FACTS": "drug of choice,\nfaster onset,\ndaily dosing,\npreferred after 1st trimester of pregnancy,\nsafe in lactation"
    }
  ],
  "HYPOthyroid Drugs": [
    {
      "CATEGORY": "HYPOthyroid Drugs",
      "DRUG NAME": "levothyroxine",
      "SPECIFIC USES": "hypothyroidism",
      "DRUG-DRUG INTERACTIONS": "fiber, antacids, iron, calcium, sucralfate, cholestyramine,\nwarfarin, rifampin, phenytoin, carbamazepine",
      "ACTIONS": "synthetic T4",
      "ADRS": "nausea/vomiting,\ndiarrhea,\nchange in appetite & weight,\nsweating,\nheadache,\ninsomnia,\nreduction in bone mineral density (rare)",
      "FACTS": "take on empty stomach,\nmonitor: TSH free T4,\nbrand/generic bioequivalence issues,\nDOC,\nsafe & preferred in pregnancy/lactation"
    },
    {
      "CATEGORY": "HYPOthyroid Drugs",
      "DRUG NAME": "liothyronine",
      "SPECIFIC USES": "diagnostic tool in T3 suppression test",
      "DRUG-DRUG INTERACTIONS": "Absorption: cholestyramine,\nferrous sulfate,\nsucralfate,\ncalcium,\nantacids,\nsodium polystyrene sulfonate\nreducing conversion of T4 to T3: cortiocosteroids,\nbeta blockers,\namiodarone\n*applies to livothyroxine too*",
      "ACTIONS": "synthetic T3",
      "ADRS": "arrhythmia,\ntachycardia,\ncardiopulmonary arrest,\nhypotension,\nMI",
      "FACTS": "monitor: TSH, T4, BP, HR, renal function,\nnot intented for monotherapy,\nshort half life,\nexpensive"
    },
    {
      "CATEGORY": "HYPOthyroid Drugs",
      "DRUG NAME": "liotrix",
      "SPECIFIC USES": "hypothyroidism",
      "DRUG-DRUG INTERACTIONS": "fiber, antacids, iron, calcium, sucralfate, cholestyramine,\nwarfarin, rifampin, phenytoin, carbamazepine",
      "ACTIONS": "combination T4 & T3 (4:1)",
      "ADRS": "tachycardia,\nangina,\nmyxedema coma (exaggerated hypothyroidism),\ndecreased bone mineral density ",
      "FACTS": "monitor: TSH, T4, BP, HR, renal function,\nexpensive,\ncomplex dosing,\nNOT RECOMMENDED FOR USE (no benefit over T4 alone)"
    },
    {
      "CATEGORY": "HYPOthyroid Drugs",
      "DRUG NAME": "desiccated thyroid",
      "SPECIFIC USES": "hypothyroidism",
      "DRUG-DRUG INTERACTIONS": "fiber, antacids, iron, calcium, sucralfate, cholestyramine,\nwarfarin, rifampin, phenytoin, carbamazepine",
      "ACTIONS": "porcine or beef TH",
      "ADRS": "allergy,\ntachycardia,\nangina,\nmyxedema coma (exaggerated hypothyroidism),\ndecreased bone mineral density ",
      "FACTS": "monitor: TSH, T4, clinical S/S,\nbioequivalence issues,\nNO LONGER RECOMMENDED FOR USE"
    }
  ],
  "Typical Antipsychotics": [
    {
      "CATEGORY": "Typical Antipsychotics",
      "SUB-CATEGORY": "phenothiazines",
      "DRUG NAME": "chlorpromazine",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes",
      "ACTIONS": "D2 receptor blocker,\nmuscarinic blocker,\nhistamine 1 blocker (inversely proportional to D2 blockage strength),\nalpha-1 blocker,\nminimal alpha-2 blocker",
      "ADRS": "extra pyramidal symptoms (EPS),\nworsening of negative symptoms,\n↑prolactin,\nworse cognition\nneuroleptic malignant syndrome (NMS)(muscle rigidity, hyperpyrexia, autonomic instability, altered consciousness, elevated WBC, CPK, LFT, myoglobinemia/uria, death [arrhythmias, renal failure, respiratory failure])"
    },
    {
      "CATEGORY": "Typical Antipsychotics",
      "SUB-CATEGORY": "phenothiazines",
      "DRUG NAME": "fluphenazine",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes",
      "ACTIONS": "D2 receptor blocker,\nmuscarinic blocker,\nhistamine 1 blocker (inversely proportional to D2 blockage strength),\nalpha-1 blocker,\nminimal alpha-2 blocker",
      "ADRS": "extra pyramidal symptoms (EPS),\nworsening of negative symptoms,\n↑prolactin,\nworse cognition\nneuroleptic malignant syndrome (NMS)(muscle rigidity, hyperpyrexia, autonomic instability, altered consciousness, elevated WBC, CPK, LFT, myoglobinemia/uria, death [arrhythmias, renal failure, respiratory failure])"
    },
    {
      "CATEGORY": "Typical Antipsychotics",
      "DRUG NAME": "thiothixene",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes",
      "ACTIONS": "D2 receptor blocker,\nmuscarinic blocker,\nhistamine 1 blocker (inversely proportional to D2 blockage strength),\nalpha-1 blocker,\nminimal alpha-2 blocker",
      "ADRS": "extra pyramidal symptoms (EPS),\nworsening of negative symptoms,\n↑prolactin,\nworse cognition\nneuroleptic malignant syndrome (NMS)(muscle rigidity, hyperpyrexia, autonomic instability, altered consciousness, elevated WBC, CPK, LFT, myoglobinemia/uria, death [arrhythmias, renal failure, respiratory failure])"
    },
    {
      "CATEGORY": "Typical Antipsychotics",
      "SUB-CATEGORY": "butyrophenones",
      "DRUG NAME": "haloperidol",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes",
      "ACTIONS": "D2 receptor blocker,\nmuscarinic blocker,\nhistamine 1 blocker (inversely proportional to D2 blockage strength),\nalpha-1 blocker,\nminimal alpha-2 blocker",
      "ADRS": "extra pyramidal symptoms (EPS),\nworsening of negative symptoms,\n↑prolactin,\nworse cognition\nneuroleptic malignant syndrome (NMS)(muscle rigidity, hyperpyrexia, autonomic instability, altered consciousness, elevated WBC, CPK, LFT, myoglobinemia/uria, death [arrhythmias, renal failure, respiratory failure])"
    },
    {
      "CATEGORY": "Typical Antipsychotics",
      "SUB-CATEGORY": "phenothiazines",
      "DRUG NAME": "droperidol",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes",
      "ACTIONS": "D2 receptor blocker,\nmuscarinic blocker,\nhistamine 1 blocker (inversely proportional to D2 blockage strength),\nalpha-1 blocker,\nminimal alpha-2 blocker",
      "ADRS": "extra pyramidal symptoms (EPS),\nworsening of negative symptoms,\n↑prolactin,\nworse cognition\nneuroleptic malignant syndrome (NMS)(muscle rigidity, hyperpyrexia, autonomic instability, altered consciousness, elevated WBC, CPK, LFT, myoglobinemia/uria, death [arrhythmias, renal failure, respiratory failure])",
      "FACTS": "not used due to QT prolongation risk"
    },
    {
      "CATEGORY": "Typical Antipsychotics",
      "DRUG NAME": "loxapine",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes",
      "ACTIONS": "D2 receptor blocker,\nmuscarinic blocker,\nhistamine 1 blocker (inversely proportional to D2 blockage strength),\nalpha-1 blocker,\nminimal alpha-2 blocker",
      "ADRS": "extra pyramidal symptoms (EPS),\nworsening of negative symptoms,\n↑prolactin,\nworse cognition\nneuroleptic malignant syndrome (NMS)(muscle rigidity, hyperpyrexia, autonomic instability, altered consciousness, elevated WBC, CPK, LFT, myoglobinemia/uria, death [arrhythmias, renal failure, respiratory failure])",
      "FACTS": "mild 5-HT2 antagonist"
    },
    {
      "CATEGORY": "Typical Antipsychotics",
      "DRUG NAME": "molindone",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes",
      "ACTIONS": "D2 receptor blocker,\nmuscarinic blocker,\nhistamine 1 blocker (inversely proportional to D2 blockage strength),\nalpha-1 blocker,\nminimal alpha-2 blocker",
      "ADRS": "extra pyramidal symptoms (EPS),\nworsening of negative symptoms,\n↑prolactin,\nworse cognition\nneuroleptic malignant syndrome (NMS)(muscle rigidity, hyperpyrexia, autonomic instability, altered consciousness, elevated WBC, CPK, LFT, myoglobinemia/uria, death [arrhythmias, renal failure, respiratory failure])"
    },
    {
      "CATEGORY": "Typical Antipsychotics",
      "DRUG NAME": "pimozide",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes",
      "ACTIONS": "D2 receptor blocker,\nmuscarinic blocker,\nhistamine 1 blocker (inversely proportional to D2 blockage strength),\nalpha-1 blocker,\nminimal alpha-2 blocker",
      "ADRS": "extra pyramidal symptoms (EPS),\nworsening of negative symptoms,\n↑prolactin,\nworse cognition\nneuroleptic malignant syndrome (NMS)(muscle rigidity, hyperpyrexia, autonomic instability, altered consciousness, elevated WBC, CPK, LFT, myoglobinemia/uria, death [arrhythmias, renal failure, respiratory failure])",
      "FACTS": "most D2 selective "
    }
  ],
  "Atypical Antipsychotics": [
    {
      "CATEGORY": "Atypical Antipsychotics",
      "DRUG NAME": "clozapine",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes,\ndepression/anxiety (w/ SSRI's)",
      "ACTIONS": "D2 antagonist (improve positive symptoms),\n5-HT2 antagonist (improve negative symptoms, improved cognition, antidepressant/antianxiety)",
      "ADRS": "EPS (less than typical antipsychotics),\nweight gain,\nsedation,\nconstipation,\npostural hypotension,\nsexual dysfunction,\n↑prolactin,\nworse cognition"
    },
    {
      "CATEGORY": "Atypical Antipsychotics",
      "DRUG NAME": "risperidone",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes,\ndepression/anxiety (w/ SSRI's)",
      "ACTIONS": "D2 antagonist (improve positive symptoms),\n5-HT2 antagonist (improve negative symptoms, improved cognition, antidepressant/antianxiety)",
      "DDI's": "metabolized by CYP2D6",
      "ADRS": "EPS (less than typical antipsychotics),\nweight gain,\nsedation,\nconstipation,\npostural hypotension,\nsexual dysfunction,\n↑prolactin,\nworse cognition",
      "FACTS": "high EPS,\nhigh akathisia,\nlowest sedation risk,\nmoderate risk of weight gain"
    },
    {
      "CATEGORY": "Atypical Antipsychotics",
      "DRUG NAME": "olanzapine",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes,\ndepression/anxiety (w/ SSRI's)",
      "ACTIONS": "D2 antagonist (improve positive symptoms),\n5-HT2 antagonist (improve negative symptoms, improved cognition, antidepressant/antianxiety)",
      "DDI's": "metabolized by CYP1A2 & CYP2D6",
      "ADRS": "EPS (less than typical antipsychotics),\nweight gain,\nsedation,\nconstipation,\npostural hypotension,\nsexual dysfunction,\n↑prolactin,\nworse cognition",
      "FACTS": "low EPS,\nlow akathisia,\nhigh sedation risk,\nhighest risk of weight gain"
    },
    {
      "CATEGORY": "Atypical Antipsychotics",
      "DRUG NAME": "quetiapine",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes,\ndepression/anxiety (w/ SSRI's)",
      "ACTIONS": "D2 antagonist (improve positive symptoms),\n5-HT2 antagonist (improve negative symptoms, improved cognition, antidepressant/antianxiety)",
      "DDI's": "metabolized by CYP3A4",
      "ADRS": "EPS (less than typical antipsychotics),\nweight gain,\nsedation,\nconstipation,\npostural hypotension,\nsexual dysfunction,\n↑prolactin,\nworse cognition",
      "FACTS": "lowest EPS,\nlowest akathisia,\nhighest sedation risk,\nhigh risk of weigh gain"
    },
    {
      "CATEGORY": "Atypical Antipsychotics",
      "DRUG NAME": "ziprasidone",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes,\ndepression/anxiety (w/ SSRI's)",
      "ACTIONS": "D2 antagonist (improve positive symptoms),\n5-HT2 antagonist (improve negative symptoms, improved cognition, antidepressant/antianxiety)",
      "DDI's": "metabolized by CYP3A4",
      "ADRS": "EPS (less than typical antipsychotics),\nweight gain,\nsedation,\nconstipation,\npostural hypotension,\nsexual dysfunction,\n↑prolactin,\nworse cognition",
      "FACTS": "moderate EPS,\nmild/moderate akathisia,\nhigh sedation risk,\nhighest risk of QTc issues,\nlowest risk of weight gain,\nPO 40-160mg daily (in 2 doses),\nbest absorbed w/ food"
    },
    {
      "CATEGORY": "Atypical Antipsychotics",
      "DRUG NAME": "paliperidone",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes,\ndepression/anxiety (w/ SSRI's)",
      "ACTIONS": "D2 antagonist (improve positive symptoms),\n5-HT2 antagonist (improve negative symptoms, improved cognition, antidepressant/antianxiety)",
      "DDI's": "metabolized by CYP3A4 (can still be excreted witout metabolism)",
      "ADRS": "EPS (less than typical antipsychotics),\nweight gain,\nsedation,\nconstipation,\npostural hypotension,\nsexual dysfunction,\n↑prolactin,\nworse cognition",
      "FACTS": "moderate EPS,\nmoderate akathisia,\nmild/moderate sedation risk,\nmoderate risk of weight gain"
    },
    {
      "CATEGORY": "Atypical Antipsychotics",
      "DRUG NAME": "iloperidone",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes,\ndepression/anxiety (w/ SSRI's)",
      "ACTIONS": "D2 antagonist (improve positive symptoms),\n5-HT2 antagonist (improve negative symptoms, improved cognition, antidepressant/antianxiety)",
      "DDI's": "metabolized by CYP3A4 & CYP2D6",
      "ADRS": "EPS (less than typical antipsychotics),\nweight gain,\nsedation,\nconstipation,\npostural hypotension,\nsexual dysfunction,\n↑prolactin,\nworse cognition",
      "FACTS": "mild EPS,\nlow sedation risk,\nhigh risk of weight gain"
    },
    {
      "CATEGORY": "Atypical Antipsychotics",
      "DRUG NAME": "asenapine",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes,\ndepression/anxiety (w/ SSRI's)",
      "ACTIONS": "D2 antagonist (improve positive symptoms),\n5-HT2 antagonist (improve negative symptoms, improved cognition, antidepressant/antianxiety)",
      "DDI's": "metabolized by CYP1A2",
      "ADRS": "EPS (less than typical antipsychotics),\nweight gain,\nsedation,\nconstipation,\npostural hypotension,\nsexual dysfunction,\n↑prolactin,\nworse cognition",
      "FACTS": "mild/moderate EPS,\nmoderate sedation risk,\nmild/moderate risk of weight gain,\nsublingual 5-10mg BID,\ndo not eat or drink for 10 minutes after taking"
    },
    {
      "CATEGORY": "Atypical Antipsychotics",
      "DRUG NAME": "lurasidone",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes,\ndepression/anxiety (w/ SSRI's)",
      "ACTIONS": "D2 antagonist (improve positive symptoms),\n5-HT2 antagonist (improve negative symptoms, improved cognition, antidepressant/antianxiety)",
      "DDI's": "metabolized by CYP3A4",
      "ADRS": "EPS (less than typical antipsychotics),\nweight gain,\nsedation,\nconstipation,\npostural hypotension,\nsexual dysfunction,\n↑prolactin,\nworse cognition",
      "FACTS": "highest EPS, \nmoderate sedation (H1 antagonism),\nleast risk for QTc (K channel blocking),\nlow risk of weight gain,\nbest absorbed w/ food,\nPO 40-60mg daily"
    },
    {
      "CATEGORY": "Atypical Antipsychotics",
      "SUB-CATEGORY": "agonist/antagonist at D2",
      "DRUG NAME": "brexpiprazole",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes,\ndepression/anxiety (w/ SSRI's)",
      "ACTIONS": "D2 agonist/antagonist (equalizes level of DA at each receptor)",
      "DDI's": "metabolized by CYP2D6 & CYP3A4",
      "ADRS": "EPS (less than typical antipsychotics),\nweight gain,\nsedation,\nconstipation,\npostural hypotension,\nsexual dysfunction,\n↑prolactin,\nworse cognition"
    },
    {
      "CATEGORY": "Atypical Antipsychotics",
      "DRUG NAME": "cariprazine",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes,\ndepression/anxiety (w/ SSRI's)",
      "ACTIONS": "D2 antagonist (improve positive symptoms),\n5-HT2 antagonist (improve negative symptoms, improved cognition, antidepressant/antianxiety)",
      "DDI's": "metabolized by CYP3A4",
      "ADRS": "EPS (less than typical antipsychotics),\nweight gain,\nsedation,\nconstipation,\npostural hypotension,\nsexual dysfunction,\n↑prolactin,\nworse cognition"
    },
    {
      "CATEGORY": "Atypical Antipsychotics",
      "DRUG NAME": "aripiprazole",
      "SPECIFIC USES": "schizophrenia,\nschizoaffective disorder,\nbipolar disorder,\naggression in ASD,\nagitation,\npsychosis,\ntourettes,\ndepression/anxiety (w/ SSRI's)",
      "ACTIONS": "D2 antagonist (improve positive symptoms),\n5-HT2 antagonist (improve negative symptoms, improved cognition, antidepressant/antianxiety)",
      "DDI's": "metabolized by CYP3A4 & CYP2D6",
      "ADRS": "EPS (less than typical antipsychotics),\nweight gain,\nsedation,\nconstipation,\npostural hypotension,\nsexual dysfunction,\n↑prolactin,\nworse cognition",
      "FACTS": "highest risk of akathisia,\nhigh EPS,\nmild sedation,\nleast risk for QTc,\nmild risk of weight gain"
    }
  ],
  "Spasmolytics": [
    {
      "CATEGORY": "Spasmolytics",
      "SUB-CATEGORY": "GABA-A agonist",
      "DRUG NAME": "diazepam",
      "SPECIFIC USES": "spasm of any origin (most effective in cord resection)",
      "ACTIONS": "stimulates K influx which hyperpolarizes neurons (less action potentials)",
      "ADRS": "hypotension,\nsedation,\n↓respirations",
      "FACTS": "can accumulate in fat,\ncaution in elderly pt's,\ncan be non-selective in spinal cord,\nrapid acting (lipophillic)"
    },
    {
      "CATEGORY": "Spasmolytics",
      "SUB-CATEGORY": "GABA-B agonist",
      "DRUG NAME": "baclofen",
      "SPECIFIC USES": "muscle spasticity,\nmobility in MS,\nspinal cord injury",
      "ACTIONS": "inhibit Ca entry presynaptically (less glutamate released),\nstimulate K efflux postsynaptically (hyperpolarization)",
      "DDI's": "careful w/ other CNS depressants, will have additive effect",
      "ADRS": "sedation,\ndrowsiness,\nlost motor control,\nmuscle weakness (dose related),\nabrupt withdrawal reaction (hyperpyrexia, rebound spasticity, muscular rigidity, rhabdomyolysis, seizures)",
      "FACTS": "tolerance to sedation & symptomatic relief,\ngiven PO or IT"
    },
    {
      "CATEGORY": "Spasmolytics",
      "SUB-CATEGORY": "Alpha-2 agonists",
      "DRUG NAME": "tizanidine",
      "SPECIFIC USES": "muscle spasticity, \nMS,\nspinal cord injury",
      "ACTIONS": "inhibit Ca entry presynaptically (less glutamate released),\nMIGHT reduce action potentials",
      "ADRS": "sedation,\ndrowsiness,\nxerostomia,\nhypotension,\nbradycardia (more w/ clonidine),\nloss of strength,\nabrupt withdrawal (rebound HTN, tachycardia, hypertonia/spasticity)",
      "FACTS": "equal efficacy to diazepam & baclofen,\nsedation/drowsiness more than others,\nless muscle weakness than baclofen,\nless cardiac impact"
    },
    {
      "CATEGORY": "Spasmolytics",
      "SUB-CATEGORY": "GABA-A agonist",
      "DRUG NAME": "clonidine",
      "SPECIFIC USES": "spasm of any origin (most effective in cord resection)",
      "ACTIONS": "stimulates K influx which hyperpolarizes neurons (less action potentials)",
      "ADRS": "hypotension,\nsedation,\n↓respirations",
      "FACTS": "can accumulate in fat,\ncaution in elderly pt's,\ncan be non-selective in spinal cord,\nrapid acting (lipophillic)"
    },
    {
      "CATEGORY": "Spasmolytics",
      "SUB-CATEGORY": "TCA- related",
      "DRUG NAME": "cyclobenzaprine",
      "SPECIFIC USES": "acute, local muscle spasm",
      "ACTIONS": "central 5HT augmentation at spinal cord level,\n↓pain/tenderness,\nimproved mobility",
      "DDI's": "additive w/ CNS depressants",
      "ADRS": "anticholinergic activity,\nsedation,\nconfusion,\ntransient visual hallucinations,\narrhythmias,\ntachycardia,\nprolonged conduction time ",
      "FACTS": "should not be used for chronic spasms"
    },
    {
      "CATEGORY": "Spasmolytics",
      "DRUG NAME": "metaxalone",
      "SPECIFIC USES": "acute, local muscle spasm,\nmusculoskeletal pain",
      "ACTIONS": "depress polysynaptic neuronal transmission in spinal cord & brainstem",
      "DDI's": "additive w/ CNS depressants",
      "ADRS": "sedation,\ndrowsiness"
    },
    {
      "CATEGORY": "Spasmolytics",
      "DRUG NAME": "methocarbamol",
      "SPECIFIC USES": "acute, local muscle spasm,\nmusculoskeletal pain,\ntetanus",
      "ACTIONS": "stimulates K influx which hyperpolarizes neurons (less action potentials)",
      "DDI's": "additive w/ CNS depressants",
      "ADRS": "sedation,\ndrowsiness,\nbradycardia,\nhypotension"
    },
    {
      "CATEGORY": "Spasmolytics",
      "DRUG NAME": "orphenadrine",
      "SPECIFIC USES": "acute, local muscle spasm,\nmusculoskeletal pain",
      "ACTIONS": "stimulates K influx which hyperpolarizes neurons (less action potentials)",
      "DDI's": "additive w/ CNS depressants",
      "ADRS": "sedation,\ndrowsiness,\ntachycardia,\nxerostomia"
    },
    {
      "CATEGORY": "Spasmolytics",
      "DRUG NAME": "carisoprodol",
      "SPECIFIC USES": "acute, local muscle spasm,\nmusculoskeletal pain",
      "ACTIONS": "stimulates K influx which hyperpolarizes neurons (less action potentials)",
      "DDI's": "additive w/ CNS depressants",
      "ADRS": "sedation,\ndrowsiness",
      "FACTS": "potential for abuse (active metabolite is a controlled substance [meprobamate])"
    }
  ],
  "General IV Anesthetics": [
    {
      "CATEGORY": "General IV Anesthetics",
      "DRUG NAME": "propofol",
      "SPECIFIC USES": "anesthesia",
      "ACTIONS": "GABA-A agonist,\nsedative/hypnotic,\n↓cerebral blood flow,\n↓ICP,\nantiemetic",
      "DDI's": "allergies ",
      "ADRS": "propofol infusion syndrome (lipemia, rhabdomyolysis, acidosis),\n↑HR,\nhypotension",
      "FACTS": "\"milk of amnesia\",\nanesthetic of choice,\nno analgesia effect (often given w/ opioid),\nlong infusion does not affect half life"
    },
    {
      "CATEGORY": "General IV Anesthetics",
      "DRUG NAME": "ketamine",
      "SPECIFIC USES": "anesthesia",
      "ACTIONS": "dissocitive anesthesia,\nanalgesic effect,\ntrancelike unconscious state (low-dose),\nprevent reuptake of chatecholamines,\nalpha-1 & beta-1 agonist,\nNMDA non-competative receptor antagonist",
      "ADRS": "emergence phenomenon (hallucinations/dysphoria),\n↑cerebral blood flow,\n↑ICP,\n↑HR,\n↑MAP (mean arterial pressure),\n↑CO (cardiac output)",
      "FACTS": "no effect on respirations,\noften used to sedate animals,\ncan be given IV or IM"
    },
    {
      "CATEGORY": "General IV Anesthetics",
      "DRUG NAME": "etomidate",
      "SPECIFIC USES": "induction to anesthesia (not for long term use)",
      "ACTIONS": "GABA-A agonist,\n↓cerebral blood flow,\n↓ICP",
      "ADRS": "inhibit gluco- & mineralocorticoid synthesis (adrenal insufficiency)",
      "FACTS": "limited use as continuous infusion,\ncaution in pt w/ seizures,\nDOC for cardiovascular/hemodynamically unstable (minimal effect on CO, HR, MAP)"
    },
    {
      "CATEGORY": "General IV Anesthetics",
      "DRUG NAME": "thiopental",
      "SPECIFIC USES": "anesthesia (induction only)",
      "ACTIONS": "GABA agonist & Ach",
      "ADRS": "hypotension,\n↓cerebral blood flow,\nrespiratory depression,\n↑HR",
      "FACTS": "history: used as \"truth serum\",\nnot widely used due to ADRS,\nultra short acting"
    }
  ],
  "local anesthetics": [
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "ester-linked",
      "DRUG NAME": "benzocaine",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by esterases",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)"
    },
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "ester-linked",
      "DRUG NAME": "procaine",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by esterases",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)",
      "FACTS": "low potency, \nshort duration of action"
    },
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "ester-linked",
      "DRUG NAME": "tetracaine",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by esterases",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)"
    },
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "ester-linked",
      "DRUG NAME": "topical cocaine",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by esterases",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)",
      "FACTS": "inhibits NE reuptake producing vasoconstriction,\nused in ear, nose, throat procedures,\nlow potency (2), \nmedium duration of action"
    },
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "ester-linked",
      "DRUG NAME": "chloroprocaine",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by esterases",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)"
    },
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "amide-linked",
      "DRUG NAME": "lidocaine",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by CYP450",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)",
      "FACTS": "lowish potency (4),\nmedium duration of action"
    },
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "ester-linked",
      "DRUG NAME": "dibucaine",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by esterases",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)"
    },
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "ester-linked",
      "DRUG NAME": "mepivavaine",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by esterases",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)",
      "FACTS": "low potency (2),\nmedium duration of action"
    },
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "ester-linked",
      "DRUG NAME": "bupivacaine",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by esterases",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)",
      "FACTS": "high potency,\nlong duration of action"
    },
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "ester-linked",
      "DRUG NAME": "prilocaine",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by esterases",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)",
      "FACTS": "low potency (2),\nmedium duration of action"
    },
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "ester-linked",
      "DRUG NAME": "proivacaine",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by esterases",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)"
    },
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "ester-linked",
      "DRUG NAME": "EMLA",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by esterases",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)"
    },
    {
      "CATEGORY": "local anesthetics",
      "SUB-CATEGORY": "ester-linked",
      "DRUG NAME": "articaine",
      "SPECIFIC USES": "peripheral neuropathies,\npain",
      "ACTIONS": "non-specific inhibition of pain, motor, & autonomic pathways\nlenthened refractory period of sodium channels (less Na entry),\nlose sensation in this order:\n1. temperature\n2. proprioception\n3. motor\n4. pain\n5. light touch",
      "DDI's": "metabolized by esterases",
      "ADRS": "arrhythmia,\ntoxicity:\n1. tinnitus & metallic taste  in mouth\n2. CNS toxicity (seizures)\n3. cardiovascular (EKG changes, asystole)"
    }
  ],
  "Mu Receptor Agonists": [
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "codeine",
      "SPECIFIC USES": "pain, antitussive",
      "ACTIONS": "antitussive,\nanalgesia,\neuphoria",
      "DDI's": "CYP2D6",
      "ADRS": "↓respirations,\nCNS depression/sedation,\nmiosis,\nN/V,\nseizures,\n↓GI motility,\n↓immune function,\nhistamine release,\ndifficult/urgent urination",
      "FACTS": "often combined w/ APAP or NSAIDs",
      "Important Facts": "FOR ALL OPIATES:\nC/I: severe asthma,\nhead injuries (increased intracranial pressure)\nConsider: renal & hepatic function\nMonitoring: urine tox screen,\nsubjective pain scores,\nbowel regimen",
      "Urine Tox Screen": "norcodeine, morphine, hydrocodone, norhydrocodone, hydromorphone, hydromorphone-3-glucuronide (H3G), normorphine (M3G, M6G)"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "morphine",
      "SPECIFIC USES": "pain ",
      "ACTIONS": "antitussive,\nanalgesia,\neuphoria",
      "ADRS": "↓respirations,\nCNS depression/sedation,\nmiosis,\nN/V,\nseizures,\n↓GI motility,\n↓immune function,\nhistamine release,\ndifficult/urgent urination",
      "FACTS": "metabolized via glucuronidation (phase II),\nactive metabolite: M6G,\nM3G linked to seizures, accumulation in renal failure",
      "Important Facts": "FOR ALL OPIATES:\nC/I: severe asthma,\nhead injuries (increased intracranial pressure)\nConsider: renal & hepatic function\nMonitoring: urine tox screen,\nsubjective pain scores,\nbowel regimen",
      "Urine Tox Screen": "normorphine (M3G, M6G), hydromorphone, H3G"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "hydrocodone",
      "SPECIFIC USES": "pain",
      "ACTIONS": "antitussive,\nanalgesia,\neuphoria",
      "ADRS": "↓respirations,\nCNS depression/sedation,\nmiosis,\nN/V,\nseizures,\n↓GI motility,\n↓immune function,\nhistamine release,\ndifficult/urgent urination",
      "FACTS": "most commonly abused,\nnew federal schedule (CII)",
      "Important Facts": "FOR ALL OPIATES:\nC/I: severe asthma,\nhead injuries (increased intracranial pressure)\nConsider: renal & hepatic function\nMonitoring: urine tox screen,\nsubjective pain scores,\nbowel regimen",
      "Urine Tox Screen": "norhydrocodone"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "hydromorphone",
      "SPECIFIC USES": "pain",
      "ACTIONS": "antitussive,\nanalgesia,\neuphoria",
      "ADRS": "↓respirations,\nCNS depression/sedation,\nmiosis,\nN/V,\nseizures,\n↓GI motility,\n↓immune function,\nhistamine release,\ndifficult/urgent urination",
      "FACTS": "similar metabolism as morphine (H3G metabolite linked to seizures),\nrenal elimination",
      "Important Facts": "FOR ALL OPIATES:\nC/I: severe asthma,\nhead injuries (increased intracranial pressure)\nConsider: renal & hepatic function\nMonitoring: urine tox screen,\nsubjective pain scores,\nbowel regimen",
      "Urine Tox Screen": "H3G"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "oxycodone",
      "SPECIFIC USES": "pain",
      "ACTIONS": "antitussive,\nanalgesia,\neuphoria",
      "ADRS": "↓respirations,\nCNS depression/sedation,\nmiosis,\nN/V,\nseizures,\n↓GI motility,\n↓immune function,\nhistamine release,\ndifficult/urgent urination",
      "FACTS": "highly abused",
      "Important Facts": "FOR ALL OPIATES:\nC/I: severe asthma,\nhead injuries (increased intracranial pressure)\nConsider: renal & hepatic function\nMonitoring: urine tox screen,\nsubjective pain scores,\nbowel regimen",
      "Urine Tox Screen": "noroxycodone, oxymorphone, O3G, 6-hydroxy-oxymorphone"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "oxymorphone",
      "SPECIFIC USES": "cancer pain",
      "ACTIONS": "antitussive,\nanalgesia,\neuphoria",
      "ADRS": "↓respirations,\nCNS depression/sedation,\nmiosis,\nN/V,\nseizures,\n↓GI motility,\n↓immune function,\nhistamine release,\ndifficult/urgent urination",
      "FACTS": "very potent,\nphase II metabolism (O3G inactive, O6G active)",
      "Important Facts": "FOR ALL OPIATES:\nC/I: severe asthma,\nhead injuries (increased intracranial pressure)\nConsider: renal & hepatic function\nMonitoring: urine tox screen,\nsubjective pain scores,\nbowel regimen",
      "Urine Tox Screen": "O3G, 6-hydroxy-oxymorphone"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "fentanyl",
      "SPECIFIC USES": "pain,\nIV sedation (hospital setting)",
      "ACTIONS": "antitussive,\nanalgesia,\neuphoria",
      "ADRS": "↓respirations,\nCNS depression/sedation,\nmiosis,\nN/V,\nseizures,\n↓GI motility,\n↓immune function,\nhistamine release,\ndifficult/urgent urination",
      "FACTS": "various dosage forms (patch most common),\nquick onset,\nlipophilllic,\nshort duration,\nlittle histamine release (cardiac benefit)",
      "Important Facts": "FOR ALL OPIATES:\nC/I: severe asthma,\nhead injuries (increased intracranial pressure)\nConsider: renal & hepatic function\nMonitoring: urine tox screen,\nsubjective pain scores,\nbowel regimen",
      "Urine Tox Screen": "norfentanyl"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "meperidine",
      "SPECIFIC USES": "pain",
      "ACTIONS": "antitussive,\nanalgesia,\neuphoria",
      "ADRS": "↓respirations,\nCNS depression/sedation,\nmiosis,\nN/V,\nseizures,\n↓GI motility,\n↓immune function,\nhistamine release,\ndifficult/urgent urination",
      "FACTS": "LIMIT THERAPY TO 48 HOURS,\naccumulation of metabolite leads to renal failure",
      "Important Facts": "FOR ALL OPIATES:\nC/I: severe asthma,\nhead injuries (increased intracranial pressure)\nConsider: renal & hepatic function\nMonitoring: urine tox screen,\nsubjective pain scores,\nbowel regimen"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "buprenorphine",
      "SPECIFIC USES": "mild analgesic,\nsubstance abuse",
      "ACTIONS": "antitussive,\nanalgesia,\neuphoria",
      "ADRS": "↓respirations,\nCNS depression/sedation,\nmiosis,\nN/V,\nseizures,\n↓GI motility,\n↓immune function,\nhistamine release,\ndifficult/urgent urination",
      "FACTS": "long acting\nvarious dosage forms,\nless euphoria & respiratory depression than w/ methadone,\ncan prevent withdrawal for some",
      "Important Facts": "FOR ALL OPIATES:\nC/I: severe asthma,\nhead injuries (increased intracranial pressure)\nConsider: renal & hepatic function\nMonitoring: urine tox screen,\nsubjective pain scores,\nbowel regimen"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "methadone",
      "SPECIFIC USES": "pain,\nsubstance abuse",
      "ACTIONS": "prevents withdrawal symptoms (binds receptor w/ high affinity, but has low efficacy)",
      "ADRS": "↓respirations,\nCNS depression/sedation,\nmiosis,\nN/V,\nseizures,\n↓GI motility,\n↓immune function,\nhistamine release,\ndifficult/urgent urination",
      "FACTS": "long acting,\nadministration of other agonist causes no euphoria,\ndaily dose,\nif used for pain must write \"for pain\" on prescription",
      "Important Facts": "FOR ALL OPIATES:\nC/I: severe asthma,\nhead injuries (increased intracranial pressure)\nConsider: renal & hepatic function\nMonitoring: urine tox screen,\nsubjective pain scores,\nbowel regimen",
      "Urine Tox Screen": "EDDP"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "heroin",
      "Important Facts": "FOR ALL OPIATES:\nC/I: severe asthma,\nhead injuries (increased intracranial pressure)\nConsider: renal & hepatic function\nMonitoring: urine tox screen,\nsubjective pain scores,\nbowel regimen",
      "Urine Tox Screen": "6MAM, morphine, hydromorphone, H3G, M3G, M6G"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "SUB-CATEGORY": "Peripheral Mu Only",
      "DRUG NAME": "DTO (deodorized tincture of opium)",
      "SPECIFIC USES": "diarrhea,\nneonatal opiate withdrawal",
      "ACTIONS": "↓GI motility",
      "ADRS": "difficult/urgent urination,\nhistamine release,\n↓immune function",
      "FACTS": "given in low concentrations in infants"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "loperamide",
      "SPECIFIC USES": "diarrhea",
      "ACTIONS": "antitussive,\nanalgesia,\neuphoria",
      "ADRS": "↓respirations,\nCNS depression/sedation,\nmiosis,\nN/V,\nseizures,\n↓GI motility,\n↓immune function,\nhistamine release,\ndifficult/urgent urination",
      "FACTS": "excluded from CNS by p-glycoprotien"
    },
    {
      "CATEGORY": "Mu Receptor Agonists",
      "DRUG NAME": "diphenoxylate",
      "SPECIFIC USES": "diarrhea",
      "ACTIONS": "antitussive,\nanalgesia,\neuphoria",
      "ADRS": "↓respirations,\nCNS depression/sedation,\nmiosis,\nN/V,\nseizures,\n↓GI motility,\n↓immune function,\nhistamine release,\ndifficult/urgent urination",
      "FACTS": "usually w/ atropine"
    }
  ],
  "Mu Receptor Agonists & NE/5HT": [
    {
      "CATEGORY": "Mu Receptor Agonists & NE/5HT",
      "DRUG NAME": "tramadol",
      "SPECIFIC USES": "pain",
      "ACTIONS": "inhibits 5HT//NE uptake, \nanalgesia,\nantitussive,\neuphoria",
      "FACTS": "weak Mu agonist,\nmay have some alpha-2 agonist properties",
      "Urine Tox Screen": "nortramadol, O-desmethyltramadol"
    },
    {
      "CATEGORY": "Mu Receptor Agonists & NE/5HT",
      "DRUG NAME": "tapentadol",
      "SPECIFIC USES": "pain,\ndiabetic neuropathy pain",
      "ACTIONS": "inhibits NE & maybe 5HT reuptake,\nanalgesia,\nantitussive,\neuphoria",
      "FACTS": "strong Mu agonist (like morphine)"
    }
  ],
  "Mu Receptor Antagonists": [
    {
      "CATEGORY": "Mu Receptor Antagonists",
      "DRUG NAME": "naloxone",
      "SPECIFIC USES": "reverse opioid induced ADRS",
      "ACTIONS": "antagonizes Mu receptor to reverse ADRS",
      "FACTS": "high first pass, given intranasal,\nshort duration"
    },
    {
      "CATEGORY": "Mu Receptor Antagonists",
      "DRUG NAME": "naltrexone (naloxone w/ morphine)",
      "SPECIFIC USES": "opioid/alcohol dependence",
      "ACTIONS": "antagonizes Mu receptor  ",
      "FACTS": "oral,\nlonger duration"
    }
  ],
  "Other Analgesic Options": [
    {
      "CATEGORY": "Other Analgesic Options",
      "DRUG NAME": "capsaicin",
      "SPECIFIC USES": "pain",
      "ACTIONS": "depletes & prevents re-accumulation of substance P",
      "FACTS": "cream,\ncounseling: use gloves and wash hands after use"
    },
    {
      "CATEGORY": "Other Analgesic Options",
      "DRUG NAME": "ziconotide",
      "SPECIFIC USES": "pain",
      "ACTIONS": "calcium channel blocker preventing neurotransmitter release in dorsal horn",
      "FACTS": "intrathecal administration (directly into spine),\nNO abuse potential"
    }
  ],
  "Opioid Dependence Treatment": [
    {
      "CATEGORY": "Opioid Dependence Treatment",
      "DRUG NAME": "methadone",
      "SPECIFIC USES": "pain,\nsubstance abuse",
      "ACTIONS": "see above",
      "FACTS": "see above"
    },
    {
      "CATEGORY": "Opioid Dependence Treatment",
      "DRUG NAME": "Suboxone (buprenorphine & naloxone)",
      "SPECIFIC USES": "substance abuse",
      "ACTIONS": "has low efficacy on Mu receptor, but high affinity",
      "FACTS": "sublingual,\npoor sublingual absorption of naloxone,\nno more than 16mg/day"
    },
    {
      "CATEGORY": "Opioid Dependence Treatment",
      "DRUG NAME": "naltrexone",
      "SPECIFIC USES": "following detox to prevent relapse",
      "ACTIONS": "see above",
      "FACTS": "see above"
    },
    {
      "CATEGORY": "Opioid Dependence Treatment",
      "SUB-CATEGORY": "alpha-2 agonist",
      "DRUG NAME": "clonidine",
      "SPECIFIC USES": "alleviate withdrawal symptoms",
      "ACTIONS": "reduced sympathetic effects"
    }
  ],
  "glucocorticoid receptor agonists (steroids)": [
    {
      "CATEGORY": "glucocorticoid receptor agonists (steroids)",
      "DRUG NAME": "betamethasone",
      "SPECIFIC USES": "acute/chronic inflammation (asthma/COPD, arthritis, gout, MS, cerebral edema, etc),\nimmunosuppression,\nreplacement therapy,\nhematologic disorders",
      "ACTIONS": "inhibits phospholipid breakdown into arachidonic acid (inhibits inflammation/pain),\nimmunosuppression",
      "ADRS": "hyperglycemia,\n↑lipolysis,\nosteoporosis (limits long term use),\nweakness,\nthinning of skin,\n↓muscle mass,\npeptic ulcer disease,\ngrowth retardation (children),\nimmunosuppression,\ninsomnia,\n↓memory,\npsychosis,\ncaratracts (esp. in children),\nhypertension,\n↑intraocular pressure,\nHPA axis suppression"
    },
    {
      "CATEGORY": "glucocorticoid receptor agonists (steroids)",
      "DRUG NAME": "budesonide",
      "SPECIFIC USES": "acute/chronic inflammation (asthma/COPD, arthritis, gout, MS, cerebral edema, etc),\nimmunosuppression,\nreplacement therapy,\nhematologic disorders",
      "ACTIONS": "inhibits phospholipid breakdown into arachidonic acid (inhibits inflammation/pain),\nimmunosuppression",
      "ADRS": "hyperglycemia,\n↑lipolysis,\nosteoporosis (limits long term use),\nweakness,\nthinning of skin,\n↓muscle mass,\npeptic ulcer disease,\ngrowth retardation (children),\nimmunosuppression,\ninsomnia,\n↓memory,\npsychosis,\ncaratracts (esp. in children),\nhypertension,\n↑intraocular pressure,\nHPA axis suppression"
    },
    {
      "CATEGORY": "glucocorticoid receptor agonists (steroids)",
      "DRUG NAME": "cortisone",
      "SPECIFIC USES": "acute/chronic inflammation (asthma/COPD, arthritis, gout, MS, cerebral edema, etc),\nimmunosuppression,\nreplacement therapy,\nhematologic disorders",
      "ACTIONS": "inhibits phospholipid breakdown into arachidonic acid (inhibits inflammation/pain),\nimmunosuppression",
      "ADRS": "hyperglycemia,\n↑lipolysis,\nosteoporosis (limits long term use),\nweakness,\nthinning of skin,\n↓muscle mass,\npeptic ulcer disease,\ngrowth retardation (children),\nimmunosuppression,\ninsomnia,\n↓memory,\npsychosis,\ncaratracts (esp. in children),\nhypertension,\n↑intraocular pressure,\nHPA axis suppression"
    },
    {
      "CATEGORY": "glucocorticoid receptor agonists (steroids)",
      "DRUG NAME": "dexamethasone",
      "SPECIFIC USES": "acute/chronic inflammation (asthma/COPD, arthritis, gout, MS, cerebral edema, etc),\nimmunosuppression,\nreplacement therapy,\nhematologic disorders",
      "ACTIONS": "inhibits phospholipid breakdown into arachidonic acid (inhibits inflammation/pain),\nimmunosuppression",
      "ADRS": "hyperglycemia,\n↑lipolysis,\nosteoporosis (limits long term use),\nweakness,\nthinning of skin,\n↓muscle mass,\npeptic ulcer disease,\ngrowth retardation (children),\nimmunosuppression,\ninsomnia,\n↓memory,\npsychosis,\ncaratracts (esp. in children),\nhypertension,\n↑intraocular pressure,\nHPA axis suppression"
    },
    {
      "CATEGORY": "glucocorticoid receptor agonists (steroids)",
      "DRUG NAME": "fluticasone",
      "SPECIFIC USES": "acute/chronic inflammation (asthma/COPD, arthritis, gout, MS, cerebral edema, etc),\nimmunosuppression,\nreplacement therapy,\nhematologic disorders",
      "ACTIONS": "inhibits phospholipid breakdown into arachidonic acid (inhibits inflammation/pain),\nimmunosuppression",
      "ADRS": "hyperglycemia,\n↑lipolysis,\nosteoporosis (limits long term use),\nweakness,\nthinning of skin,\n↓muscle mass,\npeptic ulcer disease,\ngrowth retardation (children),\nimmunosuppression,\ninsomnia,\n↓memory,\npsychosis,\ncaratracts (esp. in children),\nhypertension,\n↑intraocular pressure,\nHPA axis suppression"
    },
    {
      "CATEGORY": "glucocorticoid receptor agonists (steroids)",
      "DRUG NAME": "hydrocortisone",
      "SPECIFIC USES": "acute/chronic inflammation (asthma/COPD, arthritis, gout, MS, cerebral edema, etc),\nimmunosuppression,\nreplacement therapy,\nhematologic disorders",
      "ACTIONS": "inhibits phospholipid breakdown into arachidonic acid (inhibits inflammation/pain),\nimmunosuppression",
      "ADRS": "hyperglycemia,\n↑lipolysis,\nosteoporosis (limits long term use),\nweakness,\nthinning of skin,\n↓muscle mass,\npeptic ulcer disease,\ngrowth retardation (children),\nimmunosuppression,\ninsomnia,\n↓memory,\npsychosis,\ncaratracts (esp. in children),\nhypertension,\n↑intraocular pressure,\nHPA axis suppression"
    },
    {
      "CATEGORY": "glucocorticoid receptor agonists (steroids)",
      "DRUG NAME": "methylprednisolone",
      "SPECIFIC USES": "acute/chronic inflammation (asthma/COPD, arthritis, gout, MS, cerebral edema, etc),\nimmunosuppression,\nreplacement therapy,\nhematologic disorders",
      "ACTIONS": "inhibits phospholipid breakdown into arachidonic acid (inhibits inflammation/pain),\nimmunosuppression",
      "ADRS": "hyperglycemia,\n↑lipolysis,\nosteoporosis (limits long term use),\nweakness,\nthinning of skin,\n↓muscle mass,\npeptic ulcer disease,\ngrowth retardation (children),\nimmunosuppression,\ninsomnia,\n↓memory,\npsychosis,\ncaratracts (esp. in children),\nhypertension,\n↑intraocular pressure,\nHPA axis suppression"
    },
    {
      "CATEGORY": "glucocorticoid receptor agonists (steroids)",
      "DRUG NAME": "mometasone",
      "SPECIFIC USES": "acute/chronic inflammation (asthma/COPD, arthritis, gout, MS, cerebral edema, etc),\nimmunosuppression,\nreplacement therapy,\nhematologic disorders",
      "ACTIONS": "inhibits phospholipid breakdown into arachidonic acid (inhibits inflammation/pain),\nimmunosuppression",
      "ADRS": "hyperglycemia,\n↑lipolysis,\nosteoporosis (limits long term use),\nweakness,\nthinning of skin,\n↓muscle mass,\npeptic ulcer disease,\ngrowth retardation (children),\nimmunosuppression,\ninsomnia,\n↓memory,\npsychosis,\ncaratracts (esp. in children),\nhypertension,\n↑intraocular pressure,\nHPA axis suppression"
    },
    {
      "CATEGORY": "glucocorticoid receptor agonists (steroids)",
      "DRUG NAME": "prednisolone",
      "SPECIFIC USES": "acute/chronic inflammation (asthma/COPD, arthritis, gout, MS, cerebral edema, etc),\nimmunosuppression,\nreplacement therapy,\nhematologic disorders",
      "ACTIONS": "inhibits phospholipid breakdown into arachidonic acid (inhibits inflammation/pain),\nimmunosuppression",
      "ADRS": "hyperglycemia,\n↑lipolysis,\nosteoporosis (limits long term use),\nweakness,\nthinning of skin,\n↓muscle mass,\npeptic ulcer disease,\ngrowth retardation (children),\nimmunosuppression,\ninsomnia,\n↓memory,\npsychosis,\ncaratracts (esp. in children),\nhypertension,\n↑intraocular pressure,\nHPA axis suppression"
    },
    {
      "CATEGORY": "glucocorticoid receptor agonists (steroids)",
      "DRUG NAME": "prednisone",
      "SPECIFIC USES": "acute/chronic inflammation (asthma/COPD, arthritis, gout, MS, cerebral edema, etc),\nimmunosuppression,\nreplacement therapy,\nhematologic disorders",
      "ACTIONS": "inhibits phospholipid breakdown into arachidonic acid (inhibits inflammation/pain),\nimmunosuppression",
      "ADRS": "hyperglycemia,\n↑lipolysis,\nosteoporosis (limits long term use),\nweakness,\nthinning of skin,\n↓muscle mass,\npeptic ulcer disease,\ngrowth retardation (children),\nimmunosuppression,\ninsomnia,\n↓memory,\npsychosis,\ncaratracts (esp. in children),\nhypertension,\n↑intraocular pressure,\nHPA axis suppression"
    },
    {
      "CATEGORY": "glucocorticoid receptor agonists (steroids)",
      "DRUG NAME": "triamcinolone",
      "SPECIFIC USES": "acute/chronic inflammation (asthma/COPD, arthritis, gout, MS, cerebral edema, etc),\nimmunosuppression,\nreplacement therapy,\nhematologic disorders",
      "ACTIONS": "inhibits phospholipid breakdown into arachidonic acid (inhibits inflammation/pain),\nimmunosuppression",
      "ADRS": "hyperglycemia,\n↑lipolysis,\nosteoporosis (limits long term use),\nweakness,\nthinning of skin,\n↓muscle mass,\npeptic ulcer disease,\ngrowth retardation (children),\nimmunosuppression,\ninsomnia,\n↓memory,\npsychosis,\ncaratracts (esp. in children),\nhypertension,\n↑intraocular pressure,\nHPA axis suppression"
    }
  ],
  "glucocorticoid receptor antagonist": [
    {
      "CATEGORY": "glucocorticoid receptor antagonist",
      "DRUG NAME": "mifepristone",
      "SPECIFIC USES": "cushing syndrome",
      "ACTIONS": "inhibit glucocorticoid receptor activation"
    }
  ],
  "mineralocorticoid receptor agonist (aldosterone analog)": [
    {
      "CATEGORY": "mineralocorticoid receptor agonist (aldosterone analog)",
      "DRUG NAME": "fludrocortisone",
      "SPECIFIC USES": "Addison's disease (adrenal insufficiency)",
      "ACTIONS": "Na/H2O retention,\nK efflux",
      "ADRS": "hypertension,\nhypokalemia"
    }
  ],
  "aldosterone antagonist": [
    {
      "CATEGORY": "aldosterone antagonist",
      "DRUG NAME": "spironolactone",
      "SPECIFIC USES": "CHF,\nhypertension,\nMI,\nhyperaldosteronism",
      "ACTIONS": "Na/H2O excretion,\nK influx",
      "ADRS": "hyperkalemia,\ngynecomastia,\nimpotence"
    },
    {
      "CATEGORY": "aldosterone antagonist",
      "DRUG NAME": "eplerenone",
      "SPECIFIC USES": "CHF,\nhypertension,\nMI,\nhyperaldosteronism",
      "ACTIONS": "Na/H2O excretion,\nK influx",
      "ADRS": "hyperkalemia,\ngynecomastia,\nimpotence"
    }
  ],
  "synthetic ACTH": [
    {
      "CATEGORY": "synthetic ACTH",
      "DRUG NAME": "cosyntropin",
      "ACTIONS": "↑cortisol,\n↑aldosterone"
    }
  ],
  "\"Calcimimetic\"": [
    {
      "CATEGORY": "\"Calcimimetic\"",
      "DRUG NAME": "cinacalcet",
      "SPECIFIC USES": "secondary hyperparathyroidism due to CKD,\nhypercalcemia (in primary hyperPTism & PT carcinoma)",
      "ACTIONS": "inhibits PTH release from PT",
      "ADRS": "N/V/D",
      "FACTS": "C/I: hypocalcemia"
    }
  ],
  "Anabolic Agents (promote bone growth)": [
    {
      "CATEGORY": "Anabolic Agents (promote bone growth)",
      "DRUG NAME": "Forteo (teriperatide)",
      "SPECIFIC USES": "moderate/severe osteoporosis (pt w/ high fracture risk),\nhypoPTism",
      "ACTIONS": "increase osteoblast activity (low daily dosing),\nincrease Ca absorption,\nincrease Ca reabsorption ",
      "ADRS": "mild hypercalcemia,\nhyperuricemia,\northostatic hypotension,\nosteosarcoma (Black Box Warning)",
      "FACTS": "recombinant PTH,\ngiven in low daily dose to ensure osteoblast >> osteoclast,\nw/ continuous infusion osetoclast >> osteoblast (BAD)"
    },
    {
      "CATEGORY": "Anabolic Agents (promote bone growth)",
      "SUB-CATEGORY": "Vitamin D Analogs",
      "DRUG NAME": "cholecalciferol (D3)",
      "SPECIFIC USES": "osteoporosis",
      "ACTIONS": "incr. Ca absorption,\nincr. Ca reabsorption,\nregulates bone formation/resorption",
      "ADRS": "kidney stones (in presence of high phosphorus)",
      "FACTS": "converted by liver then kidney"
    },
    {
      "CATEGORY": "Anabolic Agents (promote bone growth)",
      "DRUG NAME": "ergocalciferol (D2)",
      "SPECIFIC USES": "moderate/severe osteoporosis (pt w/ high fracture risk),\nhypoPTism",
      "ACTIONS": "increase osteoblast activity (low daily dosing),\nincrease Ca absorption,\nincrease Ca reabsorption ",
      "ADRS": "mild hypercalcemia,\nhyperuricemia,\northostatic hypotension,\nosteosarcoma (Black Box Warning)",
      "FACTS": "more concentrated, can be given at higher doses"
    },
    {
      "CATEGORY": "Anabolic Agents (promote bone growth)",
      "DRUG NAME": "calcitriol",
      "SPECIFIC USES": "moderate/severe osteoporosis (pt w/ high fracture risk),\nhypoPTism",
      "ACTIONS": "increase osteoblast activity (low daily dosing),\nincrease Ca absorption,\nincrease Ca reabsorption ",
      "ADRS": "mild hypercalcemia,\nhyperuricemia,\northostatic hypotension,\nosteosarcoma (Black Box Warning)",
      "FACTS": "\"active\" vitamin D"
    },
    {
      "CATEGORY": "Anabolic Agents (promote bone growth)",
      "DRUG NAME": "paricalcitol",
      "SPECIFIC USES": "moderate/severe osteoporosis (pt w/ high fracture risk),\nhypoPTism",
      "ACTIONS": "increase osteoblast activity (low daily dosing),\nincrease Ca absorption,\nincrease Ca reabsorption ",
      "ADRS": "mild hypercalcemia,\nhyperuricemia,\northostatic hypotension,\nosteosarcoma (Black Box Warning)"
    },
    {
      "CATEGORY": "Anabolic Agents (promote bone growth)",
      "DRUG NAME": "doxercalciferol",
      "SPECIFIC USES": "moderate/severe osteoporosis (pt w/ high fracture risk),\nhypoPTism",
      "ACTIONS": "increase osteoblast activity (low daily dosing),\nincrease Ca absorption,\nincrease Ca reabsorption ",
      "ADRS": "mild hypercalcemia,\nhyperuricemia,\northostatic hypotension,\nosteosarcoma (Black Box Warning)",
      "FACTS": "require hepatic activation, does NOT require renal activation,\nused in pt w/ renal disease,\ndo not use in pt w/ liver disease"
    }
  ],
  "Anti-Resorptive (reduce bone resorption)": [
    {
      "CATEGORY": "Anti-Resorptive (reduce bone resorption)",
      "DRUG NAME": "Calcium Salts",
      "SPECIFIC USES": "reduces hyperPTism due to age,\nosteoporosis",
      "ACTIONS": "incr. bone mineralization (w/ phosphorus)",
      "ADRS": "constipation,\nkidney stones (hypercalciuria)",
      "FACTS": "plateu effect"
    },
    {
      "CATEGORY": "Anti-Resorptive (reduce bone resorption)",
      "DRUG NAME": "Miacalcin (salmon calcitonin)",
      "SPECIFIC USES": "hypercalcemia, \nosteoporosis,\nPaget's ",
      "ACTIONS": "inhibit osteoclast activity,\nreduces Ca reabsorption,\nreduced serum Ca,\nslight analgesic effect",
      "ADRS": "nasal stuffiness,\nN/V,\nflushing,\nsalty taste,\nrash,\nanaphylactic reaction,\npotential for antibody formation ",
      "FACTS": "given intranasally (sometimes parenteral),\nunclear mechanism of analgesic effect,\nplateau effect"
    },
    {
      "CATEGORY": "Anti-Resorptive (reduce bone resorption)",
      "DRUG NAME": "Estrogens",
      "SPECIFIC USES": "prevent osteoporosis associated w/ menopause",
      "ACTIONS": "reduce osteoclast activity",
      "ADRS": "see gonadal hormones sheet",
      "FACTS": "do not reverse already lost bone density,\nplateau effect"
    },
    {
      "CATEGORY": "Anti-Resorptive (reduce bone resorption)",
      "SUB-CATEGORY": "SERM",
      "DRUG NAME": "raloxifene",
      "SPECIFIC USES": "osteoporosis (less efficatious than estrogens)",
      "ACTIONS": "activate estrogen receptor in bone (reduced resorption),\nantagonizes estrogen effect in breast & uterus",
      "ADRS": "see gonadal hormones sheet",
      "FACTS": "plateau effect"
    },
    {
      "CATEGORY": "Anti-Resorptive (reduce bone resorption)",
      "SUB-CATEGORY": "bisphosponates",
      "DRUG NAME": "alendronate",
      "SPECIFIC USES": "osteoporosis  ",
      "DRUG-DRUG INTERACTIONS": "binds Ca: drug/food interaction",
      "ACTIONS": "bind serum Ca Salts,\ninhibit osteoclast activity,\nInhibits formation/aggregation/dissolution of hydroxyapatite crystals in bone,\npossible apoptosis of osteoclast",
      "ADRS": "myalgia,\nosetonecrosis of jaw,\nerosive esophagitis (careful pt w/ GERD)",
      "FACTS": "poor oral absorption,\ncounceling points:\ntake right away in  morning w/ full glass of water, wait 30 min to take other meds/food,\ndo not lay down within first 30 min of taking (prevent erosive esophagitis),\nplateau effect"
    },
    {
      "CATEGORY": "Anti-Resorptive (reduce bone resorption)",
      "DRUG NAME": "etidronate",
      "SPECIFIC USES": "reduces hyperPTism due to age,\nosteoporosis",
      "ACTIONS": "incr. bone mineralization (w/ phosphorus)",
      "ADRS": "constipation,\nkidney stones (hypercalciuria)",
      "FACTS": "plateu effect"
    },
    {
      "CATEGORY": "Anti-Resorptive (reduce bone resorption)",
      "DRUG NAME": "ibandronate",
      "SPECIFIC USES": "reduces hyperPTism due to age,\nosteoporosis",
      "ACTIONS": "incr. bone mineralization (w/ phosphorus)",
      "ADRS": "constipation,\nkidney stones (hypercalciuria)",
      "FACTS": "plateu effect"
    },
    {
      "CATEGORY": "Anti-Resorptive (reduce bone resorption)",
      "DRUG NAME": "pamidronate",
      "SPECIFIC USES": "reduces hyperPTism due to age,\nosteoporosis",
      "ACTIONS": "incr. bone mineralization (w/ phosphorus)",
      "ADRS": "constipation,\nkidney stones (hypercalciuria)",
      "FACTS": "plateu effect"
    },
    {
      "CATEGORY": "Anti-Resorptive (reduce bone resorption)",
      "DRUG NAME": "risedronate",
      "SPECIFIC USES": "reduces hyperPTism due to age,\nosteoporosis",
      "ACTIONS": "incr. bone mineralization (w/ phosphorus)",
      "ADRS": "constipation,\nkidney stones (hypercalciuria)",
      "FACTS": "plateu effect"
    },
    {
      "CATEGORY": "Anti-Resorptive (reduce bone resorption)",
      "DRUG NAME": "zoledronic acid",
      "SPECIFIC USES": "reduces hyperPTism due to age,\nosteoporosis",
      "ACTIONS": "incr. bone mineralization (w/ phosphorus)",
      "ADRS": "constipation,\nkidney stones (hypercalciuria)",
      "FACTS": "plateu effect"
    },
    {
      "CATEGORY": "Anti-Resorptive (reduce bone resorption)",
      "DRUG NAME": "Prolia (denosumab)",
      "SPECIFIC USES": "osteoporosis associated w/ menopause (preferred in high fracture risk pt's),\ncertain cancers",
      "ACTIONS": "inhibits action of RANKL (block osteoclast activation, formation, & survival)",
      "ADRS": "incr. risk of infection (RANKL on immune cells),\nosteonecrosis of jaw",
      "FACTS": "dosing: SQ q6 months,\nplateau effect"
    }
  ],
  "Oral Contraceptives (OPCs)": [
    {
      "CATEGORY": "Oral Contraceptives (OPCs)",
      "SUB-CATEGORY": "Estrogens",
      "DRUG NAME": "ethinyl estradiol",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓risk of osteoporosis,\n↑HDL,\n↓LDL,\n",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production"
    },
    {
      "CATEGORY": "Oral Contraceptives (OPCs)",
      "SUB-CATEGORY": "Estrogens",
      "DRUG NAME": "mestranol",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓risk of osteoporosis,\n↑HDL,\n↓LDL,\n",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production"
    },
    {
      "CATEGORY": "Oral Contraceptives (OPCs)",
      "SUB-CATEGORY": "Progestins",
      "DRUG NAME": "norgestrel",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\nimpaired sperm penetration,\nimpaired egg implantation,\nslight corticoid receptor agonist",
      "ADRS": "acne, \nhirsutism,\nweight gain,\nhyperpigmentation,\nspotting,\nbreakthrough bleeding,\n↓BMD,\n↓HDL,\n↑LDL,\nN/V,\ndepression,\nfatigue,\nmood swings",
      "FACTS": "potentially harmful to fetus in first 4 months"
    },
    {
      "CATEGORY": "Oral Contraceptives (OPCs)",
      "SUB-CATEGORY": "Estrogens",
      "DRUG NAME": "levonorgestrel",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓risk of osteoporosis,\n↑HDL,\n↓LDL,\n",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production"
    },
    {
      "CATEGORY": "Oral Contraceptives (OPCs)",
      "SUB-CATEGORY": "Estrogens",
      "DRUG NAME": "norethindrone",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓risk of osteoporosis,\n↑HDL,\n↓LDL,\n",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production"
    },
    {
      "CATEGORY": "Oral Contraceptives (OPCs)",
      "SUB-CATEGORY": "Estrogens",
      "DRUG NAME": "ethynoldiol",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓risk of osteoporosis,\n↑HDL,\n↓LDL,\n",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production"
    },
    {
      "CATEGORY": "Oral Contraceptives (OPCs)",
      "SUB-CATEGORY": "Estrogens",
      "DRUG NAME": "norgestimate",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓risk of osteoporosis,\n↑HDL,\n↓LDL,\n",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production"
    },
    {
      "CATEGORY": "Oral Contraceptives (OPCs)",
      "SUB-CATEGORY": "Estrogens",
      "DRUG NAME": "desogestrel",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓risk of osteoporosis,\n↑HDL,\n↓LDL,\n",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production"
    },
    {
      "CATEGORY": "Oral Contraceptives (OPCs)",
      "SUB-CATEGORY": "Estrogens",
      "DRUG NAME": "drosperinone",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓risk of osteoporosis,\n↑HDL,\n↓LDL,\n",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production"
    }
  ],
  "Other Contraceptives": [
    {
      "CATEGORY": "Other Contraceptives",
      "SUB-CATEGORY": "combination",
      "DRUG NAME": "xulane (ethinyl estradiol & norelgestromin)",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "see estrogen & progesterone actions",
      "ADRS": "see estrogen & progesterone ADRS",
      "FACTS": "transdermal patch"
    },
    {
      "CATEGORY": "Other Contraceptives",
      "SUB-CATEGORY": "combination",
      "DRUG NAME": "NuvaRing (ethinyl estradiol & etonogestrel)",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "see estrogen & progesterone actions",
      "ADRS": "see estrogen & progesterone ADRS",
      "FACTS": "intravaginal ring"
    },
    {
      "CATEGORY": "Other Contraceptives",
      "SUB-CATEGORY": "Progestin only",
      "DRUG NAME": "depo-provera (medroxyprogesterone)",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "see estrogen & progesterone actions",
      "ADRS": "see estrogen & progesterone ADRS",
      "FACTS": "IM/SQ q6 months"
    },
    {
      "CATEGORY": "Other Contraceptives",
      "SUB-CATEGORY": "combination",
      "DRUG NAME": "levonorgestrel",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "see estrogen & progesterone actions",
      "ADRS": "see estrogen & progesterone ADRS",
      "FACTS": "IUD,\nMirena, Skyla/Liletta dosed q3 yrs,\nMirena/Kyleena dosed q5 yrs"
    },
    {
      "CATEGORY": "Other Contraceptives",
      "SUB-CATEGORY": "combination",
      "DRUG NAME": "Nexplanon (etonogestrel)",
      "SPECIFIC USES": "contraception",
      "ACTIONS": "see estrogen & progesterone actions",
      "ADRS": "see estrogen & progesterone ADRS",
      "FACTS": "implant dosed q3 yrs"
    }
  ],
  "Hormone Replacement Therapy (HRT)": [
    {
      "CATEGORY": "Hormone Replacement Therapy (HRT)",
      "SUB-CATEGORY": "estrogens",
      "DRUG NAME": "estradiol",
      "SPECIFIC USES": "menopause",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓vasomotor symptoms,\n↓risk of osteoporosis,\n↓LDL,\n↑HDL",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production",
      "FACTS": "many brands & formulations"
    },
    {
      "CATEGORY": "Hormone Replacement Therapy (HRT)",
      "SUB-CATEGORY": "estrogens",
      "DRUG NAME": "premarin/enjuvia (conjugated estrogen)",
      "SPECIFIC USES": "menopause",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓vasomotor symptoms,\n↓risk of osteoporosis,\n↓LDL,\n↑HDL",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production",
      "FACTS": "oral tablet"
    },
    {
      "CATEGORY": "Hormone Replacement Therapy (HRT)",
      "SUB-CATEGORY": "estrogens",
      "DRUG NAME": "Menest (esterified estrogen)",
      "SPECIFIC USES": "menopause",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓vasomotor symptoms,\n↓risk of osteoporosis,\n↓LDL,\n↑HDL",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production",
      "FACTS": "oral tablet"
    },
    {
      "CATEGORY": "Hormone Replacement Therapy (HRT)",
      "SUB-CATEGORY": "estrogens",
      "DRUG NAME": "estropiate",
      "SPECIFIC USES": "menopause",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓vasomotor symptoms,\n↓risk of osteoporosis,\n↓LDL,\n↑HDL",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production"
    },
    {
      "CATEGORY": "Hormone Replacement Therapy (HRT)",
      "SUB-CATEGORY": "progestins",
      "DRUG NAME": "progesterone",
      "SPECIFIC USES": "menopause,\n↓uterine cancer risk",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\nimpaired sperm penetration,\nimpaired egg implantation,\nslight corticoid receptor agonist",
      "ADRS": "acne, \nhirsutism,\nweight gain,\nhyperpigmentation,\nspotting,\nbreakthrough bleeding,\n↓BMD,\n↓HDL,\n↑LDL,\nN/V,\ndepression,\nfatigue,\nmood swings",
      "FACTS": "oral tablet, vaginal gel, or vaginal insert"
    },
    {
      "CATEGORY": "Hormone Replacement Therapy (HRT)",
      "SUB-CATEGORY": "estrogens",
      "DRUG NAME": "medroxyprogesterone",
      "SPECIFIC USES": "menopause",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓vasomotor symptoms,\n↓risk of osteoporosis,\n↓LDL,\n↑HDL",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production",
      "FACTS": "oral tablet "
    },
    {
      "CATEGORY": "Hormone Replacement Therapy (HRT)",
      "SUB-CATEGORY": "estrogens",
      "DRUG NAME": "norethindrone",
      "SPECIFIC USES": "menopause",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓vasomotor symptoms,\n↓risk of osteoporosis,\n↓LDL,\n↑HDL",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production"
    },
    {
      "CATEGORY": "Hormone Replacement Therapy (HRT)",
      "SUB-CATEGORY": "combination",
      "DRUG NAME": "conjugated estrogens & \nmedroxyprogesterone",
      "SPECIFIC USES": "menopause,\n↓uterine cancer risk",
      "ACTIONS": "see estrogen & progestin actions",
      "ADRS": "see estrogen & progestin ADRS",
      "FACTS": "oral tablets,\nbrand names:\nprempro, premphase"
    },
    {
      "CATEGORY": "Hormone Replacement Therapy (HRT)",
      "SUB-CATEGORY": "estrogens",
      "DRUG NAME": "estradiol & levonorgestrel",
      "SPECIFIC USES": "menopause",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓vasomotor symptoms,\n↓risk of osteoporosis,\n↓LDL,\n↑HDL",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production",
      "FACTS": "transdermal patch,\nbrand name: Climara Pro"
    },
    {
      "CATEGORY": "Hormone Replacement Therapy (HRT)",
      "SUB-CATEGORY": "estrogens",
      "DRUG NAME": "estradiol & norethindrone",
      "SPECIFIC USES": "menopause",
      "ACTIONS": "neg. feedback on GnRH, LH, FSH release,\nprevents ovulation,\n↓vasomotor symptoms,\n↓risk of osteoporosis,\n↓LDL,\n↑HDL",
      "ADRS": "↑risk of uterine cancer,\n↑risk of breast cancer,\n↑risk of thromboses,\n↑BP,\n↑blood glucose,\ndepression,\nheadache,\nnausea,\nedema,\nbloating,\ngenital abnormalities (if used in pregnancy),\n↓breast milk production",
      "FACTS": "transdermal patch,\nbrand name: combipatch"
    }
  ],
  "Selective Estrogen Receptor Modulators (SERMs)": [
    {
      "CATEGORY": "Selective Estrogen Receptor Modulators (SERMs)",
      "DRUG NAME": "raloxifene",
      "SPECIFIC USES": "osteoporosis,\nbreast cancer?",
      "ACTIONS": "slight benefitical effect on lipids,\n↓risk of osteoporosis,\n↓risk of breast cancer",
      "ADRS": "↑vasomotor symptoms,\nslight risk of thromboses",
      "FACTS": "No ↑ risk of uterine cancer (unlike estrogen)"
    },
    {
      "CATEGORY": "Selective Estrogen Receptor Modulators (SERMs)",
      "DRUG NAME": "tamoxifen",
      "SPECIFIC USES": "breast cancer,\nosteoporosis?",
      "ACTIONS": "slight ↓ osteoporosis,\nslight benefit on lipids,\n↓risk of breast cancer",
      "ADRS": "↑vasomotor symptoms,\n↑risk of thromboses,\nslight ↑risk of uterine cancer",
      "FACTS": "commonly only used for cancer "
    },
    {
      "CATEGORY": "Selective Estrogen Receptor Modulators (SERMs)",
      "SUB-CATEGORY": "Selective Estrogen Receptor Down-Regulator (SERD)",
      "DRUG NAME": "fulvestrant",
      "SPECIFIC USES": "2nd line in hormone receptor-positive breast cancer",
      "ACTIONS": "binds estrogen receptor as antagonist,\n↓transcription of estrogen responsive genes",
      "FACTS": "monthly IM injection,\n\"anti-estrogen\""
    },
    {
      "CATEGORY": "Selective Estrogen Receptor Modulators (SERMs)",
      "DRUG NAME": "ospemifene",
      "SPECIFIC USES": "dysparenunia (painful sexual intercourse)",
      "ACTIONS": "modulates estrogen receptors",
      "FACTS": "approved Feb 2013"
    },
    {
      "CATEGORY": "Selective Estrogen Receptor Modulators (SERMs)",
      "DRUG NAME": "Duavee (conjugated estrogens & bazedoxifene)",
      "SPECIFIC USES": "menopausal hot flashes,\nprevent post-menopausal osteoporosis",
      "ACTIONS": "modulates estrogen receptors",
      "FACTS": "approved Oct 2013"
    }
  ],
  "synthetic progestin": [
    {
      "CATEGORY": "synthetic progestin",
      "DRUG NAME": "megestrol",
      "SPECIFIC USES": "anorexia, \ncachexia,\nweight loss seen in AIDS,\nadjunct treatment in endometrial & breast cancer",
      "ACTIONS": "appetite stimulant (weight gain),\nslight corticoid receptor agonist",
      "FACTS": "NOT used as contraception"
    }
  ],
  "progesterone receptor antagonist": [
    {
      "CATEGORY": "progesterone receptor antagonist",
      "DRUG NAME": "mifepristone",
      "SPECIFIC USES": "abortion,\nCushing's syndrome",
      "ACTIONS": "endometrial degeneration,\ndetachment of blastocyst,\n↓hCG production,\n↓progesterone production"
    }
  ],
  "Dopamine Replacement": [
    {
      "CATEGORY": "Dopamine Replacement",
      "DRUG NAME": "sinemet (levodopa/carbidopa)",
      "SPECIFIC USES": "parkinsons (initial short term treatment)",
      "ACTIONS": "pre-cursor to dopamine,\nblocks L-dopa conversion to dopamine in periphery (leaving more L-dopa available to cross BBB)",
      "ADRS": "N/V,\ndizziness,\northostasis,\nventricular arrhythmias,\ntachycardia,\nhypertension,\nanxiety,\ndepression,\nagitation,\ndelusions,\nhallucinations,\ndyskinesia",
      "FACTS": "on/off phenomenon,\nmost effective in first 3 years,\ntake 30-60 min before meals,\n70-100 mg/day of carbidopa needed to inhibit conversion to dopamine and ↓ nausea"
    }
  ],
  "COMT Inhibitors": [
    {
      "CATEGORY": "COMT Inhibitors",
      "DRUG NAME": "tolcapone",
      "SPECIFIC USES": "parkinsons ",
      "ACTIONS": "prevent peripheral & central conversion of levodopa to dopamine,\n↑ daily \"on\" time by 1-2 hrs",
      "ADRS": "fatal hepatotoxicity",
      "FACTS": "used only with levodopa, \n↓ levodopa dose by 10-30%,inhibits central and peripheral COMT"
    },
    {
      "CATEGORY": "COMT Inhibitors",
      "DRUG NAME": "entacopone",
      "SPECIFIC USES": "parkinsons ",
      "ACTIONS": "prevent peripheral & central conversion of levodopa to dopamine,\n↑ daily \"on\" time by 1-2 hrs",
      "FACTS": "used only with levodopa, \n↓ levodopa dose by 10-30%,inhibits central and peripheral COMT"
    }
  ],
  "Dopamine Receptor Agonist": [
    {
      "CATEGORY": "Dopamine Receptor Agonist",
      "SUB-CATEGORY": "Ergot Derivatives",
      "DRUG NAME": "bromocriptine",
      "SPECIFIC USES": "parkinsons,\ncan be used for other indications",
      "ACTIONS": "D2/D3/D4 agonist",
      "DDI's": "CYP3A4",
      "ADRS": "↑risk of pulmonary fibrosis,\nN/V,\nanorexia,\northostasis,\ndyskinesia,\nhallucinations,\nimpulse control disorders",
      "FACTS": "extensive first pass effect,\ngiven w/ levodopa"
    },
    {
      "CATEGORY": "Dopamine Receptor Agonist",
      "SUB-CATEGORY": "Ergot Derivatives",
      "DRUG NAME": "pergolide",
      "SPECIFIC USES": "parkinsons,\ncan be used for other indications",
      "ACTIONS": "D2/D3/D4 agonist",
      "DDI's": "CYP3A4",
      "ADRS": "↑risk of pulmonary fibrosis,\nN/V,\nanorexia,\northostasis,\ndyskinesia,\nhallucinations,\nimpulse control disorders",
      "FACTS": "extensive first pass effect,\ngiven w/ levodopa\nwithdrawn from market due to potential heart valve damage"
    },
    {
      "CATEGORY": "Dopamine Receptor Agonist",
      "SUB-CATEGORY": "Non-Ergot Derivatives",
      "DRUG NAME": "pramipexole",
      "SPECIFIC USES": "parkinsons (monotherapy in mild, advanced w/ sinemet),\nrestless leg syndrome",
      "ACTIONS": "D2/D3 agonists",
      "ADRS": "N/V,\nanorexia,\northostasis,\ndyskinesia,\nhallucinations,\nimpulse control disorders,\ndizziness,\nsleepiness\n(titrate dose to avoid)",
      "FACTS": "more affinity for D3"
    },
    {
      "CATEGORY": "Dopamine Receptor Agonist",
      "SUB-CATEGORY": "Ergot Derivatives",
      "DRUG NAME": "ropinirole",
      "SPECIFIC USES": "parkinsons,\ncan be used for other indications",
      "ACTIONS": "D2/D3/D4 agonist",
      "ADRS": "↑risk of pulmonary fibrosis,\nN/V,\nanorexia,\northostasis,\ndyskinesia,\nhallucinations,\nimpulse control disorders",
      "FACTS": "more affinity for D2"
    }
  ],
  "Adjunct Drugs for PD": [
    {
      "CATEGORY": "Adjunct Drugs for PD",
      "SUB-CATEGORY": "anti-muscarinics",
      "DRUG NAME": "benztropine",
      "SPECIFIC USES": "parkinsons,\ntremors",
      "ACTIONS": "reduce tremor/rigitidy",
      "ADRS": "tachycardia, \nbronchodilation, \nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition"
    },
    {
      "CATEGORY": "Adjunct Drugs for PD",
      "SUB-CATEGORY": "anti-muscarinics",
      "DRUG NAME": "trihexyphenidyl",
      "SPECIFIC USES": "parkinsons",
      "ACTIONS": "reduce tremor/rigitidy",
      "ADRS": "tachycardia, \nbronchodilation, \nmydriasis,\n ↓ secretions, \n↓ GI motility,\n ↓ urination, \nvasoconstriction, \n↓ cognition"
    },
    {
      "CATEGORY": "Adjunct Drugs for PD",
      "SUB-CATEGORY": "Dopamine receptor agonist",
      "DRUG NAME": "apomorphine",
      "SPECIFIC USES": "akinesia during \"off\" periods of PD",
      "ACTIONS": "potent dopamine receptor agonist",
      "ADRS": "severe N/V,\nhypotension",
      "FACTS": "limited clinical use due to ADRS,\ninjection,\neffect seen in 10 min"
    },
    {
      "CATEGORY": "Adjunct Drugs for PD",
      "SUB-CATEGORY": "antiviral compound",
      "DRUG NAME": "amantadine",
      "SPECIFIC USES": "mild PD,\ndyskinesia in advanced PD",
      "ACTIONS": "blocks dopamine reuptake in presynaptic neurons, \nincreases dopamine release from presynaptic neurons"
    }
  ],
  "Huntington's Disease Treatment": [
    {
      "CATEGORY": "Huntington's Disease Treatment",
      "DRUG NAME": "reserpine",
      "SPECIFIC USES": "HD",
      "ACTIONS": "inhibits VMAT (↓catecholamine uptake, catecholamine storage vesicle destruction -> sympathetic dysfunction)",
      "ADRS": "hypotension,\nsedation,\ndiarrhea,\ndepression"
    },
    {
      "CATEGORY": "Huntington's Disease Treatment",
      "DRUG NAME": "tetrabenazine",
      "SPECIFIC USES": "chorea from HD",
      "ACTIONS": "depletes pre-synaptic dopamine storage,\nantagonizes D2",
      "ADRS": "less than reserpine",
      "FACTS": "more selective for dopamine than reserpine"
    }
  ],
  "Restless Leg Syndrome Treatments": [
    {
      "CATEGORY": "Restless Leg Syndrome Treatments",
      "DRUG NAME": "gabapentin"
    },
    {
      "CATEGORY": "Restless Leg Syndrome Treatments",
      "DRUG NAME": "D2 receptor agonists"
    }
  ],
  "Tremor Treatment": [
    {
      "CATEGORY": "Tremor Treatment",
      "DRUG NAME": "propranolol"
    },
    {
      "CATEGORY": "Tremor Treatment",
      "DRUG NAME": "benztropine",
      "SPECIFIC USES": "see above",
      "ACTIONS": "see above",
      "DDI's": "see above",
      "ADRS": "see above",
      "FACTS": "see above"
    }
  ],
  "Insulin": [
    {
      "CATEGORY": "Insulin",
      "SUB-CATEGORY": "Short Acting (Regular)",
      "DRUG NAME": "Humulin R",
      "SPECIFIC USES": "diabetes (type 1 & 2)",
      "ACTIONS": "↓blood glucose",
      "ADRS": "hypoglycemia,\nlipoatrophy,\nlipohypertrophy,\nweight gain",
      "FACTS": "given IV,\nonset: 30-60 min,\npeak: 2-4 hrs,\nduration: 5-7 hrs"
    },
    {
      "CATEGORY": "Insulin",
      "SUB-CATEGORY": "Short Acting (Regular)",
      "DRUG NAME": "Novolin R",
      "SPECIFIC USES": "diabetes (type 1 & 2)",
      "ACTIONS": "↓blood glucose",
      "ADRS": "hypoglycemia,\nlipoatrophy,\nlipohypertrophy,\nweight gain",
      "FACTS": "given IV,\nonset: 30-60 min,\npeak: 2-4 hrs,\nduration: 5-7 hrs"
    },
    {
      "CATEGORY": "Insulin",
      "SUB-CATEGORY": "Rapid-Acting",
      "DRUG NAME": "Lispro",
      "SPECIFIC USES": "diabetes (type 1 & 2)",
      "ACTIONS": "↓blood glucose",
      "ADRS": "hypoglycemia (less than short acting),\nlipoatrophy,\nlipohypertrophy,",
      "FACTS": "used in insulin pumps,\nonset: 5-15 min,\npeak: 1-3 hrs,\nduration: 3-5 hrs"
    },
    {
      "CATEGORY": "Insulin",
      "SUB-CATEGORY": "Short Acting (Regular)",
      "DRUG NAME": "Aspart",
      "SPECIFIC USES": "diabetes (type 1 & 2)",
      "ACTIONS": "↓blood glucose",
      "ADRS": "hypoglycemia,\nlipoatrophy,\nlipohypertrophy,\nweight gain",
      "FACTS": "given IV,\nonset: 30-60 min,\npeak: 2-4 hrs,\nduration: 5-7 hrs"
    },
    {
      "CATEGORY": "Insulin",
      "SUB-CATEGORY": "Short Acting (Regular)",
      "DRUG NAME": "Glulisine",
      "SPECIFIC USES": "diabetes (type 1 & 2)",
      "ACTIONS": "↓blood glucose",
      "ADRS": "hypoglycemia,\nlipoatrophy,\nlipohypertrophy,\nweight gain",
      "FACTS": "given IV,\nonset: 30-60 min,\npeak: 2-4 hrs,\nduration: 5-7 hrs"
    },
    {
      "CATEGORY": "Insulin",
      "SUB-CATEGORY": "Inhaled Insulin",
      "DRUG NAME": "Afrezza",
      "SPECIFIC USES": "diabetes type 1 & 2 (esp. in pt w/ fear of injection/needles)",
      "ACTIONS": "↓blood glucose",
      "ADRS": "hypoglycemia,\n↑bronchoconstriction (not recommended for use in asthma or smokers)",
      "FACTS": "dry powder of human recombinant insulin,\nrequires routine PFT's (@ baseline, 6 months, anually),\nC/I: COPD,\nonset: 12-15 min,\npeak: 30 min,\nduration: 3 hrs"
    },
    {
      "CATEGORY": "Insulin",
      "SUB-CATEGORY": "intermedite-acting",
      "DRUG NAME": "neutral protamine hagedorn (NPH)",
      "SPECIFIC USES": "diabetes (type 1 & 2)",
      "ACTIONS": "↓blood glucose",
      "ADRS": "hypoglycemia,\nweight gain,\nlipoatrophy,\nlipohypertrophy",
      "FACTS": "variable absorption,\nrecombinant human insulin w/ zinc and protamine (delayed absorption & extended action),\nonset: 2-4 hrs,\npeak: 6-8 hrs,\nduration: 12-16 hrs"
    },
    {
      "CATEGORY": "Insulin",
      "SUB-CATEGORY": "long-acting",
      "DRUG NAME": "glargine",
      "SPECIFIC USES": "diabetes (type 1 & 2)",
      "ACTIONS": "↓blood glucose",
      "ADRS": "burning at injection site (acidic solution),\nweight gain,\nlipoatrophy,\nlipohypertrophy,\nhypoglycemia",
      "FACTS": "pH=4,\nonset: 1 hr,\npeak: none,\nduration: 10-24 hrs"
    },
    {
      "CATEGORY": "Insulin",
      "SUB-CATEGORY": "Short Acting (Regular)",
      "DRUG NAME": "detemir",
      "SPECIFIC USES": "diabetes (type 1 & 2)",
      "ACTIONS": "↓blood glucose",
      "ADRS": "lipoatrophy,\nlipohypertrophy,\nweight gain,\nhypoglycemia",
      "FACTS": "neutral pH,\nhighly albumin bound,\nonset: 1 hr,\npeak: none,\nduration: 10-24 hrs"
    },
    {
      "CATEGORY": "Insulin",
      "SUB-CATEGORY": "ultra long acting",
      "DRUG NAME": "degludec",
      "SPECIFIC USES": "diabetes (type 1 & 2)",
      "ACTIONS": "↓blood glucose",
      "ADRS": "lipatrophy,\nlipohypertrophy,\nweight gain,\nhypoglycemia",
      "FACTS": "limited albumin binding,\nonset: 30-90 min,\npeak: none,\nduration: up to 42 hrs"
    }
  ],
  "Sulfonylureas": [
    {
      "CATEGORY": "Sulfonylureas",
      "SUB-CATEGORY": "first generation",
      "DRUG NAME": "chlorpropamide",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "↑insulin release",
      "ADRS": "hypoglycemia (more in 1st Gen) [take w/ food],\n↑appetite,\nweight gain,\nGI upset,\nimpaired cardiac ischemic preconditioning",
      "FACTS": "not used"
    },
    {
      "CATEGORY": "Sulfonylureas",
      "SUB-CATEGORY": "second generation",
      "DRUG NAME": "glyburide",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "↑insulin release",
      "ADRS": "hypoglycemia (more in 1st Gen) [take w/ food],\n↑appetite,\nweight gain,\nGI upset,\nimpaired cardiac ischemic preconditioning",
      "FACTS": "longest half life (highest 2nd gen hypoglycemia risk),\nused in pregnancy"
    },
    {
      "CATEGORY": "Sulfonylureas",
      "SUB-CATEGORY": "first generation",
      "DRUG NAME": "glipizide",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "↑insulin release",
      "ADRS": "hypoglycemia (more in 1st Gen) [take w/ food],\n↑appetite,\nweight gain,\nGI upset,\nimpaired cardiac ischemic preconditioning"
    },
    {
      "CATEGORY": "Sulfonylureas",
      "SUB-CATEGORY": "first generation",
      "DRUG NAME": "glimeperide",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "↑insulin release",
      "ADRS": "hypoglycemia (more in 1st Gen) [take w/ food],\n↑appetite,\nweight gain,\nGI upset,\nimpaired cardiac ischemic preconditioning"
    }
  ],
  "Glinides": [
    {
      "CATEGORY": "Glinides",
      "DRUG NAME": "repaglinide",
      "SPECIFIC USES": "diabetes",
      "ACTIONS": "↑insulin release",
      "ADRS": "hypoglycemia (less than sulfonylureas),\nweight gain (less than sulfonylureas)",
      "FACTS": "rapid onset,\ntake 10 min before each meal"
    },
    {
      "CATEGORY": "Glinides",
      "DRUG NAME": "nateglinide",
      "SPECIFIC USES": "diabetes",
      "ACTIONS": "↑insulin release",
      "ADRS": "hypoglycemia (less than sulfonylureas),\nweight gain (less than sulfonylureas)",
      "FACTS": "rapid onset,\ntake 10 min before each meal"
    }
  ],
  "Biguanide": [
    {
      "CATEGORY": "Biguanide",
      "DRUG NAME": "metformin",
      "SPECIFIC USES": "diabetes,\npre-diabetes",
      "ACTIONS": "↓hepatic glucose production,\n↑insulin sensitivity in peripheral tissue",
      "ADRS": "diarrhea,\nnausea,\nanorexia,\nmetallic taste,\nGI upset,\n↓ B12 absorption",
      "FACTS": "do not use if GFR <30,\ncaution if GFR <45,\nmonitor renal function,\ncan be used in pregnancy,\nstop prior to IV contrast"
    }
  ],
  "Thiazolidinediones (TZD's)": [
    {
      "CATEGORY": "Thiazolidinediones (TZD's)",
      "DRUG NAME": "pioglitazone",
      "SPECIFIC USES": "diabetes,\npre-diabetes",
      "ACTIONS": "↑insulin sensitivity,\n↓free fatty acids in circulation,\n↓gluconeogenesis",
      "ADRS": "weight gain,\nedema leading to exacerbation of CHF,\n↑LFT's,\n↑bone fractures (women),\nanemia,\nmacular edema",
      "FACTS": "delayed effect (8-12wks)"
    },
    {
      "CATEGORY": "Thiazolidinediones (TZD's)",
      "DRUG NAME": "rosiglitazone",
      "SPECIFIC USES": "diabetes,\npre-diabetes",
      "ACTIONS": "↑insulin sensitivity,\n↓free fatty acids in circulation,\n↓gluconeogenesis",
      "ADRS": "weight gain,\nedema leading to exacerbation of CHF,\n↑LFT's,\n↑bone fractures (women),\nanemia,\nmacular edema",
      "FACTS": "delayed effect (8-12wks)"
    }
  ],
  "Alpha-Glucosidase Inhibitors": [
    {
      "CATEGORY": "Alpha-Glucosidase Inhibitors",
      "DRUG NAME": "acarbose",
      "SPECIFIC USES": "diabetes",
      "ACTIONS": "inhibit intestine enzymes that break down starches,\ndelay dietary absorption of sugars",
      "ADRS": "flatulence,\nbloating,\nabdominal pain,\npoor absorption",
      "FACTS": "must take at start of each main meal,\nmost people can't tolerate GI ADRS"
    },
    {
      "CATEGORY": "Alpha-Glucosidase Inhibitors",
      "DRUG NAME": "miglitol",
      "SPECIFIC USES": "diabetes",
      "ACTIONS": "inhibit intestine enzymes that break down starches,\ndelay dietary absorption of sugars",
      "ADRS": "flatulence,\nbloating,\nabdominal pain,\npoor absorption",
      "FACTS": "must take at start of each main meal,\nmost people can't tolerate GI ADRS"
    }
  ],
  "DPP-4 Inhibitors": [
    {
      "CATEGORY": "DPP-4 Inhibitors",
      "DRUG NAME": "sitagliptin",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "inhibits breakdown of GLP-1",
      "ADRS": "headache,\nnasopharyngitis,\nrash,\nURI,\nmuscle pains,\ngenerally well tolerated"
    },
    {
      "CATEGORY": "DPP-4 Inhibitors",
      "DRUG NAME": "saxagliptin",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "inhibits breakdown of GLP-1",
      "ADRS": "headache,\nnasopharyngitis,\nrash,\nURI,\nmuscle pains,\ngenerally well tolerated",
      "FACTS": "↑ risk of HF admissions"
    },
    {
      "CATEGORY": "DPP-4 Inhibitors",
      "DRUG NAME": "linagliptin",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "inhibits breakdown of GLP-1",
      "ADRS": "headache,\nnasopharyngitis,\nrash,\nURI,\nmuscle pains,\ngenerally well tolerated"
    },
    {
      "CATEGORY": "DPP-4 Inhibitors",
      "DRUG NAME": "alogliptin",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "inhibits breakdown of GLP-1",
      "ADRS": "headache,\nnasopharyngitis,\nrash,\nURI,\nmuscle pains,\ngenerally well tolerated"
    }
  ],
  "GLP-1 receptor agonists (incretin mimetics)": [
    {
      "CATEGORY": "GLP-1 receptor agonists (incretin mimetics)",
      "DRUG NAME": "exenatide",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "slows gastic emptying,\n↓appetite,\n↑insulin release by activating beta cells",
      "ADRS": "nausea,\nweight loss,\nfetal abnormalities,\npancreatitis?",
      "FACTS": "longer acting than endogenous \nGLP-1,\nSQ injections"
    },
    {
      "CATEGORY": "GLP-1 receptor agonists (incretin mimetics)",
      "DRUG NAME": "liraglutide",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "slows gastic emptying,\n↓appetite,\n↑insulin release by activating beta cells",
      "ADRS": "nausea,\nweight loss,\nfetal abnormalities,\npancreatitis?",
      "FACTS": "longer acting than endogenous \nGLP-1,\nSQ injections"
    },
    {
      "CATEGORY": "GLP-1 receptor agonists (incretin mimetics)",
      "DRUG NAME": "abiglitide",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "slows gastic emptying,\n↓appetite,\n↑insulin release by activating beta cells",
      "ADRS": "nausea,\nweight loss,\nfetal abnormalities,\npancreatitis?",
      "FACTS": "longer acting than endogenous \nGLP-1,\nSQ injections"
    },
    {
      "CATEGORY": "GLP-1 receptor agonists (incretin mimetics)",
      "DRUG NAME": "dulaglitide",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "slows gastic emptying,\n↓appetite,\n↑insulin release by activating beta cells",
      "ADRS": "nausea,\nweight loss,\nfetal abnormalities,\npancreatitis?",
      "FACTS": "longer acting than endogenous \nGLP-1,\nSQ injections"
    },
    {
      "CATEGORY": "GLP-1 receptor agonists (incretin mimetics)",
      "DRUG NAME": "lixenetide",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "slows gastic emptying,\n↓appetite,\n↑insulin release by activating beta cells",
      "ADRS": "nausea,\nweight loss,\nfetal abnormalities,\npancreatitis?",
      "FACTS": "longer acting than endogenous \nGLP-1,\nSQ injections"
    }
  ],
  "Sodium Glucose transport 2 (SGLT-2) inhibitors": [
    {
      "CATEGORY": "Sodium Glucose transport 2 (SGLT-2) inhibitors",
      "DRUG NAME": "canaglifozin",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "↓reabsorption of glucose in kidneys",
      "ADRS": "polyuria,\n↑risk of infection (UTI),\n↑LDL,\nvolume depletion,\nhyperkalemia,\nweight loss"
    },
    {
      "CATEGORY": "Sodium Glucose transport 2 (SGLT-2) inhibitors",
      "DRUG NAME": "empagliflozin",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "↓reabsorption of glucose in kidneys",
      "ADRS": "polyuria,\n↑risk of infection (UTI),\n↑LDL,\nvolume depletion,\nhyperkalemia,\nweight loss"
    },
    {
      "CATEGORY": "Sodium Glucose transport 2 (SGLT-2) inhibitors",
      "DRUG NAME": "dapagliflozin",
      "SPECIFIC USES": "diabetes ",
      "ACTIONS": "↓reabsorption of glucose in kidneys",
      "ADRS": "polyuria,\n↑risk of infection (UTI),\n↑LDL,\nvolume depletion,\nhyperkalemia,\nweight loss"
    }
  ],
  "amylin analog": [
    {
      "CATEGORY": "amylin analog",
      "DRUG NAME": "pramlintide",
      "SPECIFIC USES": "diabetes (type 1 & 2)",
      "ACTIONS": "slows gastric emptying",
      "ADRS": "nausea,\nvomiting,\nanorexia,\n↑risk of insulin-induced hypoglycemia",
      "FACTS": "use only w/ mealtime insulin (must reduce insulin dose by 50% or more to avoid hypoglycemia)"
    }
  ]
}